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Abstract 
The topic addressed by the 2011 WHO‘s World Health Day was antibacterial 
resistance. This action served to highlight the serious problem bacterial resistance 
now presents to healthcare professionals globally. This investigation focussed on 
the action of four cationic antimicrobial agents against E. coli, S. aureus and P. 
aeruginosa. Triclosan is widely used clinically and as an ingredient of personal care 
products that has come under renewed scrutiny by the FDA last year. Colistin is 
used clinically as salvage therapy against multi-drug resistant bacteria, particularly 
P. aeruginosa and A. baumanii. NP101 and NP108 are novel antimicrobial peptides, 
considered as a class with huge future potential in the treatment of not only 
bacterial but also viral and fungal infections in humans. The action of triclosan on 
all three test bacteria, including P. aeruginosa, historically considered resistant to 
triclosan, revealed concentration dependent bacteriostatic/bactericidal effects; 
reduction in bacterial growth; inhibition of second-phase logarithmic growth in S. 
aureus; induction of minimal K+ loss in all bacterial species; non-septation and 
aggregation in all test species. Colistin use was abandoned clinically between 1970-
2000 and is not used clinically against Gram-positive species. Colistin exposure 
induced a common response from test bacteria including the Gram-positive S. 
aureus; concentration dependent retardation in onset of bacterial growth, without 
reduction in final bacterial density; significant K+ loss from S. aureus and E. coli but 
not P. aeruginosa; the development of resistance to the inhibitory colistin 
concentration by P. aeruginosa and S. aureus but not E. coli; production of small 
colony variants by P. aeruginosa; formation of spherical aggregates; membrane 
blebbing and inhibition of normal bacterial septation. Similar responses to NP101 
and NP108 were observed to the test bacteria; an all or nothing effect on bacterial 
growth; prevention of second phase logarithmic growth in S. aureus; induction of 
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significant K+ loss in all bacteria; size and shape alterations; extrusion of 
intracellular material, membrane blebbing; inhibition of bacterial septation and 
interruption of binary fission. Each of these peptides was incorporated into 
lyophilised wafers and tested for in vitro topical antibacterial efficacy and shown to 
have antibacterial activity against all test species. 
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Chapter One 
Introduction 
1. Background on innate human defences 
1.1 Development of antibiotics for clinical Use 
Before the introduction of sulphonamides in the 1930s, death due to infection was 
common and whether a patient lived or died from an illness was due in part to the 
strength of their immune system, the level of medical care received and availability 
of food (Jayarman 2009). Early antibiotics were seen as truly miraculous drugs and 
were initially reserved for military use during World War II (Alanis 2005). Many 
classes of antibiotic have been developed since (Table 1.1); unfortunately bacteria 
have developed at least one resistance factor to each of these antibacterials 
(Woods 2006).  
The increase in microorganisms that have developed resistance to currently 
available antimicrobial agents has become a major cause for concern worldwide and 
while these organisms are widespread in hospitals they are becoming increasingly 
prevalent in the community (Alanis 2005). Resistance can be defined as, bacteria 
surviving exposure to a concentration of antimicrobial (biocide), which is lethal to 
the rest of the bacterial population (Maillard 2007). Penicillin was developed in 
1943 and penicillin resistant bacteria were first detected in 1946 (Alanis 2005) 
while tetracycline was developed in 1948 and resistance emerged only five years 
later (Quadri Luis 2007).  In 1945, while being interviewed by The New York Times, 
Sir Alexander Fleming predicted the development of resistant, mutant forms of S. 
aureus if penicillin was used inappropriately. 
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Class of antibacterial Mode of action Resistance mechanism 
Penicillins, Cephalosporins, 
Carbapenems, Monobactams, 
Glycopeptides,  
cyclic Lipopeptides 
Inhibition of cell 
wall synthesis 
β-lactamases, alterations in 
penicillin-binding proteins 
Tetracycline, Aminoglycosides, 
Oxazolidonones, Ketolides, 
Lincosamides, Macrolides, 
Streptogramins 
Inhibition of 
protein synthesis 
Active- efflux, 
Ribosomal alterations 
Fluoroquinolones Inhibition of 
DNA synthesis 
Active- efflux, 
 DNA-gyrase modifications 
Rifampicin Inhibition of 
RNA synthesis 
Rifampicin resistant rna 
polymerase β-subunit 
Sulphonamides, Trimethoprim Inhibition of 
bacterial folic acid 
synthesis 
Sulphonamide transposable 
element (Tnβ) dfrA1 
Polymyxins Membrane 
disrupting agents 
Reduction of negative 
charges on bacterial surface 
Metronidazole Other 
mechanisms 
Nonsense or deletion 
mutations in rdxA 
Table 1.1 Antibiotic class, mechanism of action and resistance mechanisms 
 
As more antibiotics were discovered their use became widespread and they were 
employed to treat trivial and non-susceptible infections (Alanis 2005). The 
consequences of antibiotic overuse are the alarming levels of bacterial resistance to 
existing antimicrobials and the dearth of effective antimicrobials for clinical use 
against multi drug resistant bacteria.  
Serious infections caused by bacteria resistant to commonly used antibiotics are 
now a major problem in the 21st Century (Alanis 2005). The estimated cost of 
treating drug-resistant nosocomial bacterial infections in North America annually is 
5 billion dollars and these infections result in over 63,000 deaths per annum 
(Kindrachuk et al. 2007). Some of these strains are multi-resistant and the agents 
available to treat infections caused by them are few and dwindling (Finch and 
Hunter 2006).  
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1.1.2 Bacterial resistance 
Bacteria have developed resistance to antibiotics of natural (penicillins), semi-
synthetic (cephalosporins) and completely synthetic origin (fluoroquinolones) as 
well as agents that do not even enter the bacterial cell (vancomycin) (Jayarman 
2009).  The most implicated factor in the development of antibiotic resistance is the 
un-necessary and un-controlled use of antibiotics in both community and 
hospitalised patients and in the care of animals for food production (Alanis 2005). 
Bacterial resistance to antibiotics can be intrinsic or acquired and can be 
transmitted horizontally as well as vertically. The most frequent resistance type 
seen is acquired; transmitted horizontally via conjugation by plasmids (Alanis 
2005). 
There are only two requirements necessary for bacterial antimicrobial resistance to 
occur, an antibiotic capable of inhibiting the majority of bacteria in a colony and 
one bacterium in the colony with the genetic make-up capable of developing 
resistance to that antibacterial (Levy and Marshall 2004). Once genetic mutation 
has occurred, resulting in a change in bacterial DNA, transfer of this genetic 
material to other bacteria can occur rapidly by conjugation, transformation or 
transduction (Alanis 2005).  
A report ― Overcoming  Antimicrobial Resistance‖ in 2000, issued by the World 
Health Organisation (WHO) on bacterial resistance to antimicrobials, identified the 
problem as critical for public health due to the faster emergence and spread of 
resistant bacteria than previously observed, the global nature of resistance that is 
rapidly spread through international travel and the treatment of infections beset by 
either a total lack of effective antimicrobials or the exorbitant and prohibitive cost 
of new anti-infective agents (Finch and Hunter 2006). This increased level of 
bacterial resistance has produced pandrug-resistant isolates, i.e. bacteria resistant 
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to all available antibiotics. (Falagas and Bliziotis 2007) Untreatable pan-resistant 
bacterial infections have become far more frequent in the last five years (Projan 
and Bradford 2007). Deaths in patients following bacterial infections are increasing, 
even in patients infected with bacteria susceptible to current antimicrobials, as 
patients most at risk of contracting an infection caused by multidrug-resistant 
pathogens, are the most seriously ill patients. Multidrug-resistant infections in 
otherwise healthy adults are now frequently identified in the community setting, 
compared to this being a predominantly hospital phenomenon in the past (Projan 
and Bradford 2007).  
Multiple solutions are required to combat this problem, amongst them, education of 
the public that antibiotics are not always necessary or needed, better global 
regulation of antimicrobial use, research to permit the development of new agents 
and increased worldwide monitoring of bacterial resistance (Finch and Hunter 
2006). 
1.1.3 Host defence system 
Humans are constantly exposed to potentially harmful pathogens in normal 
everyday life. Our survival depends on an effective host defence system, comprised 
of the innate immune system and acquired immune responses (Reddy, Yedery and 
Aranha 2004). The function of the immune system is to identify invading 
pathogens, contain and neutralise the threat and restore health (Martin and Dodds 
2006). Many factors comprise the innate immune defence system; physical barriers 
such as the stratum corneum of the skin; leukocytes such as macrophages and 
neutrophils monitor blood for potential pathogenic infection: while epithelia 
synthesise and secrete small cationic peptides to counteract infection (Schauber et 
al. 2006). The difference between the innate and acquired immune system is that 
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each human is born with an already functioning innate immune system whereas 
humans require exposure to infections in order to acquire immunity to them: 
thereby developing their acquired immune system. Generally once exposure to 
infection has occurred, humans produce antibodies to that antigen within four days 
(Wood 2006). The ability of the acquired immune system to carry out its function 
lies in its recognition of certain molecules as foreign to the human body. These are 
distinct, evolutionary conserved, molecular patterns such as lipopolysaccharide, 
peptidoglycan and flagellin in bacteria (Martin and Dodds 2006). As these molecules 
are specific for bacteria and essential for their survival, ceasing their production to 
avoid detection by the immune system is not possible. The host cell receptors that 
recognise these bacterial molecules are termed pattern recognition receptors, which 
include Toll-like receptors (TLRs) and Nod like receptors (NLRs) (Wood 2006). TLRs 
are located throughout the human body from epithelial cells to the endothelial cells 
of coronary arteries; once molecules are bound to these receptors a cascade of 
responses is released including the transcription of antimicrobial peptides (Martin 
and Dodds 2006). 
1.1.4 Inappropriate prescribing patterns 
Prescribing guidelines were developed in the 1980s and 1990s to promote 
appropriate prescribing and reduce the risk of resistance. Towards the end of the 
1990s, the Consensus Group on Resistance and Prescribing in Respiratory Tract 
Infections was set up to optimise treatment for lower respiratory tract infections 
(RTI). They targeted primary care antibiotic prescribing which accounted for 80% of 
antibiotic prescriptions, 75% of which are prescribed for RTIs (Ball 2007). 
Antibacterial prescribing for the common cold in the US alone is reported as 36%, 
(Gilberg et al. 2003) yet the medical profession is well aware that the causative 
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factor in the majority of colds is an adenovirus which is unaffected by the 
prescribed antibacterial. 
The importance of RTIs as a cause of death is rising and it is estimated by 2020 the 
number of deaths due to chronic obstructive pulmonary disease and pneumonia will 
be surpassed only by chronic heart disease and stroke (Murray and Lopez 1997). 
Three bacterial species, Streptococcus pneumoniae, Haemophilus influenzae and 
Moxarella catarrhalis are mainly involved in respiratory disease and drug resistance 
in clinical isolates of all three species is rising (Ball 2007). SENTRY and PROTEKT, 
two global surveillance studies, have shown the worldwide increase in penicillin-
resistant isolates of S. pneumoniae.  
1.1.5 Reduction in bacterial fitness  
Studies have shown that by whatever means antibiotic resistance is acquired by 
bacteria, there is a cost involved, which may be manifested as a reduction in 
bacterial growth, virulence or transmission between patients (Andersson 2006). 
Experimental studies have demonstrated the cost of resistance is a main 
determinant of both the rate and extent of resistance development whilst under a 
given antibiotic pressure (Andersson 2006). The cost of resistance can also be 
measured by examining the rate by which resistance declines if antibiotic use is 
reduced (Andersson 2006). If the resistance-conferring gene is linked genetically 
with other selected genetic markers, that resistance-conferring gene could remain 
in the bacterial population (even though it exerts a fitness cost) solely due to the 
genetic link - as shown by the prevalence of sulphonamide resistance to date 
(40/45%) in E. coli despite a 97% reduction in sulphonamide use since the 1990‘s 
(Enne et al. 2004). Sulphonamide resistance is carried on sul2-encoding plasmids 
which normally reduce the competitive fitness of the host but these plasmids also 
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encode resistance to at least one other currently used antimicrobial suggesting 
maintenance in the bacterial population is due to the clinical use of these agents 
(Enne et al. 2004). Unfortunately studies of fitness costs of resistance on bacteria 
have shown that resistant bacteria do not disappear even if antibiotic use is 
reduced but persist long term even in the absence of antibiotic selective pressure 
(Andersson 2006).  
1.1.6 Minimisation of resistance  
Because bacteria have developed resistance to so many existing antibacterial 
agents, any factors that can help slow the development of resistance to both 
current and future antibacterials should be utilised. Properly conducted 
epidemiological studies of risk factors for the development of antibiotic resistance 
are essential for interventions, based on these studies, to be effective in curbing 
the rising tide of resistance (Gasink et al. 2007).  
For example, early in vitro studies revealed exposure of E. coli to fluoroquinolones 
resulted in selection of resistance mutations conferring fluoroquinolone resistance. 
(Watanabe et al. 1990)(MacAdam et al. 2006). Ecological studies also observed a 
strong correlation between fluoroquinolone-resistant E. coli and the increase in the 
use of fluoroquinolones (Lautenbach et al. 2004)(MacAdam et al. 2006). Logically, 
clinical studies investigating risk factors for fluoroquinolone-resistant E. coli should 
utilise this information in formulating treatment guidelines (MacAdam et al. 2006). 
1.2. Background on development of antimicrobial agents 
1.2.1 Research and development strategies 
In spite of nearly seven decades using antimicrobial agents, infectious diseases 
continue to have a massive impact both on human morbidity and mortality 
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throughout the world and place a major burden on healthcare services. The 
antibacterial drugs poised for licensing in the US are mostly active against Gram-
positive bacteria, particularly MRSA, but the growing unmet medical need of 
antibacterials to treat multi-drug resistant Gram-negative infections remains 
currently un-addressed (Projan and Bradford 2007).  
The Infectious Diseases Society of America has called for a ―10 x 20 initiative‖, 
requesting a global commitment to deliver a minimum of 10 new antibacterials by 
2020 (Moellering Jr.  2011). The search for new antimicrobial agents possessing 
wide antibacterial activity, little potential for selection of resistant mutants in 
combination with minimal human toxicity, is now urgent (Kindrachuk et al. 2007).  
Amongst the factors that have contributed to the lack of new antimicrobials 
entering clinical use, is the global consolidation of pharmaceutical companies since 
1990 and the lack of interest by the remaining big pharma companies in the 
development of new antibacterial agents (Moellering Jr.  2011). Increasing 
development costs of new drugs coupled with a 10-14 year span from discovery of 
a promising drug candidate to the development of a new medicine, combined with 
regulatory agencies requiring ever increasing volumes of data on safety and 
efficacy of these drugs from clinical trials, has caused pharmaceutical companies to 
reassess their research portfolio in favour of medicines which show the greatest 
return for the money invested over a lengthy product lifetime (Moellering Jr.  
2011).   
It makes sound financial sense for pharmaceutical companies to develop 
therapeutic agents such as anti-hypertensives, which once prescribed for the 
patient are life long medicines, maximising the long term financial return for the 
pharmaceutical company holding the patent. Compare this to a similar time and 
monetary investment by the same company for the production of an antimicrobial 
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agent with a prescribing pattern for short tem, infrequent clinical use and it is 
immediately apparent that the development of antimicrobial agents is not in the 
best long term financial interest of pharmaceutical companies.  
Another factor affecting drug development is that the patent life of a medicine only 
lasts 20 years from the date of discovery (Shlaes and Moellering 2002). The nature 
of the product being developed also discourages financial investment; if the 
antimicrobial agent is novel and clinically effective an embargo will initially be 
imposed on its use in an effort to curtail the development of resistance and 
thereafter the product will only show a financial return while clinically effective, 
before bacterial resistance to this agent develops, ending the financial reward for 
the company involved (Projan and Bradford 2007).  
1.2.2 New antimicrobial agents 
Mapping of the first bacterial genome that of Haemophilus influenzae, occurred in 
1995, whereupon the focus of development of new antibacterials fell on targets 
elucidated from the genomic sequencing of bacteria (Brötz-Oesterhelt and Brunner 
2008). This strategy of one gene one target has not been successful in the 
development of novel antimicrobials and is contrary to the complex mechanisms of 
action of developed antibacterials, where bacterial inactivation is not merely due to 
the binding of a unique enzyme target (Brötz-Oesterhelt and Brunner 2008). 
Strategies used in the development of new antibacterial agents range from classic 
screening methods, chemical modification of existing antimicrobial agents, 
potentiation of activity of known compounds, to synergistic combinations of agents 
(Moellering Jr.  2011). Through development of a novel screening method for un-
culturable microorganisms, Novobiotics has discovered the glycosylated 
macrolactams; novolactamycin and novobiomycin (Moellering Jr.  2011).  
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Novelty in future drugs requires in essence a molecular target, previously un-used 
in drug formulation and original drug core architecture (Quadri Luis 2007). For this 
to happen, innovation is required in the target and lead discovery phases to 
produce a new arsenal of anti-infective weapons (Quadri Luis 2007). This work is 
hoped to result in an array of drugs that prevent pathogens producing infections 
due to antimicrobial activity and drugs that do so by other activities, as for example 
the inhibition of a bacterial iron scavenging mechanism, as iron is essential for 
correct multiplication in most bacteria (Quadri Luis 2007).  
1.3. Re-evaluating the anti-bacterial arsenal 
1.3.1 Re-assessment and re-investigation 
The dearth of new antimicrobials in the antibacterial development pipeline for 
clinical use has focussed the spotlight on the existing agents in the antimicrobial 
arsenal. The FDA identified Triclosan for re-evaluation in 2010, in response to 
reports of altered thyroid function and changes to bacterial resistance by the 
bisphenol (Focus on Surfactants 2010a) (Focus on Surfactants 2010b). Triclosan 
was developed in the early 1960‘s and is marketed as Irgasan DP300 for use in skin 
products and Irgacare MP for oral care formulations (Jones et al. 2000). Triclosan 
was launched onto the healthcare market in 1972 as a surgical scrub (Jones et al. 
2000). 
Re-examination of discarded antibiotics such as polymyxins is currently being 
undertaken (Woods 2006.) The clinical use of Colistin (polymyxin E) was 
abandoned worldwide around 1980 except in the treatment of cystic fibrosis 
patients, due to reports of serious nephrotoxicity and neurotoxicity problems 
(Falagas and Michalopoulos 2006). Colistin use has been revived recently and it is 
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currently used as a salvage treatment against multi-drug resistant Gram-negative 
bacteria (Zavascki et al. 2007).  
Under-investigated areas such as antimicrobial peptides are being re-examined; 
antimicrobial proteins - lactoferrin and histones – were first reported in 1930, but 
the discovery of antibiotics, which were much easier to synthesise, drew the 
attention of researchers away from these antimicrobial proteins (Lupetti et al. 
2003). 
1.3.2 Triclosan 
Triclosan (Irgasan DP 300; 2,4,4‘-trichloro-2‘-hydroxydiphenyl ether) is a 
chlorinated diphenyl ether or bisphenol that is employed in a variety of ways, 
including incorporation into mouthwashes, cosmetic preparations and plastics due 
to its high anti-bacterial activity and safety profile (Gomez- Escalada et al. 2005).  
 
 
Figure 1.1: Chemical structure of triclosan 
 
Triclosan is a tasteless, white, non-ionic, odourless crystalline powder (Qian, Guan 
and Xiao 2008), which is highly lipophilic, requiring sufficiently alkaline pH for 
significant aqueous solubility in anionic form (Amiri et al. 2007). The typical 
concentration of the diphenyl ether in healthcare products ranges from 0.1 - 0.3% 
and the widespread use of such products has led to the identification of triclosan 
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in 2002 as one of seven most commonly detected compounds in a United States 
freshwater survey (Liu et al. 2009.)  
Triclosan exhibits high activity against Escherichia coli and Staphylococcus aureus 
while Pseudomonas aeruginosa is highly resistant (Russell 2004)(Russell 2004). 
Triclosan enters all three organisms by diffusion, the rate of which has been 
reported as proportional to the lipid content of the cell membrane (Schweizer 
2001). Triclosan displays activity against many Gram-positive and Gram-negative 
non-sporulating bacteria, Plasmodium falciparium, some fungi and Toxoplasma 
gondii (Russell 2004). Triclosan is bacteriostatic at low concentrations (sub-
inhibitory) but bactericidal at higher concentrations (supra-inhibitory) (Russell 
2004).  
1.3.2.1 Triclosan; an atypical biocide 
Triclosan has been termed an atypical biocide, through targeting only one specific 
site within the bacterial cell, namely the gene fabI (Russell 2002). 
Characteristically biocides possess many target sites upon which they exert their 
action within a bacterium. (Suller and Russell 2000) Biocide composition can 
include several active compounds resulting in multiple bacterial intracellular 
targets (Randall et al. 2007).  
Concentration is the most important factor governing the antimicrobial activity of 
a biocide, even at low concentrations biocides exert a selective pressure upon a 
bacterial population and a stress response is induced from the bacteria (Maillard 
and Denyer 2009). High biocide concentrations for disinfection and antiseptic use 
greatly exceed bacterial MICs, resulting in rapid microbial kill through interaction 
with multiple target sites, with little possibility of the development of bacterial 
resistance (Maillard 2005). Unfortunately high biocide concentration does not 
guarantee the absence of microorganisms, as contaminated formulations 
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incorporating a high biocide concentration have been reported (Maillard and 
Denyer 2009).  
Increased public awareness of microbial contamination and infection has greatly 
increased biocide use in the domestic and healthcare market, resulting in the 
commercial availability of products containing low concentrations of biocides 
(Maillard and Denyer 2009). The dilution factor in the environment of these low 
biocide concentrations and their subsequent effects on bacteria remains 
unevaluated (Maillard 2007). Some researchers have proposed that it is the 
residual concentrations of Triclosan in the environment that may play a role in 
selecting for organisms with reduced susceptibility (Aiello et al. 2004).  
1.3.2.2 Triclosan Mechanisms of Action 
Triclosan exerts antibacterial activity by targeting a specific site within bacterial 
cells, namely an NADH-dependent enoyl-acyl carrier protein reductase, FabI (Yu, 
Kim and Pan 2010). The fabI gene encodes this enoyl reductase enzyme, which 
uses NADH to reduce double bonds during fatty acid elongation, making this an 
important element of lipid synthesis (Suller and Russell 2000). E. coli, S. aureus 
and P. aeruginosa all possess fabI however P. aeruginosa also possesses fabK, a 
triclosan resistant gene which catalyses fatty acid synthesis in this bacterium 
(Escalada et al. 2005).  
Levy et al reported the formation of a ternary complex in E. coli between FabI, 
NAD+ and triclosan (Levy et al. 1999)(Levy and Marshall 2004). Heath et al have 
demonstrated that FabI is the target of Triclosan in S. aureus (Heath et al. 2000). 
E. coli FabI specifically requires NADH whereas S. aureus FabI exhibits specific 
and positive co-operative binding of NADPH (Heath et al. 2000). P. aeruginosa is 
reported to be inherently resistant to triclosan as it possesses a non-susceptible 
enoyl reductase (Yu, Kim and Pan 2010). Bacterial growth is inhibited by blocking 
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lipid synthesis through inhibition of this reductase in susceptible bacteria (Yu, Kim 
and Pan 2010).  
Escalada et al demonstrated though complete inhibition of fatty acid biosynthesis 
was achieved via triclosan‘s targeting of enoyl reductase, significant reductions in 
viable bacterial counts were not recorded (Escalada et al. 2005). The action of 
triclosan at the concentrations employed was therefore bacteriostatic, though 
long-term prevention of lipid synthesis would result in bacterial death (Escalada et 
al. 2005). If inhibition of fatty acid synthesis is the primary target of triclosan, 
when complete inhibition of fatty acid synthesis by triclosan was demonstrated by 
Escalada et al, this did not correlate to a bactericidal effect but rather to a 
bacteriostatic effect prompting Escalada et al to suggest that triclosan possesses 
another as yet un-determined bactericidal mechanism of action, un-connected to 
fatty acid biosynthesis (Escalada et al. 2005).  
A.D. Russell attributed triclosan to have more than one mechanism of action due 
to its biocide nature (Russell 2004)(Russell  2004). Other research groups have 
proposed that the antibacterial action of triclosan is due to more than inhibition of 
fabI (Yu, Kim and Pan 2010). Suller et al showed logarithmic and stationary 
phases in S. aureus were equally sensitive to triclosan (Suller and Russell 2000). 
Were fabI the only triclosan target in the bacterium the logarithmic growth phase 
should have been more severely affected than every other phase of bacterial 
growth and this was clearly shown not to be the case (Suller and Russell 2000). 
Other studies have proposed the action of triclosan is due in part to its effect on 
bacterial membranes, where triclosan was incorporated into phospholipid 
membranes interacting with them without inducing lysis but resulting in the 
formation of perturbed membrane structures, this usually occuring at higher 
triclosan concentrations (Russell 2002)(Russell 2003)(Russell 2003)(Villalaín et al. 
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2001). Triclosan has also been shown to inhibit F-ATPase, glycolytic enzymes, 
transmembrane protein carriers and biofilm formation in oral bacteria (Yu, Kim 
and Pan 2010).  
1.3.2.3 Mechanisms of  bacterial resistance to triclosan 
Bacterial resistance mechanisms to biocides include changes in permeability of 
bacterial membranes; resulting in decreased concentration of biocide entering the 
cells and increased bacterial efflux that reduces biocide concentration in the 
cytoplasm (Russell 2003)(Russell 2003). Efflux pumps are transport proteins that 
remove toxic substrates from within cells to the external environment. These 
proteins are found in Gram-negative and Gram-positive bacteria and may be 
specific for one substrate or may transport structurally dissimilar compounds. As 
antibiotic sensitive as well as resistant bacteria carry and express genes encoding 
efflux transporters it is possible that the pumps arose so that noxious substances 
could be transported out of the organism permitting survival. 
Biocide resistance through mutation of target sites is unusual but triclosan‘s activity 
at low concentrations is through inhibition of fabI; therefore mutation or over 
expression of this gene could lead to the development of resistance (Russell 2003). 
Bacteria develop triclosan resistance through target mutations, enzymatic 
modification and active efflux (Chuanchuen, Karkhoff-Schweizer and Schweizer 
2003). The presence of a fabI homologue is responsible for resistance to triclosan in 
S. aureus (Tkachenko et al. 2007). The high triclosan resistance level of P. 
aeruginosa has been attributed to its constitutive MexAB-OprM efflux system 
(Champlin et al. 2005). Development of triclosan resistance in E. coli is through up-
regulation of RND efflux pumps or mutation of fabI (McBain and Gilbert 2001).  
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1.3.2.4 Triclosan use and cross resistance to antibiotics 
The potential for cross resistance to develop occurs when the same target is 
attacked by different anti-microbial agents, when two agents initiate a common 
pathway to cell death, or when antimicrobials share a common route of access to 
different targets (Chapman 2003). Chuanchuen et al described exposure of P. 
aeruginosa to triclosan that resulted in the development of a high level of 
resistance not only to triclosan but also to ciprofloxacin through induction of 
expression of a multi drug efflux pump (Chuanchuen, Karkhoff-Schweizer and 
Schweizer 2003). By whatever means cross-resistance is achieved the end result is 
identical; the development of resistance to a particular antibacterial agent is co-
joined to resistance being displayed to another agent (Chapman 2003). 
Triclosan is a biocide that has been implicated as a possible cause for the selection 
and persistence of bacterial strains with low-level antibiotic resistance (Russell 
2002). The development of cross-resistance between triclosan and antibiotics 
through utilisation of target mutations, enzymatic modification and active efflux has 
been demonstrated in bacteria under laboratory conditions (Schweizer 2001). A 
recent community based clinical trial examined biocide usage and development of 
antimicrobial resistance in bacteria (Carson et al. 2008). At baseline Carson et al 
demonstrated no significant association between high triclosan MICs and high 
benzalkonium chloride (BZK) MICs for any bacteria tested. After completion of the 
one-year study their data showed a significant association in community isolates of 
high BZK MICs, high triclosan MICs and resistance to one or more antibiotics. The 
selective pressure of biocides on bacteria has the potential to result in the co-
selection of genes, which could bestow reduced susceptibility to both biocides and 
antibiotics (Carson et al. 2008).  
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Cottell et al in their 2009 study demonstrated increased susceptibility to 
aminoglycosides by triclosan tolerant E. coli. The authors speculated the link 
between triclosan tolerance and aminoglycoside susceptibility in E. coli, as 
attributable to plasmid loss or changes in outer bacterial membranes (Cottell et al. 
2009). Increased tolerance to antibiotics such as gentamicin and quinolones has 
been shown in triclosan tolerant S. aureus (Cottell et al. 2009). Tkachenko et al 
credit alteration in structural and functional proteins of bacterial cell membranes 
with triclosan/ciprofloxacin resistance in S. aureus (Tkachenko et al. 2007). 
1.3.2.5 Triclosan toxicity 
Triclosan has been shown to possess a favourable mammalian safety profile (Liu et 
al. 2009)(Jones et al. 2000)(Escalada et al. 2005). Though triclosan‘s efficacy in 
preventing gingivitis through incorporation in toothpaste has been demonstrated 
(Focus on Surfactants 2010a) (Focus on Surfactants 2010b), infrequent incidents of 
immuno- and neurotoxic reactions have been reported (Latosińska, Tomczak and 
Kasprzak 2008).  
Reported concentrations of triclosan in human breast milk have varied from 0 up to 
2100 µg/kg lipid (Paul et al. 2010). Other noted triclosan side effects include 
interactions with thyroid hormones and skin irritations (Latosińska, Tomczak and 
Kasprzak 2008). In 2010 an animal study conducted by Paul et al reported reduced 
levels of thyroxine and triiodothyronine after exposure to triclosan (Paul et al. 
2010). Reports of interactions with human pregnane X receptor, P450-dependent 
enzymes and UDP-glucuronosyltransferases by triclosan also exist (Krishnan et al. 
2010). Inhibition of a type I fatty acid synthase in breast cancer cells by triclosan 
has been described (Escalada et al. 2005).  
Laboratory studies conducted by Ciba Speciality Chemicals have identified the 
mineralization half-life of triclosan varies between 15 – 35 days (Thompson et al. 
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2005). Combined with the efficiency of UK water treatment plants in triclosan 
removal from waste water ranging from 58-98%, there is a potential for significant 
triclosan exposure for all living organisms (Thompson et al. 2005). Given the very 
polar nature of triclosan, bioaccumulation of the diphenyl ether is likely (Thompson 
et al. 2005). The long term significance, if any of these various interactions by 
triclosan on humans remain to be unequivocally determined (Krishnan et al. 2010).  
1.3.3 Colistin 
Colistin is marketed as colistin sulphate for oral and topical use and as 
colistimethate sodium (an inactive pro-drug) for parenteral and inhalation 
administration (Maviglia, Nestorini and Pennisi 2009). The polypeptide was 
discovered in 1949 and used clinically from the 1950s (Montero et al. 2009). 
Colistin, also known as polymyxin E, is a decapeptide antibiotic with an 
antimicrobial spectrum which includes Gram-negative bacteria (Falagas and 
Michalopoulos 2006). Narrow spectrum of activity coupled with a rapid 
concentration dependent bactericidal onset of action against most Gram-negative 
aerobic bacilli are colistin‘s best attributes (Maviglia, Nestorini and Pennisi 2009). 
Colistin is not active against Gram-positive bacteria or anaerobes (Falagas, 
Rafailidis and Matthaiou 2010)(Falagas et al. 2010). Knowledge of the effect of 
colistin on bacteria is lacking as licensing bodies such as the Medicines and 
Healthcare Regulatory Agency (MHRA) were not in existence and the body of 
microbiological and pharmacological evidence that would have to be submitted 
nowadays in order to license an antibiotic simply was not required (Nation and Li 
2009).  
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1.3.3.1 Mechanism of action of colistin 
Colistin exerts a bactericidal effect on bacteria by permeabilizing the outer Gram-
negative bacterial membrane (Vaara 2010). Colistin binds to and de-stabilizes the 
lipopolysaccharide (LPS) layer by displacing the calcium and magnesium bridges, 
entering the bacterium through the self-promoted uptake pathway (Zavascki et al. 
2007). Thus neither diffusion nor any transport mechanism is required by colistin to 
reach the bacterial cytoplasmic membrane, upon which colistin exerts its 
bactericidal effect through a surface detergent mechanism of action (Nasnas, Saliba 
and Hallak 2009). This results in leakage of cell components and subsequent cell 
death (Maviglia, Nestorini and Pennisi 2009). Colistin has also demonstrated 
bactericidal activity through inhibition of cell growth, at concentrations far lower 
than those required for breaching membrane permeability, through as yet unknown 
mechanism of action (Maviglia, Nestorini and Pennisi 2009).  
1.3.3.2 Resistance to colistin 
The reason multi-drug resistant Gram-negative bacteria have not acquired any 
significant degree of colistin resistance to date is very probably due to the 
infrequent clinical use of polymyxins over the last few decades (Zavascki et al. 
2007). Not only is resistance to colistin seldom seen, it appears as a result of 
chromosomal mutation which is manifested as decreased permeability of the 
bacterial wall to colistin (Nasnas, Saliba and Hallak 2009). Modification of the outer 
bacterial membrane structure is the most significant resistance mechanism to 
colistin (Falagas, Rafailidis and Matthaiou 2010)(Falagas et al. 2010)(Falagas and 
Michalopoulos 2006). These LPS modifications prevent or reduce the initial 
interaction between the Gram-negative bacterium and colistin. P. aeruginosa and E. 
coli modify lipid A reducing the overall net negative LPS charge, hence reducing 
colistin binding and increasing resistance to the antimicrobial (Zavascki et al. 
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2007). As this resistance mechanism compromises the normal functioning of the 
outer bacterial membrane, permeability of other antimicrobial agents may be 
enhanced (Vaara 2010). Plasmid mediated resistance has not been reported to date 
for colistin (Nasnas, Saliba and Hallak 2009).  
Global resistance to colistin is generally less than 10%, however certain areas such 
as Korea and Singapore exhibit higher resistance levels (Falagas, Rafailidis and 
Matthaiou 2010). A report in 2010 from Milne et al noted a 16% resistance rate to 
colistin amongst cystic fibrosis patients in Scotland (Milne and Gould 2010). 
Concerns have been raised that sub-optimal colistin dosing is responsible for the 
development of resistance to the polymyxin agent (Rattanaumpawan, Ungprasert 
and Thamlikitkul 2011).  
1.3.3.3 Therapeutic doses and risk factors 
A 2010 study examining colistin use over a 12-month period gave the median 
duration of therapy and cumulative dose of IV colistin to onset of nephrotoxicity as 
7 days and 1200mg respectively (Rattanaumpawan, Ungprasert and Thamlikitkul 
2011). The authors also list a number of independent risk factors in the 
development of nephrotoxicity to be considered with colistin use, notably; 
concomitant use of vancomycin, old age and long duration coupled with high IV 
colistin doses (Rattanaumpawan, Ungprasert and Thamlikitkul 2011).  
1.3.3.4 Colistin toxicity 
As previously mentioned the clinical use of colistin was largely abandoned due to 
perceived toxicity problems. The most serious reported toxicity was renal damage, 
which may be explained by the extensive tubular re-absorption of colistin, leading 
to the accumulation of and subsequent damage by the polymyxin to the renal 
proximal tubular cells (Vaara 2010).  
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A recent retrospective review of patients treated with intravenous colistin in a 
Beirut hospital identified no renal failure or major neurological toxicity under 
treatment (Nasnas, Saliba and Hallak 2009). The average cumulative dose of 
colistin administered to patients during this study was 86 x 106 international units, 
with durations of treatment ranging from 16 to 65 days (Nasnas, Saliba and Hallak 
2009). A systematic review of colistin use has shown higher reported rates of 
nephrotoxicity in studies undertaken prior to 1995 compared to those carried out 
after 1995 (Hartzell et al. 2009). This could be partly attributed to impairment in 
renal function being defined by different standards, chemical impurities in the 
earlier synthesis of colistin, better modern critical care unit monitoring of patients in 
conjunction with non-administration of concurrent known nephrotoxic medication 
(Falagas and Rafailidis 2009)(Falagas et al. 2010).  
Hartzell et al identified that it is the total cumulative dose of colistin that is 
associated with nephrotoxicity, therefore shortening the duration of colistin 
administration should reduce the rate at which nephrotoxicity develops (Hartzell et 
al. 2009).  
1.3.3.5 Colistin anti-endotoxic activity 
Death or division of bacteria can result in release of lipopolysaccharide (LPS) from 
the surface of bacteria into the bloodstream of the host. This can be a potent 
stimulus for the activation of an immune response leading to sepsis and septic 
shock with potentially fatal consequences for the patient (Gutsmann, T. 2005). 
Sepsis is the response of the body to infection, which can deteriorate to an 
uncontrolled immunological reaction with the potential to result in multiple organ 
failure and death from septic shock (Giuliani, Pirri and Rinaldi 2010).  
Some antibiotics kill bacteria while simultaneously facilitating unwanted release of 
endotoxin, but cannot bind or neutralise endotoxin (Gutsmann et al. 2005). 
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Endotoxin is responsible for >2% of total hospital admissions annually in the US 
and >400,000 deaths there per year (Zhang and Falla 2006). Polymyxins B and E 
are the only antibiotics in current clinical use that can bind and neutralise endotoxin 
(Nasnas, Saliba and Hallak 2009).  
A two-step approach is thought to be the mechanism by which colistin binds to LPS; 
the correct orientation and position of polymyxin and LPS is achieved through 
electrostatic interaction of the positively charged polymyxin ring followed by binding 
of the polymyxin hydrophobic acyl chain to the non-polar centre of the LPS lamellar 
phase (Davies and Cohen 2011, Davies and Maillard 2001).  
Japan has been using a specially designed polymyxin column for use in patients 
suffering from severe sepsis since 1994 (Davies and Cohen 2011). The polymyxin is 
attached to polystyrene fibres in the column via covalent bonding; blood is passed 
through the cartridge and LPS is removed through binding to the polymyxin via the 
remaining charged amino acid groups (Davies and Cohen 2011). Despite 
widespread clinical use of endotoxin removal devices in Japan, lack of efficacy from 
clinical trials for these devices has meant worldwide adoption of this procedure has 
not yet occurred, however further clinical trials are on going (Davies and Cohen 
2011).  
1.3.4 Cationic Antimicrobial Peptides (CAPs) 
1.3.4.1 CAPs 
CAPs, once recognised as nature‘s antibiotics are now regarded as promising 
candidates for development as novel antimicrobials (Hale and Hancock 2007). The 
presence of CAPs has been identified in practically every living entity, ranging from 
bacteria to humankind (Hale and Hancock 2007).  More than 1000 natural cationic 
peptides have been identified while many others possessing equivalent spectrums 
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of activity as their natural counterparts, have been synthesised (Hale and Hancock 
2007). CAPs are broad-spectrum antimicrobials, active against Gram-positive and 
Gram-negative bacteria, viruses, fungi and parasites (Zhang and Falla 2006)(Zaiou  
2007).  
CAPs enter Gram-negative bacterial cells in a similar manner to colistin, through 
the self-promoted uptake pathway (Hancock and Sahl 2006, Hancock and Chapple 
1999). Evidence indicates that antimicrobial peptides such as  and β defensins and 
cathelicidins, link the innate with the acquired immune response (Lupetti et al. 
2003). Compared to the acquired immune response, the constitutively expressed or 
induced endogenous CAPs provide a fast response to bacterial invasion (Reddy, 
Yedery and Aranha 2004)(Hale and Hancock 2007). 
John K. Spitznagel and colleagues were pioneers in 1963 for the quest for 
antimicrobial proteins and studied the polymorphonuclear leukocyte (PMN). They 
showed that there were a number of cationic antimicrobial proteins associated with 
the granules of PMN that coated bacteria during phagocytosis. Little research in the 
area of CAPs was conducted until the 1980s, when technology was sufficiently 
developed to permit investigators to isolate, purify and sequence these proteins. 
The identification of proteins with antimicrobial activity from PMN such as the  
defensins was instrumental in moving this field forward (Pereira 2006).  
1.3.4.2 CAP Composition 
CAPs are gene-encoded, ribosomally synthesised polypeptides that diffuse rapidly 
into cells due to their small size and quickly neutralise a broad range of 
microorganisms (Perron, Zasloff and Bell 2005)(Hale and Hancock 
2007)(Papagianni  2003)(Reddy, Yedery and Aranha 2004). CAPs are generally 
composed of between 12 – 50 amino acids; possess an overall positive charge 
between +2 to +9 and are hydrophobic (Hale and Hancock 2007)(Hancock and Sahl 
24 
 
2006). CAPs can be classified into five major types namely; -helical, -sheet, 
looped, extended and cyclic (Hancock and Sahl 2006)(Zhang and Falla 2006). 
Primary and secondary structures display variability but CAPs display common 
structural arrangement at tertiary level, through the formation of amphiphilic 
molecules with the segregation into groups of charged (polar) and hydrophobic 
residues on membrane interaction (Hale and Hancock 2007)(Papagianni  2003). 
1.3.4.3 CAP mechanisms of action 
CAPs can be divided into membrane lytic and non-membrane lytic agents (Zhang 
and Falla 2006). Membrane lysis is induced via several recognised modes of action; 
barrel stave, carpet, toroidal and aggregate models (Hale and Hancock 
2007)(Reddy, Yedery and Aranha 2004)(Brogden 2005). 
 
          
Figure 1.2 (a) barrel stave, (b) carpet and (c) toroidal models. Adapted from (Brogden 
2005) 
 
It has been suggested that all CAPs can induce membrane perturbation if the 
concentration employed is higher than a physiologically relevant one (Hale and 
Hancock 2007). Similar mechanisms of action have been observed for non-
membrane lytic agents and sub-MIC concentrations of membrane lytic agents, 
through interference of cell division, inhibiting synthesis of intracellular 
macromolecules and disruption of gene regulation (Hale and Hancock 2007)(Zhang 
(a) (b) (c) 
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and Falla 2006). Activation of autolytic enzymes, inhibition of DNA and protein 
synthesis has also been recorded (Zaiou 2007)(Reddy, Yedery and Aranha 2004). 
CAPs have been shown to form ion channels through which loss of K+ and other 
cellular components are induced (Reddy, Yedery and Aranha 2004). CAPs also 
possess non-antimicrobial activities, including reduction in inflammation and 
promoting wound healing (Zhang and Falla 2006). Chemokine like activities 
through binding of CAPs with some chemokine receptors have also been recorded 
(Zaiou 2007).  
1.3.4.4 CAP regulation in the human body 
Six  defensins have been identified in humans; human neutrophil proteins 1-4 
(HNP1-4) are predominantly produced by granulocytes and certain leukocytes and 
function as danger signals at concentrations well below those required for their 
antimicrobial action (Kim and Kaufmann 2006). Micromolar concentrations of  
defensins are necessary to disrupt bacterial membranes, inhibit activation of NADPH 
or interact with complement compared to nanomolar concentrations of  defensins 
 necessary for chemotactic, mitogenic and corticostatic activities (Yang et al. 
2000)(Yang et al. 2010). 
The concentration of HNP1-3 in plasma under normal physiological conditions is 
approximately 40 ng ml-1 but can rise to 0.9-170 μg ml-1 during severe infections on 
stimulation of their production (Kim and Kaufmann 2006). Evidence suggests the 
antimicrobial activity of HNP1-3 is effected through binding to specific bacterial 
receptors rather than permeabilising bacterial membranes (Kim and Kaufmann 
2006). HNP1-3 promote wound healing by stimulating cell proliferation and have 
been shown to neutralize toxins secreted by bacterial pathogens including lethal 
factor from Bacillus anthracis (Kim and Kaufmann 2006). HNP1-3 also block the 
fibrinolytic activities of staphylokinase produced by S. aureus by binding to the 
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Lys74 position of staphylokinase used in interaction with human plasminogen (Kim 
and Kaufmann 2006).  
1.3.4.5 Resistance to CAPs 
There are very few naturally peptide-resistant organisms such as Burkholderia, 
Proteus and Serratia species (Hale and Hancock 2007)(Marr, Gooderham and 
Hancock 2006).  The development of resistance to CAPs that are, and have been, 
effective in tackling bacterial infections in humans for 108 years, seems remote 
(Perron, Zasloff and Bell 2005). The huge variety of CAPs in the human body 
together with the obligatory interaction of these peptides with the bacterial 
cytoplasmic membrane plus the multiple CAP targets within cells, challenges 
bacterial machinery on many levels before resistance to CAPs can occur (Perron, 
Zasloff and Bell 2005).  
Some resistance mechanisms have been described (Marr, Gooderham and Hancock 
2006). However the resulting recorded increase in resistance was only two to four-
fold, with no general peptide cross-resistance mechanism in existence whereby 
bacteria are resistant to every single peptide, probably as a result of CAP diversity 
(Marr, Gooderham and Hancock 2006). Certain bacteria such as S. aureus and P. 
aeruginosa have reduced their sensitivy to CAPs through increased incorporation of 
positively charged protein in their membranes, thereby reducing the overall net 
negative charge (Brogden 2005). Bacteria have developed resistance to CAPs by 
production of proteolytic enzymes; for example, cathelecidin LL-37 is cleaved and 
inactivated by a S. aureus metalloproteinase, termed aureolysin (Brogden 2005).  
Active efflux, trapping proteins and modification of host cellular processes are other 
resistance mechanisms elucidated through experimental investigations (Zaiou 
2007). Bader et al in 2005 have raised the possibility that intracellular pathogens 
can tap into the innate immune program of their host and trigger a defence system 
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that gives resistance to CAPs as well as other virulence traits (Bader et al. 2005). 
One of the most significant ways in which pathogens assess host environments is 
through their two-component regulatory systems; Bishop et al in 2005 showed the 
PhoP-PhoQ system of Salmonella is activated by binding to CAPs and in doing so 
gene transcription necessary for Salmonella survival within the human or mouse 
host is promoted (Bishop and Finlay 2006). Perron et al in 2005 documented the 
experimental evolution of resistance to a CAP known as pexiganan, by growing 
bacterial colonies in continuously increasing CAP concentrations for 600/700 
generations under laboratory conditions (Perron, Zasloff and Bell 2005).  
Other experimental work has shown that 30 passages in sub-MIC peptide 
concentrations was necessary to increase resistance in Ps. aeruginosa by two- to 
four-fold i.e. from 8 to 16 µg/ml or 16 to 64 µg/ml (Zhang et al. 2005)(Marr, 
Gooderham and Hancock 2006). Under the same conditions resistance to the 
aminoglycoside antibiotic gentamicin increased by 190-fold or from 0.5 to 90 µg/ml 
(Steinberg et al. 1997)(Marr, Gooderham and Hancock 2006). 
Resistance evolution however is linked to the extent of exposure as has been seen 
with naturally occurring antibiotics such as penicillins and streptomycin, bacterial 
resistance to these antibiotics was low when their widespread clinical use began in 
the 1940‘s, whereas nowadays resistant strains are commonplace (Buckling and 
Brockhurst 2005). The bactericidal nature of CAPs plus their diverse mechanisms of 
action are the reasons quoted by many for a low frequency of resistance to CAPs 
emerging (Zhang and Falla 2006) (Zhang and Falla 2010). Nonetheless, there is 
concern that the therapeutic use of CAPs could lead to the evolution of resistance 
and the subsequent possibility of cross-resistance to human defence peptides 
(Perron, Zasloff and Bell 2005). 
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1.3.4.6 Presence and absence of CAPs in the human body 
Low levels of CAPs are associated with severe pathogenic conditions; people lacking 
-defensins due to a specific granule deficiency syndrome suffer regular and severe 
bacterial infections (Zaiou 2007). Patients suffering from Morbus Kostmann 
condition are afflicted with frequent oral bacterial infections and severe periodontal 
disease due to a deficiency in human cathelicidin peptide LL-37 and human 
neutrophil peptides (HNP 1-3) (Zaiou 2007). Cathelicidins are also involved in 
protecting the gastric mucosa against Helicobacter pylori; down regulation of 
cathelicidin expression in colon epithelium by Shigella allows these cells to 
penetrate the mucosa (Schauber et al. 2006)(Schauber and Gallo 2008).  
The skin scales of people suffering from psoriasis (a common immune mediated, 
chronic skin condition) contain several CAPs, which are credited with protecting the 
inflamed skin from infections as psoriasis sufferers rarely suffer from skin infections 
(Harder 2008)(Zaiou 2007). Some peptides are salt sensitive and under 
physiological conditions lose their antibacterial activity; this has important 
implications for certain patients, in particular cystic fibrosis patients, where 
increased salinity of the broncho-pulmonary fluid is due to the defective chloride 
channel causing the disease. The subsequent impairment of the β-defensin 
bactericidal activity against P. aeruginosa, results in persistent chronic lung 
infections caused by the bacterium in these patients (Marr, Gooderham and 
Hancock 2006).  
Crohn‘s disease and ulcerative colitis are chronic inflammatory bowel diseases; the 
pathology of Crohn‘s disease is due in part to diminished levels of human -
defensins, while ulcerative colitis is considered to be partly due to the inability of 
CAPs to cope with pathogenic bacteria in the intestine (Zaiou 2007). 
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1.3.4.7 Synthetic CAPs 
As previously mentioned synthetic CAPs have been shown to possess equivalent 
spectrums of activity as naturally occurring CAPs. Appelt et al formulated a set of 
non-peptide compounds possessing antimicrobial activity based on 3D structures of 
natural CAPs (Appelt et al. 2007). All of the compounds they formulated exhibited 
antibacterial activity using the carpet model mode of membrane permeabilization 
and the activity of the synthetic non-peptide compounds matched that of the 
original CAPs, prompting them to propose that CAP activity is due to the precise 
arrangement of relevant functional groups and not to the inherent CAP peptidic 
nature (Appelt et al. 2007).  
They further demonstrated experimentally that the peptide backbone acted as 
scaffolding, allowing appropriate orientation of the side chains of the amino acids, 
while a sufficient number of indole rings and guanidinium groups was critical for 
antimicrobial activity (Appelt et al. 2007). 
Activity was also linked to distance between the charged groups and the aromatic 
rings as compounds with pentane chains demonstrated far superior antimicrobial 
activity compared to compounds with ethane linkers (Appelt et al. 2007). 
Fluorinated versions of a potent amphibian CAP – pexiganan - were formulated by 
Marsh et al in 2007 (Ritter 2007). The purpose of this was to enhance the stability 
of CAPs and enhance CAP efficacy as antibiotics for systemic delivery (Ritter 2007). 
The resulting fluorinated CAPs were significantly more stable than the non-
fluorinated versions, when subjected to thermal and chemical denaturation (Ritter 
2007). This experimental work has delivered a huge boost to CAPs and their 
potential uses as systemically deliverable, site-specific human medicines (Ritter 
2007). 
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1.3.4.8 CAP detractions 
Susceptibility to proteases, short half-lives, stability issues, loss of activity under 
physiological conditions, unwanted systemic side effects and high production costs 
are some of the problems associated with development of CAP therapeutics (Zhang 
and Falla 2006)(Zhang and Falla 2010)(Zaiou 2007). CAP limitations include 
cytotoxicity, the higher the antimicrobial activity the more acute the toxicity, as 
exemplified by the gramicidins; while the less toxic CAPs, though potential 
compounds for treating systemic infections, do not possess very high in vitro 
antimicrobial activity compared to conventional antibiotics (Deming  2007). 
1.3.4.9 CAP applications 
The range of biological roles of CAPs also includes endotoxin neutralization, 
chemokine–like activity and immuno-modulatory activities (Zaiou 2007)(Marr, 
Gooderham and Hancock 2006). Several CAPs including cathelicidin LL-37 have 
been shown to bind to and disrupt LPS aggregates and in vitro models have shown 
the ability of CAPs to suppress pro-inflammatory responses triggered by LPS. 
Therefore the development of these compounds could provide an excellent clinical 
tool for the treatment of Gram-negative sepsis (Giuliani, Pirri and Rinaldi 
2010)(Pereira  2006). Initiation of therapy within one hour of diagnosis of septic 
shock in patients is believed to be a critical requirement to promote their survival 
(Ewig 2011). Death from septic shock in US Critical Care Units has been shown to 
exceed 60% with an estimated cost per year of $16.7 billion (Giuliani, Pirri and 
Rinaldi 2010). 
1.3.4.10 Vehicles for the delivery of CAP therapeutics for clinical use 
Several CAP based therapies are currently under development or undergoing clinical 
trials, for example talactoferrin which is in Phase II development as first line 
treatment of advanced non-small cell lung cancer for combined clinical use with 
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chemotherapy (Zhang and Falla 2006). As previously mentioned the main problems 
associated with the development of CAPs as therapeutic agents are, degradation by 
proteases, un-wanted systemic side effects and loss of efficacy under physiological 
conditions (Zhang and Falla 2006)(Zaiou 2007). If used as topically active agents 
however these drawbacks are no longer significant. Not only do CAPs possess 
antimicrobial activity, some CAPs also exhibit anti-inflammatory and wound healing 
activities, making them ideal agents for treating chronic wounds (Zhang et al. 
2005)(Zhang and Falla 2006).  
A novel topical delivery system for the treatment of infected wounds is through 
targeted delivery of antimicrobials into the wound bed via lyophilised wafers. 
Freeze-drying polymer solutions, suspensions or gels produce lyophilised wafers 
(Matthews et al. 2008). Studies have shown that lyophilised wafers act as stable 
and effective vehicles for the delivery of insoluble therapeutic agents to wound beds 
(Matthews et al. 2005). The release rate of the incorporated therapeutic agent is 
dependent on the polymer selected for use and once in use, the rheological 
properties of the gel state (Matthews et al. 2008)(Matthews et al. 2006). Should 
lyophilised wafers prove to be a compatible and effective vehicle for the topical 
delivery of CAPs for the treatment of infected wounds, this could offer a huge 
therapeutic treatment application for CAPs.   
1.4 Project Aims: Investigation of cationic antibacterial agents 
Two antimicrobial agents in current clinical use, namely triclosan and colistin, as 
well as two novel CAPs, NP101 and NP108 were selected for investigation in this 
study. As agreed with Novabiotics, information as regards structure and 
composition of NP101 and NP108 will not be discussed. Triclosan has been shown to 
be active against Gram positive and Gram negative bacteria whilst colistin is 
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reputedly active against Gram negative but not Gran positive bacteria and the 
spectrum of activity of NP101 and NP108 is unknown. Three bacterial species, 
Escherichia coli, Staphylococcus aureus and Pseudomonas aeruginosa were selected 
to assess the antimicrobial activity of each of these agents and to observe effects 
exerted by each antimicrobial agent on actively growing cultures of each bacterial 
species, to elucidate mechanisms of action of each agent. 
Triclosan and colistin have both been attributed as being membrane active agents 
and NP101 and NP108 being CAPs; which as a group are all reported to be 
membrane active; these novel CAPs will be investigated for the exhibition of this 
mechanism of action. Quantification of potassium loss from each bacterial species 
induced by incubation with concentrations ranging from sub to supra MIC of each 
antimicrobial will be undertaken.  
If the novel CAPs display antimicrobial efficacy against Gram positive and negative 
species, the use of lyophilised wafers as a vehicle permitting their use as topical 
antimicrobial agents for the treatment of infected wounds will then be undertaken. 
1.5 Objectives of the present study 
 
The objectives of the present study were as follows: 
i. To quantitatively assess the antibacterial activity of triclosan, colistin and two 
developmental synthetic cationic antimicrobial peptides NP101 and NP108 
against Escherichia coli, Pseudomonas aeruginosa and Staphylococcus aureus 
(Chapter 3). 
ii. To seek to examine the activity of these test antimicrobial agents upon the 
cytoplasmic membrane of the selected bacteria, through quantification of 
potassium loss when exposed to the antimicrobials (Chapter 4). 
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iii. To assess via flow cytometry putative changes in the dynamics of bacterial 
cell viability as well as analysis of population responses when exposed to 
triclosan, colistin, NP101 and NP108 (Chapter 5).  
iv. To examine via scanning electron microscopy effects upon test bacterial 
populations post incubation with triclosan, colistin, NP101 and NP108, 
specifically examining for any induced changes of bacterial morphology 
(Chapter 6).  
v. To evaluate potential of the synthetic CAPs as topical antimicrobials through 
formulation within antimicrobial wafers. (Chapter 7).   
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Chapter Two  
Materials and Methods 
2.1 Chemicals and reagents 
2.1.1 Antibacterial chemicals 
Triclosan was obtained from Ciba Speciality Chemicals (Grenzach-Wyhlen, 
Germany) as Irgasan DP 300. Colistin sulphate was purchased from Sigma 
(Sigma-Aldrich Company Ltd., Poole, UK.) Antimicrobial peptides NP101 and 
NP108 were kindly supplied by NovaBiotics (Novabiotics Ltd., Craibstone, 
Aberdeen, AB21 9TR, Scotland.). 
2.1.2 Growth media and bacterial diluents 
Nutrient broth and agar were supplied by Oxoid Ltd. (Basingstoke, UK.) and all 
media was autoclaved at 121oC for 15 minutes by moist heat sterilisation. Agarose 
was purchased from Fisher Scientific UK Ltd. (Loughborough, UK.) and was 
autoclaved at 121oC for 15 minutes by moist heat sterilisation. General-purpose 
grade NaCl 0.9% was obtained in crystalline form from Fisher Scientific UK Ltd. 
(Loughborough, UK.). Phosphate buffered saline (PBS) tablets were purchased 
from Sigma. 
2.1.3 Miscellaneous chemical compounds 
Potassium dihydrogen orthophosphate SLR and glutaraldehyde were purchased 
from Fisons Scientific Apparatus (Loughborough, Leics, England). Sodium carbonate 
in crystalline form was obtained from British Drug House (BDH), (Poole, UK.). 
Acetone (technical grade reagent), formaldehyde, sodium dodecyl sulphate, 
chlorhexidine digluconate 20% and propidium iodide dye were obtained from Fisher 
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Scientific UK Ltd. Isopropanol (99+%), dimethyl sulphoxide (DMSO), guar gum and 
sodium phosphate were obtained from Sigma-Aldrich Company Ltd. Ethanol was 
purchased from Hayman Ltd. (Witham, UK.).   Polyanetholesulfonic acid sodium salt 
(PASA) was kindly supplied by Novabiotics.  
2.1.4 Fluorescent dyes 
The LIVE/DEAD BacLight™ Kit and sytox green 5 mM dye were purchased from 
Molecular Probes ((Invitrogen Ltd., Paisley, UK.).           
2.1.5 Laboratory equipment 
All plastic sterile disposable equipment was bought from Fisher Scientific. Plastic 
tips and 1.5 ml micro centrifuge tubes were sterilised by autoclaving at 134 oC for 
3¼ minutes as a porous load. All glassware was sterilised at 160 oC for 2 hours by 
dry heat sterilisation.   
2.2 Bacterial storage and sub-culture 
2.2.1 Bacterial strains 
Pseudomonas aeruginosa NCTC 6750, Escherichia coli NCTC 4174 and 
Staphylococcus aureus NCTC 6571 were obtained from the National Collection of 
Type Cultures (NCTC, Porton Down, Salisbury, UK.).  
2.2.2 Bacterial storage 
Bacteria were stored in Protect Bacterial Preservers (Technical Service Consultants 
Ltd., Lancashire, UK.) at –80 oC (Upright freezer TS80-140; Life Sciences 
International, Colchester, UK.). 
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2.2.3 Bacterial sub-culture 
Organisms were sub-cultured by inoculating single beads from the appropriate 
Protect Bacterial Preserver into 10 ml aliquots of nutrient broth and incubating 
statically for 18 to 24 hours at 37 oC (Mark II proportional temperature controller; 
LEEC Ltd., Nottingham, UK.). Master plates were prepared by streaking a loopful of 
this overnight culture onto plates containing 20 ml of nutrient agar and incubating 
these statically for 18 to 24 hours at 37 oC. These master plates were stored at 4 oC 
(Hotpoint ‗Iced Diamond‘ refrigerator; Indesit Company, Ancona, Italy.) and used 
to inoculate fresh plates each week for a maximum of four weeks. After this time 
the master plates were discarded and fresh Protect Bacterial Preserver Beads were 
taken from the freezer. 
Bacterial stock cultures were sub-cultured weekly by streaking out onto nutrient 
agar and incubated at 37 oC for 24 hours in a static incubator, these stock plates 
stored at 4 oC until discarded. A single colony from this plate was used to prepare 
broth cultures daily. These were prepared by aseptically transferring the bacterial 
colony into a 250 ml Erlenmeyer conical flask containing 100 ml of sterile nutrient 
broth. Flasks were incubated at 37 oC for 24 hours in an orbital incubator set at 100 
rpm (1OX400.XX2.C; Sanyo Gallenkamp PLC, Loughborough, UK.).  
2.3 Preparation of bacterial enumeration graphs  
Graphs of optical density versus concentration of bacterial cells (colony forming unit 
per ml (cfu/ml)) were prepared by the following viable count dilution method. 
2.3.1 Bacterial suspension preparation 
One hundred ml of a 24-hour culture grown in nutrient broth was centrifuged at 
4000 rpm for 10 minutes using an MSE Chilspin (Fisons, Loughborough, UK.). The 
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supernatant was carefully decanted and the pellet re-suspended in 5 ml of 0.9% 
(w/v) sodium chloride and re-centrifuged as previously described. The pellet was 
re-suspended in 5 ml of 0.9% (w/v) sodium chloride, from which cell concentrations 
were prepared by dilution, to yield seven suspensions ranging in absorbency from 
0.1 to 0.2 at 500 nm, as determined by a Helios E spectrophotometer (Thermo 
Spectronic Corporation, Madison, US.). 
2.3.2 Agar plate preparation 
Fourteen nutrient agar plates (90 mm diameter with triple vents) were over dried 
by placing them upright with open lids in a sterile cabinet at room temperature 
(Horizontal Laminar Flow Cabinet 5HLF B/U; Hepaire Manufacturing Ltd., Avon, 
UK.) for one hour. The base of each plate was divided into four quadrants labelled 
for dilutions 1x10-5 down to 1x10-8.  
2.3.3 Dilution of bacterial suspensions and plating out 
Each of the seven suspensions prepared in Section 2.3.1 was diluted ten-fold in a 
step-wise manner in 0.9% (w/v) sodium chloride down to 1x10-8. Five aliquots of 
20 l were carefully pipetted onto each quadrant of a pre-dried agar plate, using 
dilutions 10-5, 10-6, 10-7 and 10-8 from each suspension. Duplicate agar plates were 
prepared for each suspension; the inoculated plates were inverted and statically 
incubated for 24 hours at 37 oC.  
2.3.4 Determination of viable counts 
All agar plates were examined post incubation and the level of bacterial growth was 
quantified by identifying the dilution yielding between 40-120 colonies. The colonies 
in all ten spots (from duplicate plates) were counted and a mean value calculated. 
The concentration of cells in the original culture (measured in cfu/ml) was then 
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calculated. A graph was plotted once the original cell density values were 
determined for all seven suspensions. Graphs were plotted for each bacterial strain 
and were used for all subsequent enumeration. 
2.3.5 Determination of bacterial growth under oxygentated and 
non-oxygenated conditions 
Four 250 ml Erlenmeyer conical flasks each containing 100 ml of 1x106 cfu/ml test 
bacterial culture were prepared. Two of these flasks were incubated in a shaking 
water bath (DMS360, Fisher Scientific) at 37 oC and 150 revolutions per minute. 
The remaining two flasks were placed in an identical non-agitating water bath at 37 
oC. One ml samples were obtained from each flask at 15-minute intervals over a 
nine-hour period and again at 24 hours. Each sample was pipetted into a sterile 
semi-micro cuvette and the absorbance at 650 nm read and recorded. Graphs of 
optical density versus time were then plotted for bacterial growth under each 
condition. 
2.3.6 Preparation of agarose plates 
2.3.6.1 Agarose pour plates 
Antimicrobial peptides are known to interact and bind with polysaccharide in agar 
(personal communication Dr Derry Mercer 2010), which necessitated the 
identification of a suitable inert, but translucent solidifying agent to act as both a 
growth medium and a base for the determination of zones of growth inhibition 
produced by the peptide containing wafers. Literature sources identified agarose gel 
as a suitable base, so a 1.5% solution was prepared using sterile water and 
autoclaved. The sterile Petri dish was initially seeded with the bacterial culture to 
yield a final cell density of 1x106 cfu/ml (approximately 30 l of overnight culture) 
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to which was added 20 ml of a molten sterile suspension of agarose. The plates 
were allowed to set by placing them upright with partially open lids in a laminar 
airflow cabinet. The 2 cm diameter antimicrobial impregnated wafer to be tested 
was placed in the centre of the solidified agarose plate and this incubated at 37 oC 
for 24 hours. After incubation the plates were removed and the diameter of 
resulting zones of growth inhibition measured. 
2.3.6.2 Agarose spread plates 
A 1.5% solution was prepared using sterile water and autoclaved. Approximately 20 
ml of agar was poured into each petri dish and allowed to set with partially open 
lids in a laminar airflow cabinet. A final cell density of 1x106 cfu/ml (approximately 
30 l of overnight culture) of test bacterial culture was spread using a sterile glass 
spreader over the surface of the agarose plate. The 2 cm diameter antimicrobial 
impregnated wafer to be tested was placed in the centre of the spread agarose 
plate and this incubated at 37 oC for 24 hours. After incubation the plates were 
removed and the diameter of resulting zones of growth inhibition measured. 
2.3.6.3 Determination of zones of inhibition 
The initial diameter (D0) of a circular control or antimicrobial wafer was measured 
by digital vernier callipers (Mitutoyo, Scottish Enterprise Technology Park, East 
Kilbride, Glasgow, Scotland), prior to placement of the wafer on the centre of a 
seeded or spread agarose plate. The plates were then incubated at 37 oC for 24 
hours. The diameter of inhibition of the antimicrobial wafer was measured using a 
rigid steel engineering ruler (Mitutoyo) from one edge of the circular zone of 
inhibition to the other. The zone of inhibition was calculated by taking the average 
of two measurements of the diameter of the inhibition zone, measured at a 90o 
angle to each other. The mean diameter of the inhibition zone is termed Di. The 
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final swollen diameter of each wafer (Dt) was also measured after incubation using 
the steel ruler. Wafer expansion was calculated as the ratio of Dt/Do. The 
antimicrobial activity of NP101 or NP108 was determined as an inhibition ratio (IR) 
of Di/Do. 
2.4 Dissolution of antibacterials  
2.4.1 Triclosan 
A 5 mM triclosan stock solution was prepared in 0.1 M sodium carbonate. Triclosan 
was weighed in a glass weighing boat on a 4 place digital balance (Metter AE 50; 
Vitrium Ltd., Aberdeen, Scotland) and transferred to a 100 ml volumetric flask. 0.1 
M Sodium carbonate was added, and the flask placed in an ultrasonic water bath 
(FS Minor, Decon Laboratories Ltd., Hove, UK.) for 10 minutes to aid dissolution. 
The triclosan stock solution was stored at 4 oC for up to 5 days. All subsequent 
dilutions of the 5 mM triclosan stock solution were prepared using 0.1 M sodium 
carbonate. 
DMSO 
An iso-osmotic concentration of DMSO was prepared by diluting 100% DMSO to a 
concentration of 1.96% (v/v) in sterile de-ionised water. Triclosan powder was 
weighed as described above, added to a volumetric flask and made up to volume 
using the iso-osmotic DMSO solution. The flask was placed in an ultrasonic water 
bath for 10 minutes to aid dissolution. The triclosan stock solution in DMSO was 
stored at 4 oC for up to 5 days. 
2.4.2 Colistin and CAPs 
Colistin and CAPs were weighed in a similar manner to triclosan, transferred to 
volumetric flasks and made up to required volume with sterile distilled water. Each 
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flask was placed in an ultrasonic water bath for 5 to 10 minutes to ensure total 
antibacterial dissolution. The colistin and CAPs stock solutions were stored at 4 oC 
for up to 5 days. 
2.5 Determination of antimicrobial sensitivity 
Minimum inhibitory concentrations (MICs) were determined using both macro and 
micro broth dilution techniques.  
2.5.1 Preparation of micro-titre plates 
The Versamax Microplate Reader (Molecular Devices Ltd., Wokingham, Berkshire, 
UK.) was optimised to read in a non-agitating mode every 30 minutes for 24-hours 
duration, at a wavelength of 650 nm. To avoid inaccurate results (due to formation 
of condensation on the plate seal) only the first eight columns of the micro-titre 
plate (96 well, gamma-irradiated; Bibby Sterilin Ltd., Stone, UK.) were utilised. A 
final volume of 200 μl was transferred into each well by multi-channel pipette 
(Transferpette-8; Brandtech Scientific Inc., Wertheim, Germany). Two hundred μl 
volumes of test agent were pipetted into each well of the first row of test rows C, D, 
E and F and negative control H. 100 l aliquots of sterile distilled water were 
pipetted into each well of columns 2 to 8 of these rows. Transferring 100 l 
volumes of solution from each well in column 1 to column 2 using a multi-channel 
pipette then performed a two-fold serial dilution. This process was repeated until 
column 8 where 100 l volumes of solution were aspirated from the five wells and 
discarded. 100 l of sterile double strength nutrient broth was then added to each 
well in row H. The test bacterial strain was sub-cultured, harvested and washed as 
described in Section 2.3.1. The bacterial concentration was adjusted to 2x108 
cfu/ml using the previously prepared enumeration graph. Immediately prior to 
inoculation the bacterial cell density was adjusted to 2x106 cfu/ml by pipetting 0.2 
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ml of the 2x108 cfu/ml bacterial suspension into 19.8 ml of 200/99 strength 
nutrient broth. All wells in columns 1 to 8 of test rows C, D, E, and F and row A 
(positive control) were then inoculated with 100 l of this ~ 2 x 106 cfu/ml bacterial 
suspension using a multichannel pipette. A Gilson pipette (Anachem Ltd. Luton, 
UK.), was used to pipette 100 μl of sterile distilled water into each well of row A. 
The micro-titre plate was then sealed with an optically clear and gas-impermeable 
seal obtained from Fisher Scientific and incubated as described above.  
2.5.2 Determination of minimum bactericidal concentration of 
test antibacterial 
Once incubation of the micro-titre plate was completed, the gas tight seal was 
carefully removed and a 96-pin multi point replicator (140500 Boekel Scientific, 
Feasterville PA, US.) was used to check the bactericidal/bacteriostatic effect of 
varying concentrations of test antibacterial. One μl was transferred on the replicator 
pin tip from each micro-titre well and placed on the surface of a large 13.5 mm 
diameter nutrient agar plate, which was then inverted and incubated at 37 oC for 24 
hours. After incubation the plate was checked for bacterial growth, confirming the 
effect of each concentration of test antibacterial employed. 
2.6 Sensitisation/de-sensitisation of antibacterial 
2.6.1 Sensitisation of E. coli to triclosan 
The minimum inhibitory concentration (MIC) of E. coli NCTC 4174 1x106 cfu/ml 
against Triclosan was determined by macro and micro-broth assay. An Erlenmeyer 
flask containing a 1x106 cfu/ml E. coli culture in nutrient broth was incubated in the 
presence of the MIC of Triclosan for 24 hours in an orbital incubator.  Macro and 
micro broth MIC assays of this culture against Triclosan were performed and the 
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culture was re-incubated for a further 72 hours (96 hours in total), with MICs 
repeated every 24 hours.  
2.6.2 De-sensitisation of E. coli to triclosan 
A 1x106 cfu/ml E. coli culture in nutrient broth incubated (at 37 oC and 100 rpm) 
with the MIC of Triclosan for 24 hours was examined for de-sensitisation to the 
agent in the following way. 5 ml of the overnight suspension was aseptically 
transferred into 95 ml of fresh nutrient broth lacking triclosan in a 250 ml 
Erlenmeyer flask and incubated for 24 hours in an orbital incubator set at 100 rpm. 
A macro broth MIC assay was then performed on this culture. This E. coli strain was 
further de-sensitised to Triclosan by aseptically transferring 5 ml of this 24 hour de-
sensitised suspension, into 95 ml of fresh nutrient broth and re-incubated for a 
further 24 hours.  The previous step was repeated for a total of 5 x 24 hours de-
sensitisation growth cycles and the MIC checked after every desensitisation cycle.  
2.7 Assessment of loss of intracellular potassium 
2.7.1 Calibration of the atomic emission spectrophotemeter 
Assessment of internal potassium content of bacterial cells was undertaken on a 
flame atomic absorption spectrophotometer (Model AA3110, Perkin Elmer Las UK, 
Beaconsfield, UK.).  The instrument mode was set for standard flame emission for 
detection of potassium at 766.5 nm, slit at 0.2/0.4 nm, powered by air/acetylene 
gas mixture (B.O.C., Worsley, Manchester, UK.). A stock solution containing 1000 
g/cm3 potassium was prepared by diluting 1.907 g of potassium in 1000 ml of 
ultra pure deionised water. Five standards were prepared from this stock solution 
containing 1.0, 2.0, 3.0, 4.0, and 5.0 g/cm3 potassium, in polypropylene bottles 
(Azlon; Fisher Scientific). The five standards were used to calibrate the flame 
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photometer and the supernatant samples were processed once a correlation co-
efficient of 0.998 was obtained. A one in ten dilution was performed on all samples 
reading 5.0 g/cm3 or higher in ultra pure de-ionised water. Graphs of percentage 
potassium loss versus time were then plotted. 
2.7.2 Quantification of total intracellular bacterial potassium 
One ml of overnight bacterial suspension was pipetted into each of four sterile 1.5 
ml micro centrifuge tubes, inserted into a micro- centrifuge (Technico Maxi, Fisher 
Scientific) and spun at 14,000 rpm for 10 minutes. The supernatant was aspirated 
and the bacterial pellets re-suspended in sterile ultra pure de-ionised water and 
used to prepare 2 x 5 ml each of 1x106 and 1x107 cfu/ml cultures from previously 
prepared bacterial enumeration graphs, using sterile plastic centrifuge tubes. A one 
ml sample acting as control was removed from the centrifuge tube before 
sonication and plated out after serial dilution in normal saline to confirm bacterial 
density. The sonicator, a Misonix XL 2010 Ultrasonic Liquid Processor (Heat 
Systems, Farmingdale, NY, US.) was used at setting 10 to deliver 4 x 30 second 
sonication pulses to each test sample, paused after each 30 second sonication pulse 
to place the centrifuge tube on ice, both to cool the culture heated during 
sonication and to assist in rupturing the cells. One ml of the sonicated sample was 
pipetted into each of six sterile 1.5 ml micro centrifuge tubes and these were 
analysed for potassium content using a flame photometer. A duplicate check on 
bacterial viability was performed by serial dilution of one ml of each sonicated 
culture in 0.9 % sodium chloride, of which the 1x101, 1x102, 1x103, and 1x104 
dilutions were plated out on agar, incubated at 37 oC for 24 hours and then 
examined for bacterial colonies.  
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2.7.3 Assessment of potassium content of bacterial samples 
The test bacterial strain was sub-cultured, harvested and washed as described in 
Section 2.3.1. with final re-suspension of the bacterial pellet in sterile ultra pure de-
ionised water. The bacterial concentration was adjusted to 1x106 cfu/ml in de-
ionised water using the previously prepared enumeration graph. A control flask was 
prepared for each test antibacterial concentration analysed. All potassium detection 
triclosan experiments employed DMSO as solvent and an equivalent concentration 
of DMSO was added to each control flask for every triclosan concentration analysed. 
Concentrations of test antibacterials analysed were 1/20th MIC, MIC and either 
2xMIC or 10xMIC, at a bacterial concentration of 1x106 cfu/ml. All control and test 
cultures were prepared using high purity de-ionised water, in sterile 
polymethylpentene thermoplastic conical flasks (Nalgene; Fisher Scientific UK.), as 
potassium is known to adsorb to glass. The flasks were incubated in a shaking 
water bath (DMS360, Fisher Scientific) at 37 oC and 150 revolutions per minute. 
One ml samples were withdrawn at timed intervals, pipetted into sterile 1.5 ml 
sterile micro centrifuge tubes and centrifuged at 14,000 rpm for 60 seconds. The 
1.5 ml sterile micro centrifuge tubes were carefully removed without disturbing the 
contents and 800 μl of supernatant aspirated and pipetted into sterile 1.5 ml sterile 
micro centrifuge tubes. Potassium content of the samples was then analysed via 
flame emission photometry.  
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2.8 Analysis of bacterial growth dynamics via flow cytometry 
2.8.1 Calibration of flow cytometer 
Prior to each experiment, the laser alignment was checked using Flow Check™ 
Fluorospheres and the test samples were processed once the half peak co-efficient 
variation (HPCV) was ≤ 2% on FL1, FL2, FL3 and FL4.  
2.8.2 Preparation of bacterial samples for analysis 
Flow cytometric analysis was undertaken using an Epics©XL MCL flow cytometer 
(Beckman Coulter United Kingdom Ltd., High Wycombe, Buckinghamshire, UK.). 
Sheath fluid, Flow Check™ Fluorospheres and all plastic disposable equipment was 
purchased from Beckman Coulter. Concentrations of test antibacterials analysed 
were 1/20th MIC, MIC and either 2xMIC or 10xMIC, at a bacterial concentration of 
1x106 cfu/ml and all flasks were incubated at 37 oC in an orbital incubator. A control 
flask was prepared for each test antibacterial concentration analysed. The 
absorbance of the overnight culture was determined in a spectrophotometer 
blanked with nutrient broth at 500 nm and the cell density was calculated using the 
appropriate calibration curve. All cultures to be analysed were prepared in nutrient 
broth and incubated in an orbital incubator at 37 oC for 7 days. Samples were 
withdrawn at 24, 72 and 168 hours and prepared for analysis by flow cytometer 
using the LIVE/DEAD BacLight™ Bacterial Viability and Counting Kit as per 
manufacturer‘s instructions. A live and dead control were prepared by centrifuging 
two 1ml samples of test overnight bacterial culture at 10,000 rpm for 3 minutes to 
pellet the cells; the supernatant was aspirated and one pellet was re-suspended in 
1ml of 0.85% NaCl (live control), while the second pellet was re-suspended in 1 ml 
of 70% isopropyl alcohol (dead control). Both controls were incubated at room 
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temperature for 45 minutes and vigorously mixed every 15 minutes. The controls 
were centrifuged at 10,000 rpm for 3 minutes, then both controls were washed in 1 
ml of 0.85% NaCl at 10,000rpm for 3 minutes and both controls were re-suspended 
in 1 ml of 0.85% NaCl. Each test bacterial culture whether control or bacteria 
incubated with either 1/20th MIC, MIC or 2/10xMIC of test antimicrobial were 
prepared for flow cytometry analysis as follows; 987 µl of 0.85% NaCl was pipetted 
into a sterile labelled micro-centrifuge tube, 1.5 µl of SYTO 9 and 1.5 µl of 
propidium iodide was pipetted into the micro-centrifuge tube and 10 µl of the 
required bacterial suspension was then added to the micro-centrifuge tube and 
incubated for 15 minutes at room temperature whilst protected from light, before 
being run on the flow cytometer. The bacterial sample to be analysed wass pipetted 
into a flow cytometer polystyrene tube and sufficient 0.9% NaCl is added to bring 
the sample volume to a minimum of 100 µl. A detection time of 300 seconds per 
sample was set in which to enumerate bacteria whilst a detection limit of 10,000 
bacteria per sample was also invoked. Each flow cytometer tube was gently 
inverted prior to immediate analysis by the flow cytometer. Once the sample results 
had been obtained, overlay histograms of control, 1/20th MIC, MIC and 2 or 10xMIC 
were prepared using Beckman Coulter software.  
2.8.3 Assessment of rejuvenation of bacterial cultures on de-
sensitisation to antimicrobial peptides 
After incubation of test bacteria with MIC or 2xMIC NP101 or NP108 for seven days, 
5 ml suspension was aspirated from each control, MIC or 2xMIC flask and pipetted 
into 95 ml of fresh nutrient broth, which was then incubated for 24 hours. Samples 
were prepared for flow cytometric analysis as described in 2.8.1, to check for 
changes in bacterial growth dynamics once the antimicrobial peptide challenge had 
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been removed. These flasks were re-incubated at 37 oC for a total of 168 hours, 
with flow cytometry analysis every 24 hours. 
2.9 Examination of bacterial morphology via Scanning Electron 
Microscopy (S.E.M.) 
Bacterial cultures incubated for less than 24 hours employed 1x107 cfu/ml 
concentration for SEM analysis. Bacterial cultures incubated between 24 and 168 
hours employed a 1x106 cfu/ml concentration. Cells were concentrated from an 
initial 10 ml sample volume to 2.5 ml final volume by a three-step centrifugation 
(each centrifugation step run at 10,000 rpm x 10 minutes) and re-suspension 
process using 0.1 M phosphate buffer. Cells were trapped on a sterile 0.2 μm 
Whatman nylon membrane filter (Camlab, Cambridge, UK.) contained within an 
autoclaved Swinnex re-usable filter holder (Merck Millipore, Darmstadt, Germany). 
Bacteria trapped on the membrane filter were fixed using 5% v/v glutaraldehyde in 
0.1 M phosphate buffer (pH 7.4), which was left in contact with the monolayer for a 
minimum of 3 hours. The filter was then sequentially dehydrated for 20-minute 
intervals in 70, 80% (v/v in absolute alcohol) and 100% acetone. Filters were 
subsequently critically point dried in a Polaron critical point drier B7010 (Agar 
Scientific Ltd., Stansted, Essex, UK.), using acetone and CO2, (B.O.C., Worsley, 
Manchester, UK.). The filters were mounted on aluminium stubs and sputter coated 
with a fine metal coating of gold (Gold Sputter Coater, aluminium stubs and gold 
metal coating – Polaron SC7640, Quorum Technologies Ltd., Ashford, Kent, UK.). 
Samples were analysed using a variable pressure scanning electron microscope 
(Leo S430 Scanning Electron Microscope, Carl Zeiss SMT Ltd., Cambridge, UK.).   
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2.10 Preparation of freeze dried antimicrobial wafers 
2.10.1 Preparation of gels 
Three gel batches were prepared using 2% guar gum (Sigma Aldrich) in distilled 
water; control, NP101 1.0 mg/ml (2xMIC) and NP108 0.5 mg/ml (2xMIC). The gels 
were mixed by propeller mixer (Heidolph RZR 2102, Cole-Parmer Instrument Co. 
Ltd, Hanwell, London, UK.), with the mixer speed initially set at 630 rpm and 
gradually increased to maximum speed of 2,000 rpm over 15 minutes, until a 
homogenous gel was formed.  
2.10.2 Freeze drying process 
Each gel was cast in a 12 well polystyrene plate (Costar, Sigma Aldrich) used as a 
mould for the freeze-drying process. Each well of diameter 2 cm contained 1.5 g ± 
0.02 g of gel. Twenty-four wafers were prepared from each gel, control - containing 
only distilled water; NP101 wafers containing 14.71 mg of peptide per wafer and 
NP108 wafers containing 7.36 mg of peptide per wafer. The plates were then placed 
in a VirTis adVantage freeze drier (Biopharma Process Systems, Winchester, 
Hampshire, UK.) until the freeze drying cycle was completed after 24 hours. When 
the plates were removed these were sealed with parafilm (Fisher Scientific) and 
stored under cool, dry conditions. 
2.10.3 Rheological analysis of gels 
Analysis of guar gum flow and deformation was investigated by rheological 
measurements. Three samples of guar gum control, guar gum with NP101 and guar 
gum with NP108 were characterised by continuous flow rheometry at 25 oC. A cone 
and plate geometry was used (40 mm/ 2o steel) and flow measurements were 
performed at continuous shear rates from 0 to 600 s-1 using a dynamic rheometer 
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(TA Instrument AR 1000, Nickel Electro Ltd. Weston-S-Mare, Somerset, UK.) The 
descending flow curves were analysed with the system software using the Herschel-
Bulkley model given below; 
 
σ = η’γn + σo 
 
where σ = shear stress (Pa), η‘ = viscosity coefficient (Pa.s), γ = shear rate (s-1), n 
= rate index of pseudoplasticity, σo = yield stress (Pa). 
2.11 Statistical analysis 
All statistical analysis was carried out using Minitab® 14 software (Minitab Inc., 
Philadelphia, PA, USA) and GraphPad Software (GraphPad Software, Inc., Inc., 
California, USA). Assumptions of normality and equal variances were confirmed 
using the Minitab and GraphPad software. Analyses of variance – ANOVA – were 
performed at 95% confidence interval. Levels of statistical significance were 
annotated on graphs and legends as follows: p-value < 0.05 *; p-value <0.01 **; 
p-value <0.001 *** or alternatively p-value < 0.05 #; p-value <0.01##; p-value 
<0.001###.  
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Chapter Three 
Determination of antibacterial activity of cationic 
antimicrobial compounds 
3.1 Introduction 
The potency of each test agent was assessed by determination of both the 
minimum inhibitory concentration (MIC) and minimum bactericidal concentrations 
(MBCs) against E. coli, S. aureus and P. aeruginosa. The MIC of an antibacterial 
compound is the minimum concentration at which the compound inhibits growth of 
the test bacterium. MIC values can be determined using the broth macrodilution 
assay, the broth microdilution assay or the agar dilution assay (Clinical and 
Laboratory Standards Institute (CLSI) 2006). Broth macrodilution and microdilution 
assays were performed for triclosan and colistin. Broth microdilution assays only, 
were performed for CAPs, to conserve stock supplies, as minimal quantities of test 
agents were required to generate data using this assay. The growth of test bacteria 
under oxygenated (via agitating water bath), non-oxygenated (via non-agitating 
water bath) and micro-titre plate reader (static) conditions was first examined, to 
determine whether equivalent bacterial growth was obtainable under each of these 
test conditions.  
The MBC of an antibacterial compound is the minimum concentration at which the 
compound prevented growth of the test bacterium. MBCs were determined using 
broth microdilution assays. MBCs and MICs are rarely identical; the MBC of an 
antimicrobial compound is always higher than the MIC, sometimes by several 
multiples. These experiments were undertaken to quantitatively assess the 
antibacterial activity of triclosan, colistin, NP101 and NP108 against Escherichia coli, 
Pseudomonas aeruginosa and Staphylococcus aureus.  
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3.2 Methodologies 
3.2.1 Evaluation of bacterial growth under oxygenated and 
non-oxygenated conditions 
Examination of bacterial growth under oxygenated/non-oxygenated conditions was 
performed as described in Section 2.3.4. Assays were performed in triplicate to 
verify reproducibility of results. 
3.2.2 Quantification of the antibacterial activity of test agents 
by broth macrodilution method 
Macro broth assays were performed according to the guidelines detailed by The 
Clinical and Laboratory Standards Institute (CLSI) 2006. Assays were performed in 
triplicate to verify reproducibility of results.  
3.2.3 Quantification of the antibacterial activity of test agents 
by the broth microdilution method 
Solutions of cationic antibacterials were prepared daily as described in Section 2.4.1 
and 2.4.2. These solutions were used in the broth microdilution assay (Section 
2.5.1) to establish antibacterial activity against E. coli, S. aureus and P. aeruginosa. 
MICs were determined by examination of microtitre plates over an 18 to 24 hour 
period of incubation at 37 oC and identifying the minimum concentration of test 
agent that inhibited bacterial growth. Assays were performed in triplicate (four 
replicates per assay) for each agent and each bacterial strain to verify the 
reproducibility of the results.  
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3.2.4 Determination of minimum bactericidal concentration of 
test agents 
MBCs were determined as outlined in Section 2.5.2 as the minimum concentration 
that prevented bacterial growth. Assays were performed in triplicate (four replicates 
per assay) for each agent and each bacterial strain to verify reproducibility of 
results.  
3.2.5 Determination of MICs of E. coli sensitised/de-sensitised 
to triclosan 
MICs of E. coli sensitised/de-sensitised to triclosan were prepared as indicated in 
Section 2.6.1 and 2.6.2. Assays were performed in triplicate to verify reproducibility 
of results.  
3.3 Results  
3.3.1 Bacterial growth under non-oxygenated, oxygenated and 
micro-titre plate reader conditions 
Growth of E. coli under oxygenated or static non-oxygenated cultures in 100 ml 
Erlenmeyer flasks and static micro-titre plate settings was examined (Figure 3.1)). 
Results were analysed and indicated after 24 hours of growth E. coli yielded an 
optical density of 1.20 at 650 nm under oxygenated conditions: short lag phase, 
onset of steep log phase at 2 hours with stationary phase commencing at 6 hours. 
A shorter lag phase was observed under micro-titre plate reader conditions with 
onset of steep log phase at 3 hours, which increased gradually until stationary 
phase commenced at 21 hours incubation, resulting in E. coli growth of optical 
density 1.2 after 24 hours incubation. 
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S. aureus cultures (Figure 3.2)) also achieved optimum growth under micro-titre 
plate reader conditions where after 24 hours of growth S. aureus yielded an optical 
density of 1.1 at 650 nm under oxygenated conditions; onset of log phase 
commenced at 2 hours with stationary phase observed at 13 hours. A longer lag 
phase was visualised under oxygenated macro broth conditions and a slowly 
increasing log phase yielded S. aureus growth after 24 hours of optical density 1.05 
at 650 nm.  
Growth under static non-oxygenated macro broth conditions for both bacteria 
showed similar lag and onset of log phase but very poor bacterial growth was 
achieved over the 24-hour incubation. Automated analysis of bacterial growth was 
better than manual process due to increased surface area to volume ratio within 
the wells of a microtitre plate compared to ratios of conical flasks. 
 
 
Figure 3.1 Growth of 1x106 cfu/ml E. coli culture. N=3. Standard error of mean (S.E.M.) 
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Figure 3.2 Growth of 1x106 cfu/ml S. aureus culture. N=3. S.E.M. 
 
3.3.2 Quantification of antimicrobial sensitivity 
3.3.2.1 Triclosan 
 
A two-fold difference in MIC values of triclosan against test bacteria (Table 3.1) was 
recorded for macro and micro broth assays. A two-fold difference in values was 
recorded between MIC/MBC results for the 1x106 cfu/ml S. aureus cultures, whereas 
MBC values for 1x108 cfu/ml cultures were 24 times higher than recorded MIC 
values for 1x108 cfu/ml E. coli and 26 times higher than 1x108 cfu/ml MIC values for 
S. aureus.  
E. coli that was sensitised to triclosan (Table 3.2) for 24 hours showed a 32 fold 
increase in macro broth MIC values and 64 fold increase in micro broth MIC value. 
This increase in MIC values by E. coli appeared to be stably retained (Table 3.3), as 
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MIC values recorded during a total of five separate 24-hour de-sensitisation periods 
of cultivation and sub-culture, retained an increased MIC value. 
 
 
 
Assay conditions MIC MBC 
Assay Cell 
Density 
(cfu/ml) 
E. coli 
( g/ml) 
S.  
aureus 
( g/ml) 
P. 
aeruginosa 
( g/ml) 
E. coli 
( g/ml) 
S. 
 aureus 
( g/ml) 
Macro 
broth 
1x106  0.07 0.06 ND ND ND 
Micro 
broth 
1x106  0.14 0.11 
 
360 0.14 0.22 
 
Micro 
broth 
1x108  18.0 
 
14.0 
 
ND 425 360 
Table 3.1 MICs of bacteria incubated with triclosan. N=3. S.E.M. ND = not determined 
 
 
 
Length of exposure of E. coli 
to MIC of triclosan 0.07 μg/ml 
(Hours) 
Macro broth assay Micro broth assay  
Number of 
culture passages 
(Hours) 
Total 
exposure 
time 
(Hours) 
Culture 
Viability 
(cfu/ml) 
 
MIC 
(μg/ml) 
Culture 
Viability 
(cfu/ml) 
 
MIC 
(μg/ml) 
1x24 24 5.83x108 2.26 6.84x108 4.5 
2x24 48 6.31x108 2.26 5.93x108 4.5 
3x24 72 5.76x108 2.26 5.67x108 4.5 
4x24 96 5.70x108 2.26 5.7x108 9.0 
Table 3.2 Macro broth MICs of 1x106 cfu/ml E. coli incubated in nutrient broth with 
triclosan for varying time periods. Viabilities of cultures were checked after every 24 hour 
incubation period. N=3. S.E.M.  
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Number of  
24 hour de-
sensitisation 
cycles  
Total de-
sensitisation time 
of E. coli to 
triclosan (Hours) 
 
Culture Viability 
(cfu/ml) 
 
Macro broth MIC 
( g/ml) 
1x24 
 
24 6.8x108 2.26 
2x24 
 
48 8.29x108 1.13 
3x24 
 
72 7.44x108 1.13 
4x24 
 
96 6.58x108 1.13 
5x24 
 
120 7.72x108 1.13 
Table 3.3 Macro broth MICs of 1x106 cfu/ml E. coli de-sensitised to triclosan for varying 
time periods. Viabilities of cultures were checked after every 24 hour incubation period. 
N=3. S.E.M. 
 
3.3.2.2 Colistin 
Identical MIC and MBC results were recorded for colistin against all three test 
bacteria (Table 3.4). A considerable difference in macro and micro-broth MICs was 
obtained for E. coli, whereas identical MIC values for both assays were determined 
for P. aeruginosa. Of note, the macro broth MIC value for S. aureus against colistin 
was 35 times higher than that obtained for E. coli and 70 times higher than P. 
aeruginosa, a clear indication of why the agent is only used to treat Gram-negative 
species in clinical practice. It should also be pointed out that the lower MIC/MBC 
value recorded for colistin against 1x107 cfu/ml S. aureus culture compared to the 
1x106 cfu/ml culture, was due to refinement of the concentration scale employed. 
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Assay Cell Density 
cfu/ml 
E. coli 
MIC/MBC 
g/ml 
S. aureus 
MIC/MBC 
( g/ml) 
P. 
aeruginosa 
MIC/MBC 
( g/ml) 
Macro broth 1x106 cfu/ml 3 100 1.5 
Micro broth 1x106 cfu/ml 0.28 200 
 
1.5 
Micro broth 1x107 cfu/ml 9.8 
 
156 
 
4.9 
Table 3.4 MIC/MBCs of bacteria incubated with colistin. N=6. S.E.M. 
 
3.2.2.3 CAPs 
Identical MIC and MBC values were recorded for all CAPs against E. coli, S. aureus 
and P. aeruginosa (Table 3.5, Table 3.6 and Table 3.7). As peptides are reputed to 
bind to plastics, MIC/MBC assays were undertaken in polyethylene and 
polycarbonate micro titre plates but no difference in values were recorded. A higher 
MIC/MBC value for NP101 was recorded for E. coli compared to P. aeruginosa and 
S. aureus.  
The reason a lower MIC/MBC value for NP101 against 1x107 cfu/ml E. coli culture 
was recorded compared to the 1x106 cfu/ml culture was due to refinement of the 
concentration scale employed. Identical MIC/MBC values were recorded for NP108 
against 1x106 and 1x107 cfu/ml S. aureus cultures (Table 3.5 and Table 3.7). 
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Bacterial 
species 
CAP  MIC of CAP using 
polyethylene 
microtitre plates 
( g/μl) 
MBC of CAP using 
polyethylene 
microtitre plates 
( g/μl) 
E. coli NP101 0.5 0.5 
E. coli NP108 0.25 0.25 
S. aureus NP101 
 
0.25 0.25 
S. aureus NP108 0.25 0.25 
P. aeruginosa NP101 
 
0.25 0.25 
P. aeruginosa NP108 
 
0.25 0.25 
Table 3.5 MIC and MBCs of 1x106 cfu/ml test bacteria incubated with CAPs in             
polyethylene microtitre plates. N=6. S.E.M. 
 
 
 
 
Bacterial 
species 
CAP  MIC of CAP using 
polycarbonate microtitre 
plates ( g/μl) 
MBC of CAP using 
polycarbonate 
microtitre plates 
( g/μl) 
E. coli NP108 0.25 0.25 
S. aureus NP101 
 
0.25 0.25 
 
Table 3.6 MIC/MBCs of 1x106 cfu/ml test bacteria incubated with CAPs in polycarbonate 
microtitre plates. N=6. S.E.M. 
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Bacterial species CAP  MIC 
 ( g/μl) 
MBC 
 ( g/μl) 
E. coli NP101 0.31 0.31 
E. coli NP108 0.5 0.5 
S. aureus NP101 0.31 0.31 
S. aureus NP108 0.25 0.25 
P. aeruginosa NP101 0.31 0.31 
P. aeruginosa NP108 0.5 0.5 
Table 3.7 MICs and MBCs of 1x107 cfu/ml test bacteria incubated in polyethylene             
microtitre plates with CAPs. N=6. S.E.M. 
 
3.3.3 Bacterial growth in presence of cationic antibacterials 
3.3.3.1 Triclosan 
a) Escherichia coli 
 
Triclosan exerted a concentration dependent retardation in onset of log phase 
bacterial growth coupled with reduction in logarithmic growth on 1x106 E. coli 
culture (Figure 3.3) over a 24-hour experimental period. Onset of log phase in E. 
coli control commenced at 2 hours and bacterial growth of optical density 1.2 was 
attained at 24 hours. The retardation and reduction effects on logarithmic bacterial 
growth of E. coli increased as the concentration of triclosan increased and were 
highest at 0.07 g/ml triclosan where onset of logarithmic growth in E. coli 
commenced at 14 hours and growth of optical density 0.85 was achieved over the 
experimental period. Concentrations greater than the MIC resulted in complete 
inhibition of growth and are not plotted in order to maintain clarity. 
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Figure 3.3 E. coli 1x106 cfu/ml incubated with 0.008-1.12 μg/ml triclosan. MIC = 
0.14 μg/ml triclosan. N=3. S.E.M. 
 
A greater E. coli density of 1x108 cfu/ml exposed to a higher triclosan concentration 
range (Figure 3.4) revealed little retardation of onset of log phase however 
significant reduction of final density of bacterial growth was apparent.  
These dual effects of triclosan were also visualised in a 1x106 cfu/ml E. coli culture 
that had been serially passaged for 2x24-hour cycles in 0.07 μg/ml triclosan (MIC) 
for a total of 48 hours (Figure 3.5) and then incubated with a higher triclosan 
concentration scale. Control bacteria displayed onset of log phase growth at 2 hours 
with a final bacterial density of 1.2, compared to onset of log phase growth at 11 
hours for the serially passaged E. coli incubated with 2.25 μg/ml triclosan and a 
final cell density of 0.5. 
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Figure 3.4 E. coli 1x108 cfu/ml incubated with 1.1-72 μg/ml triclosan. MIC = 18 μg/ml 
triclosan. N=3. S.E.M.    
 
 
Figure 3.5 E. coli 1 x 106 cfu/ml serially passaged in 0.07 µg/ml triclosan for 48 hours. MIC 
= 4.5 μg/ml triclosan. N=3. S.E.M.  
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After 96 hours (four separate 24-hour periods of growth and sub-culture) this 
serially passaged E. coli culture (Figure 3.6) was again re-incubated with a high 
triclosan concentration scale and the delayed onset of log phase growth coupled 
with severe retardation of logarithmic bacterial growth was still visible compared to 
control bacteria, though the MIC value had doubled and E. coli growth was now 
apparent at 4.5 µg/ml triclosan concentration. 
 
 
          
Figure 3.6 E. coli 1x106 cfu/ml serially passaged in 0.07 µg/ml triclosan for 96 hours. MIC  
= 9 μg/ml triclosan. N=3. S.E.M. 
 
b) Staphylococcus aureus 
S. aureus 1x106 cfu/ml bacteria (Figure 3.7)) incubated with triclosan demonstrated 
a concentration dependent inhibition in onset of log phase growth in conjunction 
with slight retardation of this logarithmic bacterial growth, compared to control. The 
dual phase growth demonstrated by the control bacteria was also absent in the 
growth of the triclosan incubated bacteria.  
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Figure 3.7 S. aureus 1x106 cfu/ml incubated with 0.014-1.76 μg/ml triclosan. MIC = 0.11 
μg/ml triclosan. N=3. S.E.M. 
 
Onset of log phase growth in S. aureus control occurred at 2.25 hours and reached 
an optical density of 1.2 over the experimental period whereas onset of logarithmic 
growth in S. aureus incubated with 0.06 g/ml triclosan was at 16 hours with a final 
bacterial density of 0.75 over the same time period. As observed with E. coli 1x108 
cfu/ml cultures incubated with triclosan, little retardation in onset of log phase 
growth was visualised in the growth of 1x108 cfu/ml S. aureus bacteria incubated 
with triclosan (Figure 3.8) but similarly a marked reduction in logarithmic bacterial 
growth over the experimental was observed, compared to control, with the dual 
phase growth pattern of control bacteria absent in the triclosan incubated bacteria. 
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Figure 3.8 S. aureus 1x108 cfu/ml incubated with 0.4-56 μg/ml triclosan. MIC = 14 μg/ml 
triclosan. N=3. S.E.M. 
 
c) Pseudomonas aeruginosa 
P. aeruginosa 1x106 cfu/ml incubated with a substantially higher triclosan range 
(Figure 3.9) also exhibited the dual effects of concentration dependent retardation 
of onset on logarithmic bacterial growth with significant reduction in this bacterial 
growth compared to control. Onset of logarithmic growth in P. aeruginosa control 
bacteria commenced at 4 hours and reached a final density of 1.2 at 24 hours, 
compared to onset of logarithmic growth at 7 hours for P. aeruginosa incubated 
with 180 g/ml triclosan, with a final recorded bacterial density of 0.85 over the 
experimental period. Due to the extremely high tolerance of P. aeruginosa towards 
triclosan, attempts to determine an MIC for 1x108 cfu/ml P. aeruginosa culture 
against triclosan were restricted by the solubility of triclosan. 
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Figure 3.9 P. aeruginosa 1x106 cfu/ml incubated with 11-1445 μg/ml triclosan. MIC = 360 
μg/ml triclosan. N=3. S.E.M. 
       
3.3.3.2 Colistin 
a) Escherichia coli 
 
Growth of E. coli 1x106 cfu/ml (Figure 3.10) incubated with colistin revealed a 
moderate concentration dependent retardation of onset of log phase bacterial 
growth coupled with slight reduction in final bacterial density, compared to control. 
Logarithmic growth of control bacteria commenced at 1.5 hours with a final density 
of 1.2, compared to onset of log phase growth at 3 hours with a final optical density 
of 1.05 for 0.14 µg/ml colistin incubated E.coli. These data show that colistin 
appears to have the equivalent of an all or nothing effect on growth of E. coli at a 
density of 1x106 cfu/ml.  
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Figure 3.10 E. coli 1x106 cfu/ml incubated with 0.02-0.28 μg/ml colistin. MIC/MBC = 0.28 
μg/ml colistin. N=6. S.E.M. 
 
Both retardation of onset of logarithmic growth and minimal reduction in bacterial 
density, were visualised in the growth of the 1x107 cfu/ml E. coli culture (Figure 
3.11). Onset of log phase growth for control bacteria at one hour and final optical 
density of 1.2, compared to onset of log phase growth at 8 hours for bacteria 
incubated with 4.9 µg/ml colistin and an optical density of 1.1 at the end of the 
experimental period. The higher E. coli inoculum employed in this experiment 
demonstrated bacterial density is an important factor in the ability of this bacterium 
to withstand the effects of colistin, as growth was visualised at far higher colistin 
concentrations compared to the 1x106 cfu/ml culture, though the retardation effects 
of colistin on onset of logarithmic bacterial growth were far more severe.  
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Figure 3.11 E. coli 1x107 cfu/ml incubated with 0.3–39 μg/ml colistin. MIC/MBC was 9.8 
μg/ml colistin. N=6. S.E.M. 
 
b) Staphylococcus aureus 
A biphasic growth pattern was displayed by both S. aureus 1x106 cfu/ml control and 
colistin incubated bacteria (Figure 3.12). Reduction in final density achieved, 
coupled with retardation in onset of logarithmic growth was also manifested by S. 
aureus incubated with colistin when compared to control. However the rate of 
growth, once log phase had commenced, was equivalent in all concentrations of 
colistin up to that immediately below the MIC. S. aureus control bacteria 
demonstrated onset of logarithmic phase bacterial growth after incubation for 1 
hour, followed by a further spurt of exponential growth which commenced at 4 
hours, achieving a final density of 1.2 after 24 hours. A simultaneous onset of 
logarithmic bacterial growth for all concentrations of colistin incubated S. aureus 
occurred at 3 - 4 hours. Subsequently, a concentration dependent retardation in 
onset of a second phase of exponential growth occurred at 8 hours for S. aureus 
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incubated with 3 and 6.25 µg/ml colistin and at 13 hours for 100 µg/ml colistin 
incubated S. aureus. Markedly reduced final bacterial densities for all colistin 
incubated bacteria were recorded at 24 hours.  
 
Figure 3.12 S. aureus 1x106 cfu/ml incubated with 3–400 μg/ml colistin. MIC/MBC = 200 
μg/ml colistin. N=6. S.E.M. 
 
Similar biphasic growth patterns for control and colistin incubated bacteria were 
recorded for 1x107 cfu/ml S. aureus (Figure 3.13). The higher S. aureus density 
used in this experiment demonstrated as with E. coli, the greater ability of the 
bacterium to withstand the effects of colistin.  Onset of logarithmic growth for all 
bacteria, other than 78 µg/ml treated cells, commenced at 2 hours with a 
concentration dependent staggered onset of a further phase of exponential bacterial 
growth for control and all colistin incubated bacteria ranging from 5 hours for 
control bacteria. With S. aureus incubated with 78 g/ml colistin growth occurred at 
7-8 hours with the second phase occurring at 11 hours achieving a final bacterial 
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density of 1.1, compared to a final density of 0.9 for S. aureus 1x106 cfu/ml culture 
incubated with 100 µg/ml colistin. Bacterial inoculum density therefore is significant 
in the ability of bacteria to withstand the effects of colistin.  
 
Figure 3.13 S. aureus 1x107 cfu/ml incubated with 2.5-312 μg/ml colistin. MIC/MBC = 156 
μg/ml colistin. N=6. S.E.M. 
 
 
c) Pseudomonas aeruginosa 
As with E. coli and S. aureus, the effects of colistin on P. aeruginosa varied with the 
bacterial density employed. Colistin incubated 1x106 cfu/ml P. aeruginosa culture 
(Figure 3.14) demonstrated a concentration dependent inhibition in onset of log 
phase bacterial growth with final bacterial densities similar to control. 
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Figure 3.14 Ps. aeruginosa 1x106 cfu/ml incubated with 0.09–12 μg/ml colistin. MIC/MBC = 
1.5 μg/ml colistin. N=6. S.E.M. 
 
 
Figure 3.15 Ps. aeruginosa 1x107 cfu/ml incubated with 0.3–39 μg/ml colistin. MIC/MBC = 
4.9 μg/ml colistin. N=6. S.E.M. 
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No reduction or retardation of bacterial growth compared to control was visualised 
in 1x107 cfu/ml P. aeruginosa colistin incubated culture (Figure 3.15) except for 
bacteria incubated with 2.4 µg/ml colistin, which displayed delayed onset of 
logarithmic growth and marked reduction in final bacterial density.  
3.3.3.3 NP101 
a) Escherichia coli 
 
Recorded bacterial growth of E. coli 1x106 cfu/ml cultures incubated with NP101, 
were similar at all time points compared to control (Figure 3.16). The spike in 
measurements observed and visible during the first hour of incubation can be 
attributed to an interaction between the CAP and the nutrient broth which resulted 
in a short term reduction in solubility of the CAP. After approximately 2 hours the 
CAP had solubilised fully along with a reduction in recorded optical density. 
 
Figure 3.16 E. coli 1x106 cfu/ml incubated with 0.008–1.0 mg/ml NP101. MIC/MBC = 0.5 
mg/ml NP101. N=6. S.E.M. 
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The E. coli 1x107 cfu/ml cultures incubated with NP101 (Figure 3.17) also displayed 
very similar bacterial growth compared to control for the 0.08 and 0.16 mg/ml 
cultures. Again, interaction between the CAP and broth gave an initial high reading 
and then dropped to an optical density of 0.15 due to a solubility issue with the 
CAP, and is not indicative of bacterial growth. After 5 hours incubation a steady 
slight increase in optical density of the 0.31 mg/ml CAP culture was noted this is 
most probably due to replication of survivor bacterial cells. While MBC analysis 
confirmed no viable bacteria, slowly growing persister cells are most likely 
responsible for the increasing bacterial density.  
 
Figure 3.17 E. coli 1x107 cfu/ml incubated with 0.08–10.0 mg/ml NP101. MIC/MBC = 0.31 
mg/ml NP101. N=6. S.E.M. 
 
b) Staphylococcus aureus 
S. aureus 1x106 cfu/ml (Figure 3.18) displayed an all or nothing effect when 
incubated with NP101; when bacterial growth occurred in tolerated CAP 
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concentrations, onset of growth and final density was equivalent to that of control. 
No fitness cost to withstand the effects of increasing concentrations of NP101 was 
exhibited by S. aureus. Bacterial growth equivalent to control occurred or no 
bacterial growth was manifested. The inference that can be drawn from this is that 
when the MIC/MBC concentration of NP101 against S. aureus was reached, the 
mechanism of action by which NP101 killed these bacteria was very rapid, allowing 
no registration of bacterial growth. A noticeable absence from the growth of all 
NP101 incubated S. aureus was the biphasic growth pattern displayed by the 
control bacteria. Thus NP101 exerted an effect on S. aureus that altered the normal 
growth pattern of the bacterium.   
 
 
Figure 3.18 S. aureus 1x106 cfu/ml incubated with 0.008–1.0 mg/ml NP101. MIC/MBC = 
0.25 mg/ml NP101. N=6. S.E.M. 
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S. aureus 1x107 cfu/ml CAP incubated bacteria (Figure 3.19) displayed 
concentration dependent dual response of retarded onset of log phase bacterial 
growth and reduction of logarithmic bacterial growth of the 0.06 and 0.18 mg/ml 
NP101 cultures. The initial spike in optical density visible with the 0.031 mg/ml 
NP101 incubated bacteria resulted from a change in solubility of NP101 due to 
interaction with nutrient broth. The difference in the growth pattern of the S. 
aureus 1x107 cfu/ml CAP incubated bacteria compared to the 1x106 cfu/ml S. 
aureus CAP treated bacteria is that bacteria have now exhibited a struggle to 
overcome the effects of NP101 as visualised by a concentration dependent 
retardation in onset of logarithmic growth and reduction in final bacterial density. 
 
Figure 3.19 S. aureus 1x107 cfu/ml incubated with 0.08 – 10.0 mg/ml NP101. MIC/MBC = 
0.31 mg/ml NP101. N=6. S.E.M. 
 
Similarly, with 1x106 cfu/ml S. aureus incubated with NP101, the 1x107 cfu/ml CAP 
incubated bacteria did not display the growth pattern exhibited by the control 
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bacteria. However, the higher bacterial density resulted in a change in response of 
S. aureus to NP101 as witnessed by the bacterial struggle to survive in a higher 
NP101 concentration. A higher bacterial density offered no protection against the 
effects of NP101 and reversion to normal S. aureus growth did not occur.   
c) Pseudomonas aeruginosa 
NP101 sensitised bacterial growth of P. aeruginosa 1x106 cfu/ml culture (Figures 
3.20) was very similar to that of control over the 24-hour period, with equivalent 
final bacterial densities recorded for control and NP101 incubated bacteria. As with 
1x106 cfu/ml S. aureus and E. coli cultures, an all or nothing effect was also seen 
with the 1x106 cfu/ml P. aeruginosa culture incubated with NP101. 
 
Figure 3.20 P. aeruginosa 1x106 cfu/ml incubated with 0.008–1.0 mg/ml NP101. MIC/MBC 
= 0.25 mg/ml NP101. N=6. S.E.M. 
 
 
P. aeruginosa 1x107 cfu/ml (Figure 3.21) exhibited a struggle to withstand a higher 
concentration of NP101, in a similar manner to that displayed by NP101 S. aureus 
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1x107 cfu/ml incubated culture. What was recorded as initial bacterial growth in 
0.16 mg/ml exposed cells was due to the interaction between NP101 and broth, 
and onset of actual bacterial growth commenced at 12 hours with a final bacterial 
density of 0.8, compared to onset of growth in control bacteria at 3 hours with a 
final bacterial density of 1.3. The dual effects of retardation of onset of bacterial 
growth and reduction in logarithmic growth of P. aeruginosa 1x107 cfu/ml incubated 
with 0.16 mg/ml NP101 compared to control were exerted by the CAP. 
 
 
 
Figure 3.21 P. aeruginosa 1x107 cfu/ml incubated with 0.04–5.0 mg/ml NP101. MIC/MBC = 
0.31 mg/ml NP101. N=6. S.E.M. 
 
3.3.3.4 NP108 
a) Escherichia coli 
 
E. coli 1x106 cfu/ml incubated with all tolerated NP108 concentrations (Figure 3.22) 
displayed similar bacterial growth kinetics compared to control at all experimental 
time points. As noted previously with NP101, interaction between NP108 and 
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nutrient broth gave high optical density readings for the first two hours as a result 
of insolubility of the CAP at high concentration.  
 
 
Figure 3.22 E. coli 1x106 cfu/ml incubated with 0.008–1.0 mg/ml NP108. MIC/MBC = 0.25 
mg/ml NP108. N=6. S.E.M. 
 
 
NP108 at 0.25 mg/ml retarded onset of logarithmic bacterial growth of 1x107 cfu/ml 
E. coli culture until 8 hours incubation whereupon bacterial growth began to 
increase exponentially and was equivalent to that of control at 24 hours (Figure 
3.23). However the optical density value did not drop below 0.25 and at some point 
between 5 and 7 hours a crossover occurred where growth rather than insolubility 
was being measured. In contrast to the 1x107 cfu/ml E. coli culture incubated with 
NP101, E. coli incubated with 0.25 mg/ml NP108 displayed marked retardation in 
onset of log phase bacterial growth but achieved a similar bacterial density to 
control at 24 hours. The all or nothing effect previously displayed by E. coli when 
incubated with a CAP was absent. 
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Figure 3.23 E. coli 1x107 cfu/ml incubated with 0.016–2.0 mg/ml NP108. MIC/MBC = 0.5 
mg/ml NP108. N=6. S.E.M. 
 
 
When incubated with 0.5 mg/ml NP108, E. coli displayed a slow rise in optical 
density after 5 hours incubation and a final bacterial density of 0.4 after 24 hours 
incubation. Though checking of bacterial viability through MBC analysis confirmed 
no viable bacteria, this slowing increasing bacterial density was most likely due to 
the presence of slowly growing persister bacterial cells. This was similar to what 
was observed in 1x107 cfu/ml E. coli culture incubated with 0.31 mg/ml NP101 
(Figure 3.17). 
b) Staphylococcus aureus 
At all concentrations below recorded MIC for NP108 the growth of S. aureus 1x106 
and 1x107 cfu/ml peptide-incubated cultures were similar to that of control at all 
time points (Figures 3.24 and 3.25).  
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Figure 3.24 S. aureus 1x106 cfu/ml incubated with 0.008–1.0 mg/ml NP108. MIC/MBC = 
0.25 mg/ml NP108. N=6. SDM. 
 
 
 
Figure 3.25 S. aureus 1x107 cfu/ml incubated with 0.016–2.0 mg/ml NP108. MIC/MBC = 
0.25 mg/ml NP108. N=6. S.E.M. 
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The all or nothing effect previously seen with 1x106 cfu/ml S. aureus incubated with 
NP101 was displayed by both 1x106 and 1x107 cfu/ml S. aureus incubated with 
NP108. Obviously the effects of NP108 exerted upon S. aureus were more tolerable 
and no struggle by the 1x107 S. aureus culture was evidenced. 
c) Pseudomonas aeruginosa 
P. aeruginosa 1x106 cfu/ml incubated with NP108 (Figures 3.26) displayed similar 
bacterial growth to control, except for bacteria incubated with 0.13 mg/ml NP108, 
which exhibited a marginal reduction in final cell density of bacterial growth 
compared to control. The all or nothing effect previously seen with 1x106 cfu/ml P. 
aeruginosa incubated with NP101 was again displayed by 1x106 cfu/ml P. 
aeruginosa incubated with NP108. 
 
Figure 3.26 P. aeruginosa 1x106 cfu/ml incubated with 0.008– 1.0 mg/ml NP108. MIC/MBC 
= 0.25 mg/ml NP108. N=6. S.E.M. 
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Equivalent growth to control was recorded for P. aeruginosa 1x107 cfu/ml cultures 
incubated with all but the highest tolerated concentration of NP108 0.25mg/ml, 
which displayed combined retardation of onset of log phase with reduction in 
logarithmic bacterial growth (Figures 3.27). A similar growth pattern to that 
displayed by 1x107 cfu/ml P. aeruginosa culture incubated with 0.16 mg/ml NP101 
was displayed by the 1x107 cfu/ml P. aeruginosa culture incubated with 0.25 mg/ml 
NP108, that of severely retarded onset of logarithmic growth and reduction in 
logarithmic growth. The presence of a higher bacterial density assisted the bacteria 
in tolerating a higher CAP concentration. 
 
 
Figure 3.27 P. aeruginosa 1x107 cfu/ml incubated with 0.016– 2.0 mg/ml NP108. MIC/MBC 
= 0.5 mg/ml NP108. N=6. S.E.M. 
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3.4 Discussion 
3.4.1 Optimum bacterial growth 
The final OD650 readings of bacterial growth under macro broth oxygenated and 
micro-titre plate conditions were similar at 24 hours. Higher bacterial growth was 
recorded with micro titre incubation due to the ratio of surface area to volume 
being six times higher (0.25) for a micro titre well containing 200 µl of culture 
compared to that of the 250 ml Erlenmeyer conical flask (0.0417) containing 100 
ml of culture. This resulted in greater availability of oxygen to bacteria thus higher 
bacterial growth was recorded within the plate reader. Consequently, this 
automated analysis of bacterial growth was ideal for investigation of the effects of 
the test antimicrobials and strains to quantify activity. 
3.4.2 Triclosan activity 
MICs of triclosan against test bacteria correlated well with those in published 
literature: 128 µg/µl triclosan against P. aeruginosa, 0.09 µg/µl triclosan against E. 
coli and 0.01 µg/µl triclosan against S. aureus. (Chuanchuen, Karkhoff-Schweizer 
and Schweizer 2003)(Aiello et al. 2004)(Gomez- Escalada et al. 2005). De-
sensitisation of E. coli to triclosan appeared to show a retained tolerance to 
triclosan, this is also in agreement with work previously undertaken by Russell at al 
(Russell 2004).  
The effects of triclosan on the bacterial growth of all three test bacteria were 
revealed as concentration dependent retardation of onset of log phase bacterial 
growth and subsequent reduction in logarithmic bacterial growth compared to 
control. Retardation in onset of log phase bacterial growth was greatest in the 
1x106 cfu/ml E. coli and S. aureus incubated cultures (Figures 3.3 and 3.7), but 
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markedly reduced in the growth of the bisphenol incubated with either 1x106 P. 
aeruginosa (Figure 3.9) or 1x108 cfu/ml cultures of E. coli and S. aureus (Figures 
3.4 and 3.8). However, the growth kinetics observed in these experiments 
demonstrated a marked impact upon both growth rate and final cell density 
achieved. These effects exerted on the test bacteria are attributable to the ability of 
triclosan to inhibit fatty acid synthesis and thus reduce bacterial growth (Escalada 
et al. 2005)(McMurray, Oethinger and Levy 1998)(Heath et al. 2000). Work 
published by Escalada et al on E. coli and S. aureus has also shown a concentration 
dependent retardation in onset of bacterial growth together with a non-
concentration dependent reduction in logarithmic bacteria growth (Gomez- Escalada 
et al. 2005). This is not in agreement with the findings in this study where a 
concentration dependent inhibition in logarithmic growth has been shown in the 
1x106 and 1x108 cfu/ml triclosan incubated cultures of E. coli. A concentration 
dependent inhibition in logarithmic growth has also been shown in the 1x106 cfu/ml 
S. aureus culture incubated with triclosan (Figure 3.7). Conversely, S. aureus 1x108 
cfu/ml triclosan culture displayed a non-concentration dependent reduction in 
logarithmic bacterial growth. The concentration dependent reduction in log phase 
bacterial growth was most visible in S. aureus 1x106 cfu/ml culture (Figure 3.5). 
This reduction in logarithmic bacterial growth was much less visible in triclosan 
incubated E. coli cultures, with the exception of bacteria incubated with the highest 
tolerated triclosan concentrations. (Figure 3.3) The final OD650 readings of all 
triclosan incubated cultures of E. coli, S. aureus and P. aeruginosa were 
significantly different from untreated cultures, which is also different to the findings 
of Gomez Escalada and colleagues which were also conducted over a 24 hour period 
(Gomez- Escalada et al. 2005).  
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The growth of P. aeruginosa 1x106 cfu/ml culture, though incubated with a far 
higher range of triclosan concentrations than either E. coli or S. aureus, revealed 
the least retardation in bacterial growth. The non-concentration dependent 
reduction in final bacterial density of triclosan incubated P. aeruginosa compared to 
control was coupled with a concentration dependent reduction in log phase bacterial 
growth. Historically, Ps. aeruginosa has been accepted as resistant to triclosan 
through possession of a single multi-drug RND efflux pump (Chuanchuen, Karkhoff-
Schweizer and Schweizer 2003). However the research presented here has 
revealed triclosan exerted the same effects on this bacterium as have been shown 
for E. coli and S. aureus. Triclosan incubated E. coli and S. aureus 1x108 cfu/ml 
cultures, revealed a much-reduced retardation in logarithmic growth. This suggests 
that at higher bacterial inoculum, bacteria displayed a greater tolerance to the 
biocide.  
E. coli that had been serially passaged in triclosan was investigated after 48 and 96 
hours incubation with the bisphenol and though the MIC had risen dramatically, the 
effects of triclosan on retardation of onset of logarithmic bacterial growth and 
retardation in this growth were still visible. Long-term exposure to triclosan 
therefore does not appear to permit E. coli to develop an ability to completely 
withstand the effects of triclosan but exposure to the bisphenol does permit E. coli 
to develop tolerance to the biocide, which is manifested in higher MIC values. 
The growth pattern of triclosan incubated S. aureus was also different to that 
displayed by control bacteria (Figures 3.7 and 3.8). Un-treated S. aureus displayed 
onset of a second phase of exponential logarithmic bacterial growth a number of 
hours after initiation of logarithmic growth. This bacterial growth pattern was 
absent from the growth of triclosan incubated 1x106 and 1x107 S. aureus. The 
inference that can be drawn from this is that a brake or restraint on S. aureus 
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growth had been removed and total bacterial numbers trebled within one hour. The 
inhibition of this dual phased bacterial growth in S. aureus by triclosan cannot be 
explained by inhibition of fatty acid synthesis, as exponential bacterial growth does 
occur in S. aureus triclosan incubated bacteria, once growth has commenced. Nor 
can it be explained by efflux of triclosan from S. aureus, as this would increase 
tolerance to the bisphenol by the bacterium. Perhaps triclosan interfered with 
quorum sensing in S. aureus, which resulted in the altered growth pattern of 
triclosan-incubated bacteria compared to control. Bacteria communicate for two 
purposes, to assist in conjugation and in adaptation to the environment (Lyon and 
Novick 2004). Gram-positive bacteria employ small peptides for both signalling 
purposes whereas Gram-negative bacteria employ homoserine lactones (Lyon and 
Novick 2004). The ability of bacteria to communicate with each other has resulted 
in the evolution of structured colonies which mutually co-operate to promote 
increased adaptation to environmental conditions (Ben Jacob et al. 2004). 
Synthesis changes in enzymes such as proteases and lipases involved with the 
spread and nutrition of S. aureus have been shown to occur in response to 
activation of the two-component agr system, which is activated by quorum sensing 
(Lyon and Novick 2004). Normal communication between un-treated S. aureus 
could be responsible for this dual phased logarithmic growth through stimulation of 
increased enzyme synthesis which resulted in the observed growth pattern of S. 
aureus control cells.  
3.4.3 Colistin activity 
Currently, colistin is used clinically as a last resort option in the treatment of multi 
drug resistant Ps. aeruginosa infections (Nation and Li 2009). Resistance to colistin 
is rare but reports of clinical isolates tolerant to colistin have been reported. One 
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resistance mechanism is the development of an adaptive tolerance by P. aruginosa 
to colistin, through aminoarabinose modified lipid A (Cummins et al. 2009). Colistin 
MIC values determined against Gram-negative bacteria compare favourably with 
those recorded by Li et al (Li et al. 2005)(Li et al. 2006). MIC values of 200 µg/ml 
were recorded for colistin against S. aureus NCTC 6571 in this investigation, while 
Alhanout et al reported an MIC > 128 µg/ml for S. aureus ATCC 25923 (Alhanout et 
al. 2010). The high MIC values can perhaps be explained by the imperviousness of 
the outer cell wall of the Gram-positive bacterium to colistin, given that colistin is 
predominantly reported in literature as being membrane active (Li et al. 2005). 
Cummins et al reported an MIC of 2.4 g/ml for colistin against wild type P. 
aeruginosa, comparable to 1.5 g/ml colistin reported in this work (Cummins et al. 
2009). Growth of all three 1x106 cfu/ml test bacterial cultures incubated with 
colistin (Figures 3.10, 3.12 and 3.14) also demonstrated the concentration 
dependent dual effects of retardation in onset of log phase bacterial growth, 
coupled with minimal reduction in final bacterial density compared to control. These 
dual effects were markedly reduced in the colistin incubated 1x107 cfu/ml cultures 
of all test bacteria. (Figure 3.11, 3.13 and 3.15) This concurs with the triclosan 
findings, where the higher bacterial inoculum resulted in greater bacterial tolerance 
to the antibacterial employed. Colistin may affect the metabolic activities of the test 
bacteria in order to retard onset of logarithmic growth and reduce final bacterial 
density compared to that of control. Clauselle et al have suggested the mechanism 
of action of colistin at MIC concentration is through alteration of lipid regulation 
between the phospholipid interfaces bounding the periplasmic space (Clausell et al. 
2003). Such effects on lipid regulation would certainly account for both the 
observed retardation in onset of log growth and reduction in final bacterial density.  
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Biphasic growth was also displayed by S. aureus control and colistin incubated 
bacteria (Figures 3.12 and 3.13). This biphasic growth exhibited by S. aureus 
control bacteria was absent from the growth of S. aureus triclosan incubated 
bacteria and this distinguishes the effects that colistin and triclosan exerted on the 
growth kinetics of S. aureus. Growth of untreated and colistin treated S. aureus 
displayed similar growth patterns; therefore no interference in the trigger that 
prompted onset of the dual phased logarithmic growth was exerted by colistin.  
3.4.4 CAP activity 
The MIC/MBC values recorded for all the CAPs tested correlated well with those 
determined by Novabiotics (D. Mercer, Personal communication, 2009). MICs and 
MBCs of all CAPs tested in this investigation coincided; several researchers have 
reported this phenomenon of identical MIC/MBC values for CAPs and there are 
many such reports in published literature (Marr, Gooderham and Hancock 2006)(Lai 
et al. 2008). Graphs of all three 1x106 cfu/ml bacterial species incubated with 
NP101 and NP108 (Figures 3.16, 3.18, 3.20, 3.22, 3.24 and 3.26) displayed 
identical growth patterns equivalent to control at all time points. No dose 
dependent response to CAPs was shown by any of the test bacteria, suggesting a 
very fast bacteriostatic/ bactericidal onset of action, as has been attributed to CAPs 
in published literature (Brogden 2005). The bacterial growth of 1x106 cfu/ml 
cultures of the test bacteria displayed an all or nothing effect, bacteria grew 
displaying the same onset of logarithmic growth and final bacterial densities as the 
control bacteria or no growth was evident. Growth at half the MIC concentrations 
was similar to growth displayed by control, this is substantially different to the 
growth patterns displayed by the test bacteria in half MIC concentrations of 
triclosan and colistin, where the bacteria revealed delayed onset of logarithmic 
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growth and reduced final density compared to control. CAPs therefore affect the 
test bacteria in a different manner to triclosan and colistin. CAPs, permitting onset 
of log growth and similar final densities to control, do not target the metabolic 
processes of the bacteria at this bacterial density. The reported bactericidal effects 
of CAPs include, inhibition of DNA and protein synthesis, interference with cell 
division and disruption of gene regulation (Hale and Hancock 2007)(Zhang and 
Falla 2006)(Zaiou 2007)(Reddy, Yedery and Aranha 2004). NP101 and NP108 could 
exert a bactericidal effect on the test bacteria through exertion of one of these CAP 
attributed mechanisms of action.  
The response of the 1x107 cfu/ml cultures to NP101 and NP108 were markedly 
different. E. coli incubated with sub MIC concentration of NP101 displayed growth 
patterns similar to control. (Figure 3.17) This was in contrast to E. coli 1x107 cfu/ml 
culture incubated with 0.25 mg/ml NP108 (Figure 3.23), which displayed reduction 
in onset of logarithmic growth and retardation in log phase bacterial growth 
compared to control.  
S. aureus 1x107 cfu/ml culture incubated with NP101 displayed the dual effects of 
retardation in onset of log phase coupled with reduction in logarithmic bacterial 
growth. (Figure 3.19) S. aureus 1x107 cfu/ml culture incubated with NP108 
displayed similar growth to control. (Figure 3.25) However the concentration of 
NP108 in which both S. aureus densities displayed growth, was identical. S. aureus 
1x107 cfu/ml culture was not able to tolerate a higher CAP concentration at an 
increased bacterial density.  
P. aeruginosa 1x107 cfu/ml incubated with NP101 and NP108 (Figures 3.21 and 
3.27) displayed a struggle with the CAPs similar to E. coli at higher CAP 
concentrations; a markedly delayed onset of logarithmic growth combined with 
reduced logarithmic bacterial growth. The growth of S. aureus and P. aeruginosa 
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1x107 cfu/m NP101 incubated cultures displayed a different effect exerted by the 
CAP on the increased bacterial densities; metabolic processes in P. aeruginosa are 
now being targeted as evidenced by the retarded onset of logarithmic bacterial 
growth and reduction in log growth. This effect was also seen in the growth of E. 
coli and P. aeruginosa 1x107 cfu/ml NP108 incubated cultures; if metabolic 
processes were targeted this could account for the retarded onset of logarithmic 
bacterial growth and reduction in log growth. NP101 and 108 therefore exert 
different effects on bacterial cultures dependent on the density of bacteria present.  
The biphasic growth pattern of S. aureus control was also absent in the growth of 
the CAP incubated bacteria (Figures 3.18, 3.19, 3.24 and 3.25) as has been 
previously shown with the triclosan incubated bacteria (Figures 3.17 and 3.18). This 
is in contrast to the growth of colistin incubated S. aureus (Figures 3.12 and 3.13) 
where the growth pattern of the un-treated and test bacteria was identical. The 
inference that can be drawn from these results is that triclosan, colistin and CAPs 
exert different and distinct effects to one another on the growth dynamics of S. 
aureus. This data suggests S. aureus was most affected by NP101 and NP108, 
followed by P. aeruginosa whilst E. coli appeared to tolerate the actions of the 
peptides best of the three test species.  
3.5 Conclusion 
In summary, dual effects of concentration dependent retardation in onset of 
logarithmic bacterial growth coupled with reduced logarithmic bacterial growth were 
visualised in all three test bacteria incubated with triclosan. This indicated that 
triclosan directly lengthened the replication time required by all test bacteria while 
also retarding the metabolic activity of each of the test bacterial species. Triclosan 
also affected the normal dual-phased growth pattern of S. aureus by abolishing the 
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presence of secondary logarithmic growth in triclosan incubated S. aureus, as 
displayed by control bacteria.  
Colistin delayed onset of logarithmic growth in all test bacteria with slight reduction 
in final bacterial densities. The dual-phased growth of S. aureus was un-affected by 
incubation with colistin. 
NP101 and NP108 exerted different actions on the test bacteria dependent on the 
bacterial densities present. An all or nothing effect was seen with all 1x106 cfu/ml 
CAP incubated cultures, where either onset of bacterial growth and final bacterial 
density was equivalent to control or no growth was evident. This was markedly 
different to the delayed onset of logarithmic growth and reduced final bacterial 
densities displayed by the 1x107 cfu/ml test bacterial cultures incubated with NP101 
and NP108. As with triclosan incubated S. aureus, the growth pattern displayed by 
control bacteria was not displayed when S. aureus was incubated with NP101 and 
NP108. 
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Chapter Four 
Detection of cytoplasmic membrane damage by measuring 
loss of internal potassium induced by cationic 
antibacterials 
4.1 Introduction 
In Chapter 3 it was established that triclosan, colistin, NP101 and NP108 display 
extensive antibacterial activity. The manner in which these compounds exert their 
antibacterial activity on the test species now has to be considered. An essential 
requirement of all living organisms is a fully functional selectively permeable 
biological membrane, such as the cytoplasmic membrane in bacterial cells (Xu, 
Tillman and Tang 2009)(Singleton 1999). Interaction of an antimicrobial with 
bacterial cell membranes could result in any or all of the following; partial leakage 
of intracellular solutes, disruption of membrane associated metabolic activity, 
specific or non-specific changes in membrane permeability and cell lysis (Denyer 
and Russell 2004)(Singleton 1999). Quantification of leaked intracellular solutes has 
been an effective means for the detection of membrane damage induced by 
antibacterial agents (Denyer and Russell 2004). As loss of intracellular potassium is 
known to be the first sign of membrane damage resulting in permeability (Denyer 
and Russell 2004), the quantification of potassium leakage from bacterial cells was 
selected as the method to examine membrane activity in the test antibacterial 
agents.  
Normally potassium ions can be transported efficiently through bacterial 
membranes via the varied specific potassium ion channels such as KcsA and Trk 
(Chongsiriwatana and Barron 2010). Potassium plays a number of significant roles 
in bacterial cells, one being as a cytoplasmic-osmotic solute. Potassium influx into 
the bacterial cell occurs in response to osmotic up-shift, thereby permitting bacteria 
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to retain cell water in media with elevated osmolality, as occurs in E. coli through 
the Trk system (Epstein 2003)(Singleton 1999). Conversely, potassium efflux from 
the bacterial cell via for example the MscL channel in E. coli occurs when the 
osmolality of the media decreases (Epstein 2003)(Singleton 1999). Another 
significant role played by potassium is the activation or induction of enzymes and 
transport systems enabling cell adaptability to elevated osmolality: as in the Kdp 
transport system in E. coli, which is induced by potassium in conditions of high 
osmolality (Singleton 1999). A further role for potassium is to promote uptake or 
synthesis of compatible solutes; these are small molecules that can be accumulated 
at high concentrations within the cell without adversely affecting cell viability 
(Epstein 2003)(Singleton 1999)(Roosild et al. 2009). These compatible solutes 
replace some of the accumulated intracellular potassium ions, which are 
physiologically less friendly if present in high concentrations (Epstein 
2003)(Singleton 1999). Potassium is also responsible for regulation of internal pH 
of bacterial cells, achieved by proton displacement from buffer anions within the 
cell, an example being phosphate groups of nucleic acids. This process requires a 
mono-valent cation and potassium, being the major intracellular cation, fulfils an 
important function in this process (Roosild et al. 2009)(Epstein 2003). 
Historically it has been accepted and data supports the proposition that triclosan 
and colistin are membrane active agents, while many research groups have 
attributed membrane activity as one of several mechanisms of action of CAPs (Hale 
and Hancock 2007)(Reddy, Yedery and Aranha 2004). Several studies have shown 
that triclosan interacts with the bacterial cytoplasmic membrane and these research 
groups have suggested triclosan exerts antibacterial activity through damage to 
this structure (Villalaín et al. 2001)(Gomez- Escalada et al. 2005). Triclosan has 
also been shown to possess a slow, competitive, irreversible mechanism of action 
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by inhibition of the bacterial enoyl-acyl carrier protein (ACP) reductase (FabI) at 
low concentrations (Gomez- Escalada et al. 2005)(Levy et al. 1999).  
Colistin is tightly bound to the lipid A component of LPS in the outer membrane of 
Gram-negative bacteria (Falagas, Rafailidis and Matthaiou 2010)(Falagas et al. 
2010)(Denyer and Russell 2004). Distortion of the outer membrane leaflet occurs, 
segments of which are released and the permeability barrier destroyed (Falagas, 
Rafailidis and Matthaiou 2010)(Denyer and Russell 2004). Colistin then targets the 
cytoplasmic membrane, binding to phospholipids, disrupting membrane integrity 
and inducing irreversible leakage of cell components (Falagas, Rafailidis and 
Matthaiou 2010)(Falagas et al. 2010)(Denyer and Russell 2004). Colistin is much 
less active against Gram-positive species. 
It was long considered that the sole antibacterial mechanism of action of CAPs was 
membrane disruption, however non-membrane bacterial targets have been 
reported either in addition or alternative to membrane activity (Hale and Hancock 
2007)(Reddy, Yedery and Aranha 2004). These attributed mechanisms of action 
include interference with bacterial septation, inhibition of nucleic acid or protein 
synthesis, or disruption of cell wall synthesis and cell division (Hale and Hancock 
2007)(Reddy, Yedery and Aranha 2004). 
This phase of the work was therefore undertaken to examine the activity of test 
antimicrobial agents upon the cytoplasmic membrane of the selected bacteria, 
through quantification of potassium loss when exposed to the antimicrobials.  
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4.2 Methodologies 
4.2.1 Detection and quantification of K+ levels in extra pure de-
ionised water and 1% SDS 
The K+ content of ultra pure de-ionised water and SDS was checked in triplicate 
prior to each experiment as described in Section 2.7.3. 
4.2.2 Development of experimental protocol suitable for 
examination of K+ loss from cationic antibacterial – treated 
bacteria 
The purpose of the experimental work in this section was solely to refine the assay 
for measuring cationic antibacterial-induced K+ loss. Samples were taken at times 
0, 2, 5 and every 5 minutes thereafter until sixty minutes or at hourly intervals 
from time zero to eight hours and also at 24-hours. The effect of various 
parameters upon K+ loss was investigated using the basic methodology described in 
Section 2.7.3. All glassware and plastic ware were steeped in ultra pure de-ionised 
water for 24 hours prior to the K+ detection experiments to minimise the leeching of 
K+ from the glass/plastic ware into the experimental media.  
Glass flasks were used in addition to polymethylpentene flasks for K+ detection in 
colistin and NP108 experiments, as both these compounds are known to bind to 
plastics. Experiments were performed in which different bacterial densities were 
employed, initially 1 x 107 cfu/ml and then 1 x 106 cfu/ml.  
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4.2.3 Quantification of total cytoplasmic K+ present in E. coli, S. 
aureus and P. aeruginosa 
Total intracellular bacterial K+ was quantified using the sonication method as 
described in Section 2.7.2. 
4.2.4 Examination of the effect of 1% SDS and 5% 
chlorhexidine on K+ loss from E. coli, S. aureus and P. 
aeruginosa 
Bacterial K+ loss induced by 1% SDS and 5% chlorhexidine was undertaken as 
described in Section 2.7.3. The quantification of K+ loss in the test bacteria induced 
by incubation with known membrane permeable agents (SDS and chlorhexidine) 
was undertaken to check the robustness of the optimised protocol and for 
comparison purposes with the K+ loss induced by the test cationic antibacterial 
agents. 
4.2.5 Examination of the effects of triclosan, colistin and NP108 
on K+ loss from cells of E. coli, S. aureus and P. aeruginosa  
Bacterial K+ loss induced by incubation with triclosan, colistin or NP108 was 
undertaken as described in Section 2.7.3.  
4.3 Results 
4.3.1 Detection and quantification of K+ levels in extra pure de-
ionised water and 1% SDS 
The K+ content of ultra pure de-ionised water was checked in triplicate prior to each 
experiment and recorded as zero on every occasion. The K+ content of known 
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potassium standards was assessed before and after addition of 1% SDS. Samples 
containing only 1% SDS were also checked for K+ content. The results obtained are 
displayed in Table 4.1.  
 
K+ standard 
(mg/L) 
K+ content 
measured 
(mg/L) 
 
K+ content measured 
after addition of 1% 
SDS  (mg/L) 
Difference in 
K+ content 
measured 
(mg/L) 
0.2  0.204 0.541 0.337 
0.4  0.415 0.940 0.525 
0.6  0.562 0.806 0.244 
0.8  0.815 1.134 0.319 
1.0  1.036 1.305 0.269 
1% SDS 0.251 N/A N/A 
Table 4.1 Assessment of K+ content (mg/L) in 1% SDS via flame photometer. Potassium 
concentrations shown represent the mean from three experiments. Sample volume was 
10ml. N/A = Not applicable 
 
1% SDS added 0.251 mg/L K+ to 10 ml sample volume or 0.02 mg/L to each 
sample volume of 800 µl assayed for K+ content in these experiments. 
4.3.2 Detection and quantification of K+ levels in 5% 
chlorhexidine 
The K+ content of ultra pure de-ionised water and known potassium standards were 
assessed before and after the addition of 5% chlorhexidine. Samples only 
containing 5% chlorhexidine were also checked for K+ content. The results obtained 
are displayed in Table 4.2. 5% chlorhexidine added 0.066 mg/L K+ to 10 ml sample 
volume or 0.0053 mg/L to each sample volume of 800 µl assayed for K+ content in 
these experiments. 
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K+ standard 
(mg/L) 
K+ content 
measured 
(mg/L) 
 
K+ content 
measured after 
addition of 5% 
chlorhexidine  
(mg/L) 
Difference in 
K+ content 
measured 
(mg/L) 
0.1 0.104 0.175 0.071 
0.2  0.205 0.280 0.075 
0.3  0.310 0.398 0.088 
0.4  0.415 0.485 0.07 
0.5  0.516 0.585 0.069 
5% chlorhexidine 0.066 N/A N/A 
Table 4.2 Assessment of K+ content (mg/L) in 5% chlorhexidine via flame photometer. 
Potassium concentrations shown represent the mean from three experiments. Sample 
volume was 10ml. N/A = Not applicable 
 
4.3.3 Development of an experimental protocol suitable for 
examination of K+ loss from cationic antibacterial – treated 
bacteria  
4.3.3.1 Comparison of the results obtained with 1 x 106 cfu/ml and 1 x 
107 cfu/ml bacterial populations 
Determination of K+ content in samples taken from 1 x 106 cfu/ml and 1 x 107 
cfu/ml bacterial populations, was the initial step in the development of an assay to 
quantify K+ loss induced in bacteria incubated with triclosan, colistin or NP108. 
Results gained through experimental work demonstrated that K+ leakage induced 
through incubation with an antimicrobial agent in a bacterial culture density of 
1x106 cfu/ml for each test bacterial species was accurately quantifiable by flame 
photometer. Sample dilution was not required and this bacterial concentration was 
employed for all further K+ assays.   
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4.3.4. Quantification of total K+ present in E. coli, S. aureus and 
P. aeruginosa 
The total K+ content of E. coli, S. aureus and P. aeruginosa (re-suspended in ultra 
pure K+ free de-ionised water) obtained through sonication, is shown in Table 4.3.  
 
 
Bacterial species 
 
Density 
(cfu/ml) 
Concentration 
of K+ (mg/L) 
Bacterial 
viability after 
24 hours 
(cfu/ml) 
E. coli un-sonicated control 
 
1x106 0.293 4.76 x 106 
E. coli sonicated sample 1x106 3.20 
 
< 10 
E. coli un-sonicated control 
 
1x107 0.422 8.7 x 107 
E. coli sonicated sample 1x107 3.62 
 
< 10 
S. aureus un-sonicated 
control 
1x106 0.096 
 
5.2 x 106 
S. aureus sonicated 
sample 
1x106 2.80 
 
< 10 
S. aureus un-sonicated 
control 
1x107 0.238 5.3 x 107 
S. aureus sonicated 
sample 
1x107 3.42 
 
< 10 
Ps. aeruginosa un-
sonicated control 
1x106 0.295 
 
5.17 x 106 
Ps. aeruginosa sonicated 
sample 
1x106 3.20 < 10 
Ps. aeruginosa un-
sonicated control 
1x107 0.42 4.1x107 
Ps. aeruginosa sonicated 
sample 
1x107 3.89 < 10 
Table 4.3 Total K+ content of bacterial cells. Data shown represented the mean from six 
experiments, each performed in triplicate. All cultures were prepared at time 0 to contain a 
cell density of 1x106 cfu/ml 
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The total K+ content of E. coli or P. aeruginosa 1x106 cfu/ml culture obtained by 
sonication was identical at 3.2 mg/L, while slightly lower potassium content was 
recorded for S. aureus 1x106 cfu/ml cells. Bacterial viability was checked after 
sonication for the three bacteria and recorded as <10 cfu/ml for all three bacterial 
species. 
4.3.5 Quantification of loss of K+ in E. coli, S. aureus and P. 
aeruginosa due to incubation with 1% SDS 
K+ loss in the test bacteria, induced by incubation with 1% SDS, is shown in Figure 
4.1.  
From Figure 4.1(a) it can be seen that 8% of total cell potassium was released from 
1 x 106 cfu/ml E. coli bacteria within 5 minutes of being incubated with 1% SDS. 
Minimal further K+ leakage was detected in E. coli control cells throughout the 7-
hour experiment. Almost total K+ loss was realised in S. aureus 1 x 106 cfu/ml 
bacteria (Figure 4.1b) within 5 minutes incubation with 1% SDS; though samples 
were assessed for potassium content for a further 415 minutes, the recorded K+ 
content of samples remained constant.  Partial leaching of K+ from S. aureus 
control bacteria was detected after 2 hours, as might be anticipated given their re-
suspension in ultra pure water. Approximately 11% of total potassium content was 
lost from P. aeruginosa 1 x 106 cfu/ml (Figure 4.1c) cells on incubation with 1% 
SDS; little leakage of K+ was detected from the control cells over the 7 hour 
experimental period. Consequently it was deemed necessary to use an alternative 
membrane active agent to establish that full K+ loss and complete loss of viability of 
the Gram-negative organisms could be achieved. 
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Figure 4.1 K+ loss in bacteria induced by incubation with 1% SDS. N = 3. S.E.M.     Control 
bacteria       Bacteria incubated with 1% SDS. 
(a) E. coli 1x106 cfu/ml culture: viability of E. coli control after 7 hours was 1.0 x 107 cfu/ml; 
viability of E. coli incubated with 1% SDS after 7 hours was < 10 cfu/ml. Total K+ content of 
sonicated 1x106 cfu/ml E. coli culture was 3.2 mg/L.  
(b) S. aureus 1x106 cfu/ml culture: viability of S. aureus control bacteria and S. aureus 
incubated with 1% SDS after 7 hours was < 10 cfu/ml. Total K+ content of sonicated S. 
aureus 1x106 cfu/ml culture was 2.8 mg/L.  
(c) P. aeruginosa 1x106cfu/ml culture: Viability of P. aeruginosa control bacteria after 7 
hours was 5.0 x 106 cfu/ml; viability of P. aeruginosa incubated with 1% SDS after 7 hours 
was < 10 cfu/ml. Total K+ content of sonicated 1x106 cfu/ml P. aeruginosa culture was 3.2 
mg/L. 
 
4.3.6 Quantification of loss of K+ in E. coli, S. aureus and P. 
aeruginosa due to incubation with 5% chlorhexidine 
K+ loss due to incubation with chlorhexidine is shown in Figure 4.2. Chlorhexidine is 
a biocide with a proven mechanism of action on bacterial membranes, leading to 
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loss of intracellular contents and it can be seen from Figure 4.2 that leakage of K+ 
occurred in all three-test bacteria within 5 minutes incubation with chlorhexidine.  
 
Figure 4.2 K+ loss in bacteria induced by incubation with 5 % chlorhexidine.      Control 
bacteria.       Bacteria incubated with 5 % chlorhexidine. N=3. S.E.M. 
(a) E. coli 1x106 cfu/ml culture: viability of E. coli control after 60 minutes was 4.3 x 105 
cfu/ml; viability of E. coli incubated with 5 % chlorhexidine after 60 minutes was < 10 
cfu/ml. Total K+ content of sonicated 1x106 cfu/ml E. coli culture was 3.2 mg/L.  
(b) S. aureus 1x106 cfu/ml culture: viability of S. aureus control bacteria after 60 minutes 
was 1.65x106 cfu/ml; viability of S. aureus incubated with 5 % chlorhexidine after 60 
minutes was < 10 cfu/ml. Total K+ content of sonicated S. aureus 1x106 cfu/ml culture was 
2.8 mg/L.  
(c) P. aeruginosa 1x106 cfu/ml culture: Viability of P. aeruginosa control bacteria after 60 
minutes was 2.4 x 104 cfu/ml; viability of P. aeruginosa incubated with 5 % chlorhexidine 
after 60 minutes was < 10 cfu/ml. Total K+ content of sonicated 1x106 cfu/ml P. aeruginosa 
culture was 3.2 mg/L. 
 
 
Approximately 25% of total cell K+ was lost from 1 x 106 cfu/ml E. coli (Figure 4.2a) 
within 5 minutes incubation with 5% chlorhexidine. The K+ loss had risen to 40% 
total cell K+ at 30 minutes and 93% loss of total intracellular K+ at 60 minutes. 
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Minimal K+ leakage was detected in E. coli control cells throughout the 60-minute 
experiment. K+ release from 1 x 106 cfu/ml S. aureus (Figure 4.2b) incubated with 
5% chlorhexidine was 40% of total cell K+ within 5 minutes, with approximately 
90% total K+ lost from S. aureus cells after 60 minutes incubation with the biocide. 
Approximately 20% of total K+ content was released from P. aeruginosa 1 x 106 
cfu/ml (Figure 4.2c) cells within 5 minutes incubation with 5% chlorhexidine. At 60 
minutes, the amount of intracellular K+ that had bled from the bacterium had risen 
to 40%. Though total K+ loss from P. aeruginosa incubated with 5% chlorhexidine 
was not recorded, no viable bacteria were produced when a viability check was 
performed after 60 minutes incubation in the biocide. These assays with SDS and 
chlorhexidine confirm that the protocol is sufficiently sensitive to accurately record 
the extent of K+ lost from bacterial populations upon treatment with antimicrobials.    
4.3.7 Quantification of K+ loss in E. coli, S. aureus and P. 
aeruginosa upon incubation with cationic antibacterials 
4.3.7.1 Quantification of K+ loss from E. coli and S. aureus exposed to 
triclosan 
K+ loss over 24 hours from E. coli 1 x 106 cfu/ml cultures incubated with the MIC 
(0.07 g/ml) and 10xMIC (0.7 g/ml) of triclosan Figure 4.3(a) was quantified as 2 
and 3% respectively. K+ loss from the bacteria at 7 hours was statistically 
significant (p-value  0.001) between the control and 10xMIC triclosan incubated 
bacteria. At 24 hours a statistically significant difference in K+ loss was recorded 
between the control and MIC incubated bacteria (p-value  0.01) and 10xMIC 
triclosan incubated cells (p-value  0.001). A statistically significant K+ loss (p-value 
 0.001) was also seen between the treatment groups: MIC and 10xMIC 
concentrations at 7 and 24 hours. 
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    (a) 
 
 
Figure 4.3 K+ loss in bacteria induced by exposure to triclosan for 24 hours. Assessment of 
K+ leakage was performed in triplicate on three occasions. (S.E.M.) * indicates p-value < 
0.05, ** indicates p-values < 0.01, *** indicates p-value < 0.001 
(a) E. coli 1x106 cfu/ml culture: viability of E. coli control after 24 hours was 5.0 x 106 
cfu/ml; viability of test bacteria after 24 hours was < 10 cfu/ml. Total K+ content of 
(b) 
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sonicated 1x106 cfu/ml E. coli culture was 3.2 mg/L. E. coli solvent control contained 3.44 l 
DMSO. 
(b) S. aureus 1x106 cfu/ml culture: viability of S. aureus control bacteria after 24 hours was 
1.3 x 107 cfu/ml; viability of test bacteria after 24 hours was < 10 cfu/ml. Total K+ content 
of sonicated S. aureus 1x106 cfu/ml culture was 2.8 mg/L. S. aureus solvent control 
contained 5.4 l DMSO. 
 
 
This means the quantity of K+ lost by E. coli bacteria incubated with triclosan was 
dependent on the concentration of triclosan employed and the quantity of K+ 
extruded from the test bacteria increased as the concentration and length of time 
the bacteria were exposed to triclosan increased compared to control bacteria. 
However, it must be noted that the total quantity of K+ lost from E. coli due to 
incubation with triclosan was very low. 
Partial leaching of K+ from S. aureus control bacteria was noticed over the 
experimental period (Figure 4.3(b)), as might be anticipated given their re-
suspension in ultra pure water. As with E. coli the loss of K+ induced from S. aureus 
by exposure to triclosan was negligible and was equivalent to the 3% K+ lost from 
control cells under experimental conditions.  This means that leakage of K+ from S. 
aureus cells was not solely dependent on the length of time or concentration of 
triclosan to which the test bacteria were exposed compared to control bacteria. 
However the extent of non-specific leaching was minimal, as can be seen in Figure 
4.3(b). The very low level lost suggests triclosan does not induce K+ loss, and by 
inference membrane disruption as a key mechanism of action in either E. coli or S. 
aureus. 
 
4.3.7.2 Quantification of K+ loss from E. coli, S. aureus and P. aeruginosa 
exposed to colistin 
Loss of K+ induced from E. coli 1 x 106 cfu/ml culture incubated with MIC (3 g/ml) 
or 10xMIC (30 g/ml) colistin for 24 hours is shown in Figure 4.4(a).  
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       (a) 
 
 
Figure 4.4 K+ loss induced by incubation with colistin over 24-hours. Assessment of K+ 
leakage was performed in triplicate on three occasions. S.E.M. * indicates p-value < 0.05, 
** indicates p-values < 0.01, *** indicates p-value < 0.001. 
(b) 
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(a) E. coli 1x106 cfu/ml culture: viability of control bacteria after 24 hours was 7.0 x 106 
cfu/ml; viability of test bacteria after 24 hours was < 10 cfu/ml. Total K+ content of 
sonicated 1x106 cfu/ml E. coli culture was 3.2 mg/L. 
(b) P. aeruginosa 1x106cfu/ml culture: Viability of control bacteria after 24 hours was 9.0 x 
108 cfu/ml; viability MIC test bacteria after 24 hours was 1x107 cfu/ml;  viability 10xMIC 
test bacteria after 24 hours was 9x106 cfu/ml. Total K+ content of sonicated 1x106 cfu/ml P. 
aeruginosa culture was 3.2 mg/L. 
 
Colistin induced loss of approximately 6% of total K+ content from E. coli cells 
incubated with either MIC or 10xMIC concentration, over 24 hours incubation. This 
statistically significant K+ loss between control and test bacteria (p-value  0.001) 
occurred within 5 minutes incubation with colistin (data not shown). Incubation of 
E. coli with colistin did not show any statistically significant difference in leakage of 
K+ between MIC and 10xMIC test groups at 8 and 24 hours, meaning leakage of K+ 
was not dependent on the length of time or concentration above a critical threshold 
of colistin to which E. coli was exposed. Minimal variation in the quantity of K+ loss 
determined for samples over the 24-hour experimental period was recorded.  
K+ loss from P. aeruginosa 1 x 106 cfu/ml culture incubated with MIC (1.5 g/ml) 
and 10xMIC (15 g/ml) colistin for 24 hours is displayed in Figure 4.4 (b). P. 
aeruginosa incubated with MIC or 10xMIC colistin for 24 hours, resulted in loss of 
4% of total K+ content. This non-statistically significant K+ loss (p-value  0.05) 
from test compared to control cells was detected within 5 minutes incubation with 
the polymyxin (data not shown) and the recorded K+ content of the samples 
remained constant thereafter. Incubation of P. aeruginosa with colistin did not show 
any statistically significant leakage of K+ between test groups, meaning leakage of 
K+ was not dependent on the length of time or concentration of colistin to which P. 
aeruginosa was exposed. 
K+ loss induced in the 1 x 106 cfu/ml S. aureus culture incubated with colistin for 60 
minutes can be seen in Figure 4.5. A statically significant K+ loss from test cells 
compared to control (p-value  0.001) occurred within 5 minutes incubation of the 
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bacteria with colistin and the level of K+ detected remained constant thereafter, 
even when assessed over 24 hours (data not shown). K+ loss from S. aureus was 
also statistically significant between concentration groups of MIC (100 g/ml) and 
10xMIC (1 mg/ml) colistin incubated bacteria (p-value  0.001) at 5, 15 and 60 
minutes. Approximately 36% of total K+ content of 1 x 106 cfu/ml S. aureus cells 
was lost on incubation for 60 minutes with 10xMIC colistin, while the bacteria 
incubated with the MIC concentration lost approximately 7% of total bacterial K+. A 
noteworthy point is that the MIC of colistin against S. aureus was recorded as 100 
g/ml, making 10xMIC concentration 1 mg/ml. 
 
Figure 4.5 K+ loss in 1 x 106 cfu/ml S. aureus induced by incubation with colistin for 60-
minutes. Assessment of K+ leakage was performed in triplicate on three occasions. S.E.M. * 
indicates p-value < 0.05, ** indicates p-values < 0.01, *** indicates p-value < 0.001. 
Viability of control bacteria after 24 hours was 6.3 x 106 cfu/ml; viability of test bacteria 
after 24 hours was < 10 cfu/ml. Total K+ content of sonicated S. aureus 1x106 cfu/ml culture 
was 2.8 mg/L.  
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4.3.7.3 Quantification of K+ loss in E. coli, S. aureus and P. aeruginosa due 
to NP108 
K+ loss induced in the 1 x 106 cfu/ml E. coli culture incubated with NP108 for 60 
minutes can be seen in Figure 4.6. Approximately 38% of total K+ content of 1 x 
106 cfu/ml E. coli cells was lost on incubation with 2xMIC NP108, with 18% K+ loss 
recorded for bacteria incubated with the MIC of NP108, while incubation with 1/20th 
MIC NP108 induced 7% K+ loss from bacterial cells. 
 
Figure 4.6 K+ loss in 1 x 106 cfu/ml E. coli induced by incubation with NP108 for 60 
minutes. Assessment of K+ leakage was performed in triplicate on three occasions. S.E.M. * 
indicates p-value < 0.05, ** indicates p-values < 0.01, *** indicates p-value < 0.001. 
Viability of control bacteria after 24 hours was 5.0 x 106 cfu/ml; viability of 1/20th MIC test 
bacteria after 24 hours was 3.0 X 106 cfu/ml; viability of MIC test bacteria after 24 hours 
was 5.2 X 106 cfu/ml; viability of 2xMIC test bacteria after 24 hours was 6.6 X 105 cfu/ml. 
Total K+ content of sonicated 1x106 cfu/ml E. coli culture was 3.2 mg/L.  
 
A statistically significant K+ loss (p-value  0.001) from test compared to control, 
occurred within 5 minutes incubation of the bacteria with NP108 and the level of K+ 
detected thereafter remained constant, even when assessed over 24 hours (data 
not shown). A statistically significant K+ loss (p-value  0.001) was also seen 
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between the treatment groups; 1/20th MIC (0.025 mg/ml) compared to MIC (0.5 
mg/ml) and 2xMIC (1mg/ml) concentrations and between MIC and 2xMIC 
concentrations at 5 and 15 minutes and at 7 and 24 hours (data not shown). This 
means the quantity of K+ lost by E. coli bacteria incubated with NP108 was 
dependent on the concentration of NP108 employed and the quantity of K+ lost 
increased as the concentration and length of time the bacteria were exposed to 
NP108 compared to control bacteria.  
Loss of K+ induced from S. aureus and P. aeruginosa 1 x 106 cfu/ml cultures 
incubated with NP108 for 24 hours is shown in Figure 4.7 (a) and (b) respectively. 
K+ loss induced in S. aureus on incubation with NP108 was statistically significant 
(p-value  0.01 at 8 hours and  0.001 at 24 hours) compared to control.  
K+ loss from these bacteria was also statistically significant between concentration 
groups; 1/20th MIC (0.013 mg/ml) bacteria compared to MIC (0.25 mg/ml) and 
2xMIC (0.5 mg/ml) bacteria (p-value  0.01) at 8 hours and (p-value  0.001) at 
24 hours and between MIC and 2xMIC bacteria (p-value  0.05) at 24 hours.  
As such the quantity of K+ lost by S. aureus bacteria incubated with NP108 when 
compared to control bacteria was dependent on the concentration of NP108 
employed and the quantity of K+ released from bacterial cells increased as the 
concentration and length of time the bacteria were exposed to NP108.   
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     (a) 
 
     (b) 
 
Figure 4.7 K+ loss in bacteria incubated with NP108. Assessment of K+ leakage was 
performed in triplicate on three occasions. S.E.M. * indicates p-value < 0.05, ** indicates 
p-values < 0.01, *** indicates p-value < 0.001. 
(a) S. aureus 1x106 cfu/ml culture. Viability of control bacteria after 24 hours was 6.6 x 106 
cfu/ml; viability of 1/20th MIC test bacteria after 24 hours was 6.0 X 106 cfu/ml; viability of 
MIC test bacteria after 24 hours was 4.4 X 106 cfu/ml; viability of 2xMIC test bacteria after 
24 hours was 4.1 X 104 cfu/ml. Total K+ content of sonicated S. aureus 1x106 cfu/ml culture 
was 2.8 mg/L.  
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(b) P. aeruginosa 1x106 cfu/ml culture. Viability of control bacteria after 24 hours was 2.23 
x 1010 cfu/ml; viability of 1/20th MIC test bacteria after 24 hours was 1.2 X 109 cfu/ml; 
viability of MIC test bacteria after 24 hours was 3.86 X 106 cfu/ml; viability of 2xMIC test 
bacteria after 24 hours was 3.5 X 106 cfu/ml. Total K+ content of sonicated 1x106 cfu/ml P. 
aeruginosa culture was 3.2 mg/L. 
 
 
The K+ loss induced from P. aeruginosa cells incubated with NP108 was also 
statistically significant (p-value  0.001) compared to control at 8 and 24 hours. A 
statistically significant K+ loss between concentration groups; 1/20th MIC (0.025 
mg/ml) compared to 2xMIC (1 mg/ml) (p-value  0.01) at 8 hours and (p-value  
0.001) at 24 hours and between MIC (0.5 mg/ml) and 2xMIC bacteria (p-value  
0.01) at 24 hours was evident. As with both E. coli and S. aureus, the quantity of 
K+ lost by P. aeruginosa bacteria incubated with NP108 was dependent on the 
concentration of NP108 employed and the quantity of K+ lost increased with 
concentration and length of time the bacteria were exposed to NP108. However the 
maximum K+ loss induced from either S. aureus or P. aeruginosa cells incubated 
with NP108 over a 24-hour experimental period was recorded as 2% for those 
bacteria incubated with 2xMIC concentrations. The K+ loss that was induced 
occurred within 5 minutes (data not shown) and the K+ content of samples tested 
up to 8 hours remained constant, with a further 1% increase in K+ leakage recorded 
between 8 and 24-hours. 
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4.4 Discussion 
4.4.1 K+ content of bacterial cells 
Sonication of bacterial suspensions of known density for each test species was 
carried out to ascertain the total potassium pool present within the culture. This 
gave an absolute reference value to which the quantified potassium, lost from 
bacterial cells due to incubation with cationic antibacterial agents, could be 
compared. Subsequent to this, potassium loss induced from the test bacteria by an 
agent with an acknowledged mechanism of action of membrane perturbation, 
leading to near loss of total intracellular K+ content was performed. These assays 
confirmed the validity of the approach.  
The biocide action of 1% SDS on bacterial cell walls and membranes and the 
consequence of this action is long documented as resulting in the progressive 
leakage of cell components such as potassium (Denyer 1995). Because of this SDS 
was selected to act as a reference compound quantifying the loss of potassium from 
bacterial cells. Total loss of potassium content from S. aureus bacteria compared to 
control, was seen within 5 minutes incubation with 1% SDS. Loss of potassium 
from E. coli and P. aeruginosa cells incubated with 1% SDS was 8 and 11% 
respectively after 7 hours incubation. That less potassium was lost from the Gram 
negative compared to the Gram positive bacterium can be explained by the 
presence of a double membrane structure that comprises the bacterial envelope of 
Gram-negative cells, whereas Gram-positive bacteria solely contain a peptidoglycan 
cell wall (Allison and Gilbert 2004). A second membrane active agent, chlorhexidine 
was employed to quantify K+ loss from all three bacterial species. After 60 minutes 
incubation with 5% chlorhexidine, a loss of 90% of total intracellular K+ was 
recorded for E. coli and S. aureus while a 40% K+ loss was recorded for P. 
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aeruginosa. That there was a considerable difference in the quantity of K+ leakage 
from E. coli and P. aeruginosa is not unexpected given that the cell wall in P. 
aeruginosa forms a more protective barrier than that possessed by E. coli.  
4.4.2 Loss of intracellular K+ induced by triclosan 
 E. coli incubated with MIC triclosan (0.07 g/ml) for 24 hours and 10xMIC triclosan 
(0.7 g/ml) for 7 and 24 hours, displayed K+ loss that was statistically significant 
compared to control (Figure 4.3a)). K+ loss was also statistically significant between 
MIC and 10xMIC triclosan incubated E. coli at 7 and 24 hours. The percentage of 
total intracellular K+ lost from the MIC incubated E. coli cells was 2%, with 3% of 
total cell K+ lost from 10xMIC bacteria; compared to approximately 1% of total K+ 
cell content which leeched from control bacteria under experimental conditions. The 
conclusion that can be drawn from these results is that the slight K+ loss induced 
from E. coli by triclosan is directly dependent on the concentration of triclosan 
employed. Support for this statement can be inferred from the fact that K+ loss 
between control and 10xMIC treated bacteria and between MIC and 10xMIC 
triclosan incubated bacteria was seen at both time points analysed, whereas the K+ 
loss induced from E. coli incubated with the MIC triclosan was not statistically 
significant at 7 hours when compared to control. K+ loss from E. coli is also 
dependent on the length of time to which the bacteria were exposed to triclosan; as 
witnessed by the statistically significant loss of K+ compared to control from E. coli 
incubated with the MIC of triclosan at 24 hours but not at 7 hours. The combined 
effects of a lower triclosan concentration linked with longer exposure to the 
bisphenol were required for this effect to be manifested.  
The K+ loss from S. aureus cells incubated with MIC (0.055 g/ml) or 10xMIC 
triclosan (0.55 g/ml) over 24-hour experimental periods conducted during this 
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research was not shown to be statistically significant compared to control (Figure 
4.3b)) and was equivalent to the 3% K+ content lost from the control cells under 
experimental conditions. Partial leaching of K+ over the experimental duration was 
observed with S. aureus control populations, as might be anticipated given their re-
suspension in ultra pure water. Therefore for this set of experiments, K+ loss from 
S. aureus cells incubated with triclosan was not dependent on the length of 
exposure or the concentration of triclosan used.  
Johnston et al reported little K+ loss from S. aureus when treated with a single 
biocide – either chlorocresol or m-cresol.  However rapid K+ leakage was observed 
when the bacterium was exposed to a mixture of these two biocides (Johnston et 
al. 2003). Suller et al demonstrated no difference in K+ leakage induced from 3 
strains of S. aureus incubated with triclosan at concentrations of 2, 7.5 or 15 mg/L 
despite MICs of the three strains ranging from 0.025 – 1mg/L triclosan (Suller and 
Russell 2000). This study also recorded a maximum K+ loss of 0.2 mg/L from a 1 x 
107 cfu/ml suspension of S. aureus NCTC 6571 after incubation with 80xMIC 
triclosan (2 mg/L) over 60 minutes (Suller and Russell 2000). This ties in very well 
with the data presented in this study; 0.064 mg/L K+ loss recorded from a 1x106 
cfu/ml suspension of S. aureus after 60 minutes incubation with 10xMIC (0.55 
µg/ml) triclosan. Villalain et al reported no leakage of intracellular contents from 
Streptococcus sobrinus incubated with triclosan below 10xMIC concentration 
(Villalaín et al. 2001). Loss of amino acids from Streptococcus sobrinus was 
recorded at 0.3 mg/L (or 34xMIC) triclosan after 30 minutes exposure (Villalaín et 
al. 2001). The results from these previous studies concur with the results recorded 
in this study; that triclosan does not induce substantial levels of potassium loss 
from either E. coli or S. aureus and that membranotropic effects are slight and loss 
of membrane integrity may not be responsible even in part for the 
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bacteriostatic/bactericidal effects of triclosan. However these data do not rule out 
other membrane effects. 
4.4.3 Loss of intracellular K+ induced by colistin 
The rapid K+ loss from E. coli (data not shown) and S. aureus (Figure 4.5) 
incubated with colistin occurring within 5 minutes, proved statistically significant 
when compared to control. The quantity of K+ lost from S. aureus cells was far more 
substantial than that lost from E. coli. However, the concentration of colistin used 
was also much higher (although these were MIC and 10xMIC concentrations); 1 
mg/ml colistin for S. aureus compared to 30 µg/ml colistin for E. coli. The quantity 
of K+ lost from both bacteria between the concentrations tested (MIC and 10xMIC), 
was also statistically significantly. S. aureus incubated with the MIC colistin lost 7% 
of total K+ cell content, while 10xMIC incubated cells lost 36% of total intracellular 
K+ over the experimental period. E. coli incubated with MIC and 10xMIC colistin lost 
6% of total intracellular K+ over 24 hours compared to the natural seepage of less 
than 4% of total intracellular K+ from E. coli control cells re-suspended in ultra-pure 
water.  
This proves K+ loss induced from E. coli and S. aureus incubated with colistin was 
directly dependent on the concentration of colistin employed. Time was not a factor 
affecting K+ loss induced by colistin from these bacteria; the levels of K+ detected in 
samples taken over 24-hour periods from both E. coli (Figure 4.4(a)) and S. aureus 
(data not shown) incubated with MIC and 10xMIC colistin remained constant. K+ 
loss detected from P. aeruginosa incubated with colistin during this investigation did 
not prove to be statistically significant when compared to control bacteria. Loss of 
K+ from MIC (1.5 g/ml) and 10xMIC (15 g/ml) colistin incubated bacteria 
approximated the 4% K+ lost from the untreated control bacteria under 
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experimental conditions. Length of time or concentration to which P. aeruginosa 
was exposed to colistin did not affect the quantity of K+ lost.  
The viabilities of 1x106 cfu/ml E. coli, S. aureus and P. aeruginosa control and 
colistin incubated cells (MIC and 10xMIC) were checked by plating out on agar after 
every 24-hour incubation. All control cultures produced normal sized colonies in 
every instance, for all three test bacteria.  Only the MIC and 10xMIC colistin 
incubated P. aeruginosa cultures revealed much, much smaller colonies or pinprick 
sized colonies after viability checks compared to the control colonies. Incubation 
with inhibitory and supra-inhibitory colistin concentrations subjected the bacteria to 
stresses, which resulted in small colony variants being produced by the incubated 
bacteria. Small colony variants are produced by bacteria as a result of energy 
deficiency and display a pleiotropic phenotype characterised by factors including 
slow growth (producing small sized colonies) and non-production of virulence 
factors (Seaman, Ochs and Day 2006). P. aeruginosa alone of the test bacteria in 
this study produced these small colony variants when incubated with colistin at MIC 
and 10xMIC concentrations in response to the presence of the antibacterial, 
probably to increase bacterial survival. The possession of a large genome bestows 
the metabolic capability and flexibility to survive under environmental conditions 
that prove in hospitable to other bacteria (El Solh and Alhajhusain 2009). The 
ability of P. aeruginosa to survive under conditions that would be lethal to other 
bacteria is due in part to the minimal nutritional requirements of the bacterium (El 
Solh and Alhajhusain 2009). 
4.4.4 Colistin mechanisms of action 
Peptide antibiotics can be categorised as non-ribosomally synthesised as part of 
secondary metabolism, which are mostly bacterial in origin, as for example colistin 
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produced by Bacillus polymyxa or ribosomally synthesised such as natural peptides 
produced by all living species as part of their immune system (Hancock and 
Chapple 1999)(Hancock and Sahl 2006). Colistin is a cationic antimicrobial agent 
with an overall positive charge of +5 (Clausell et al. 2003). Though colistin has 
been used clinically for several decades the mechanism of action through which 
colistin exerts its bactericidal effect is still not precisely known (Maviglia, Nestorini 
and Pennisi 2009)(Clausell et al. 2003). Zavascki et al report colistin‘s rapid 
bactericidal action as a result of a detergent-like mechanism of action (Zavascki et 
al. 2007). Many studies have suggested that colistin acts on bacterial membranes, 
however, the concentration of colistin employed in these studies was at high MIC 
multiples (Maviglia, Nestorini and Pennisi 2009)(Clausell et al. 2003). Clauselle et al 
have suggested the mechanism of action of colistin at MIC concentration alters lipid 
regulation between the phospholipid interfaces bounding the periplasmic space 
(Clausell et al. 2003). Bulitta et al in a recent study have shown that colistin 
exerted its bactericidal activity against P. aeruginosa within less than 2 minutes 
exposure of the bacterium to the polymyxin. Their hypothesis is that colistin, 
having 670 times greater affinity for lipid binding sites than Mg2+ or Ca2+ ions, 
rapidly displaces the divalent cations, binds to, and destabilizes the outer bacterial 
membrane, reaches its target site and swiftly kills the bacterium at 16xMIC 
concentration (Bulitta et al. 2010). However due to the very rapid bacterial killing 
speed of colistin, its exact mechanism of action is yet to be elucidated (Li et al. 
2005)(Li et al. 2006). What has also been demonstrated for colistin is the ability of 
the polymyxin to bind to LPS, interact with lipid membranes, unbalance pressure 
forces and form transient pores in membranes (Ouberai et al. 2011). However, lack 
of K+ loss in the current study would suggest such pores are not suitable for 
transport of this cation. Clauselle et al also demonstrated induction in changes in 
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membrane permeability at colistin concentrations many times higher than MIC 
values. A number of studies have discovered that colistin‘s bactericidal effect is not 
as a result of membrane activity, as colistin has been shown to exhibit lethal effects 
at concentrations far lower than those required for membrane permeabilisation 
(Mortensen et al. 2009)(Clausell et al. 2003). Mortensen et al speculate employing 
colistin at a concentration of 10 g/ml as being too low to increase the permeability 
of bacterial cell membranes. This is in partial agreement with the experimental 
findings in this investigation, where colistin was employed at MIC concentrations of 
1.5 and 3 g/ml for E. coli and P. aeruginosa and K+ loss of 6% and 4% 
respectively was detected. Leakage of 36% of total K+ content occurred in S. aureus 
when incubated with an MIC of 100 g/ml.   
A recent study by Alhanout et al examined membrane disruption in P. aeruginosa 
and E. coli cells incubated with colistin at a concentration of 4 and 2 µg/ml 
respectively, through quantification of ATP release from these bacteria.  The study 
revealed a loss of only 4% and 5% loss of total ATP content respectively, from 
these cells. Alhanout et al demonstrated that colistin creates electrically active 
lesions only 9.1  1nm in diameter by interaction with the bacterial lipid bilayer, 
through which intracellular components are leaked to the external environment 
(Alhanout et al. 2010). The fact that ATP molecules have been shown to have 
leaked through lesions in the lipid bilayer of P. aeruginosa and E. coli caused by 
colistin at lower concentrations than were used in this investigation and yet leakage 
of the much smaller K+ molecule was not recorded in this investigation was 
intriguing. This may be explained by the fact that K+ is used by both these bacteria 
as an osmolarity regulator and is the first intracellular ion lost when the bacterial 
membrane is breached and is also the first ion which undergoes active influx into 
the bacterial cell on osmotic upshift; therefore a balance exists between the 
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quantity of K+ lost and as quickly re-absorbed into the bacterial cell, which could 
account for the detection of minimal K+ quantities.  Whereas the re-absorption of 
ATP would require significantly greater expenditure of energy by the already 
stressed cell to re-acquire a currently non-essential molecule.  
The same study examined ATP release by squalamine (an antimicrobial compound 
with similar activity to colistin) that created lesions in the lipid bilayer 33.5 nm in 
diameter, leading to loss of approximately 35% of total ATP content within 30 
minutes (Alhanout et al. 2010). These data are not in agreement with the findings 
in this study where little leakage of intracellular contents was observed from 
bacteria incubated with colistin. 
4.4.5 K+ loss induced by NP108 
E. coli incubated with NP108 displayed a rapid and substantial K+ loss within 5 
minutes incubation with the CAP (Figure 4.6). This statistically significant loss of 
38% total intracellular K+ occurred upon incubation with 2xMIC (0.5mg/ml) NP108 
over 60 minutes. K+ loss between E. coli cultures incubated with MIC (0.25 mg/ml) 
and 2xMIC NP108 was also statistically significant, demonstrating that 
concentration of NP108 alone was responsible for K+ loss induced in these bacteria. 
Time was not a factor affecting induction of K+ from E. coli cells as the levels of K+ 
detected from MIC and 2xMIC concentrations remained constant over the 24-hour 
experiments (data not shown).  
The statistically significant K+ loss from S. aureus incubated with NP108 (Figure 
4.7(a)) was also rapid, 3% loss of total K+ intracellular pool with 2xMIC NP108 and 
2% K+ loss with MIC NP108 over 24 hours but clearly was less substantial than that 
displayed by E. coli. Whilst the slight loss of K+ from S. aureus induced by 
incubation with MIC NP108 (0.25 mg/ml) was statistically significant when 
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compared to control. When P. aeruginosa was incubated with NP108, the slight K+ 
loss observed from the test bacteria was only statistically significant between the 
2xMIC (0.5 mg/ml) incubated bacteria (3%) and the control (1%). No statistically 
significant difference in K+ loss from the bacterium was seen between the MIC (0.25 
mg/ml) (2%) and 2xMIC NP108 concentrations. Concentration of NP108 alone was 
directly responsible for stimulating K+ loss from P. aeruginosa cells, and this 
required a concentration of 0.5 µg/µl of NP108, twice the concentration that was 
required to induce a large K+ loss from E. coli. 
As the bacterial viability checks on MIC and 10xMIC colistin incubated P. aeruginosa 
revealed small colony variants at 24 hours in; these viability checks were extended 
to include 60 minute and 24-hour analysis of NP108 incubated bacteria. The test 
bacterial control or 1/20th MIC NP108 incubated cells produced normal sized 
colonies at both 60 minutes and 24-hours. However, every bacterial species 
incubated with MIC or 2xMIC NP108 revealed small colony variants at both time 
periods. The appearances of small colony variants have been reported with equal 
frequency in planktonic cells and biofilms following antimicrobial exposure (Singh et 
al. 2009). The presence of small colony variants in bacterial cultures under stress is 
common and serves to ensure survival of the bacterial species (Singh et al. 2009). 
A Bacillus colony can collectively decide to sporulate if growth conditions become 
too stressful, once agreed by the majority of the bacteria present in the colony, 
induced through specific intracellular bacterial signalling (Ben Jacob et al. 2004). 
Bacteria use signal transduction systems to communicate with each other to 
promote adaptation of the bacterial colony to the environment and this process of 
communication is commonly termed quorum sensing (Lyon and Novick 2004). 
These signals are autoinducers and responses are dependent on the signal 
produced and population density (Lyon and Novick 2004). Signals in Gram-positive 
122 
 
bacteria attach as ligands to extracellular receptors of two component signal 
transduction modules which then internalize the signal (Lyon and Novick 
2004)(Otto 2004). The homoserine lactone signals of Gram-negative bacteria enter 
the cell by diffusion and initiate responses upon binding to intracellular receptors 
(Lyon and Novick 2004)(Ben Jacob et al. 2004). Bacteria resistant to antibiotics 
send signals to other bacteria in the colony to announce this fact and bacteria 
lacking the resistance factor emit a response which is followed by conjugation. The 
rapid development of antimicrobial resistance in a bacterial community can 
therefore result from an initial small number of resistant cells. (Ben Jacob et al. 
2004) CAPs have been shown to induce leakage from bacterial cells (Reddy, Yedery 
and Aranha 2004)(Shai 1999).  
Though a consensus of opinion exists that CAPs exert their mechanism of action by 
selectively disrupting cell membranes, an exact mechanism of action for CAPs 
remains controversial (Reddy, Yedery and Aranha 2004). Four distinct methods 
have been suggested as the means through which CAPs interact with the bacterial 
cytoplasmic membrane and disrupt membrane integrity; these are termed the 
barrel stave, carpet, toroidal pore (Figures 1a) - c)) and aggregate models  (Hale 
and Hancock 2007). The experimental results displayed here regarding K+ loss from 
all three test bacteria incubated with the novel CAP NP108, where statistically 
significant K+ loss compared to control was shown for all three bacteria, is in 
agreement with membrane disruption being caused by this CAP. That 0.5 µg/µl of 
NP108 was needed to induce K+ loss of 3% in P. aeruginosa and S. aureus while 
causing 38% K+ loss in E. coli, could be due to differences in the composition of the 
Gram-negative cell envelope of E. coli and P. aeruginosa and less binding of the 
peptide to the Gram-positive cell wall. However these data clearly point to different 
degrees of selectivity of action upon the test species. 
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4.5 Conclusion 
Loss of K+ induced by triclosan in E. coli was linked to the concentration of triclosan 
used and the length of time over which E. coli was exposed to the bisphenol. 
Neither increasing the concentration of triclosan or extending the length of 
exposure of S. aureus to triclosan, affected the quantity of K+ loss that triclosan 
induced from this bacterium.  
Incubation of E. coli and S. aureus with colistin induced K+ loss that was solely 
dependent on the concentration used. No significant K+ loss was exhibited by P. 
aeruginosa when exposed to colistin compared to control bacteria.  
The effects of NP108 on the three test bacteria were varied; swift and statistically 
significant concentration dependent K+ loss compared to control was induced in all 
three test bacterial species. The most substantial K+ loss was seen in E. coli 
incubated with NP108, with P. aeruginosa requiring a higher concentration of the 
peptide for the induction of a statistically significant potassium loss compared to 
control. K+ loss induced by NP108 was shown to be independent of the length of 
exposure of the bacteria to the peptide. 
All three bacterial species produced small colony variants in response to incubation 
with MIC and 2xMIC NP108, while only P. aeruginosa produced small colony 
variants in response to incubation with MIC and 10xMIC colistin; probably a 
mechanism by the test bacteria to improve bacterial survival under the 
antimicrobial stress. 
Overall, K+ loss induced by triclosan was demonstrated to be a combination of 
concentration and exposure time, whereas K+ loss induced by colistin and NP108 
was shown to be dependent on concentration alone.  
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Chapter Five 
Examination by flow cytometry growth dynamics and loss 
of bacterial viability upon incubation with cationic 
antimicrobial compounds 
 
5.1 Introduction 
5.1.1 Background 
Until as recently as the late 1970‘s microscopy was the sole means available to 
scientists for examination and measurement of single microorganisms (Steen 
2000). Today, it is possible to measure individual bacterial cells within a population 
at a rate of 1000 cells per second using a flow cytometer (Steen 2000). During 
World War II, the U.S. Army pioneered use of such an instrument in experiments 
designed to detect bacteria and spores, thus the application of flow cytometers to 
microbiology supersedes its use as a tool for studying mammalian cells by many 
years. The Cytoflurorograph was the first commercial laser based flow cytometer 
launched in 1970, while Becton Dickinson launched the Fluorescence-activated cell 
sorter (FACS) in 1974. Once a feature specific to their cell type has been selectively 
labelled, individual cells within a homogenous population can be identified using 
such instrumentation (Porter and Pickup 2000). In essence flow cytometry 
measures fluorescence per individual cell or particle.  
5.1.2 Components of a flow cytometer  
The internal structure of a flow cytometer can be seen in Figure 5.1.  
 
125 
 
 
 
Figure 5.1 Internal structure and components of a functional flow cytometer. FS - forward 
scatter, PMT - Photo Multiplier Tube  
 
The flow cytometer contains a laser capable of exciting fluorochromes; the 
fluorochrome absorbs energy in the form of light and emits this light at a different 
wavelength. The flow cytometer used in this investigation was an EPICS® XL™, 
which possesses an argon laser with an excitation wavelength of 488nm. There are 
four detectors in the EPICS® XL™ so depending upon the requirement up to four 
different dyes can be used simultaneously to stain a sample and these fluorescence 
signals are detected on separate filters; for example fluorescein at 525nm on FL1 
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and PE CYANINE 5 at 675nm on FL4. The instrument also utilises 2 light scatter 
parameters, known as forward scatter and side scatter. An obscuration bar blocks a 
substantial amount of fluorescence and scattered light but will allow sufficient of 
both to get into the collection system while preventing almost all of the light 
reflected from the stream from going into the collection system. 
5.1.3 Hydrodynamic focussing 
As the sample of bacterial cells from a planktonic population enters the flow 
chamber or flow cell, the sample core is focused in the centre of the faster flowing 
sheath fluid, which presents a single file of particles to the laser. This process is 
known as hydrodynamic focusing and is shown in Figure 5.2. For bacteria to 
properly intercept the single wavelength beam of light the fluids in the system must 
be properly pressurised and free of debris and air bubbles at all times. The sample 
pressure and the sheath fluid pressure are different, the sample pressure being 
greater. Sheath pressure is constant whereas sample pressure in the EPICS® XL™ 
can be low, medium or high, although all these are pressures above sheath 
pressure. A sample pressure regulator controls the sample flow rate, achieved by 
changing the sample pressure relative to the sheath pressure. Increasing the 
sample pressure increases the width of the sample core, which results in increased 
flow rate. The diameter of the core stream is critical for both the accurate 
positioning of the cells in the laser and for identifying when more than one cell is in 
the laser beam such as doublets or triplets. The diameter of the core stream should 
ideally be similar to the diameter of the bacteria being analysed.  
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    Figure 5.2 Hydrodynamic focussing in a flow cytometer 
5.1.4 Analysing the fluid stream 
When a particle enters the laser beam and starts to scatter light or fluoresce, a 
voltage pulse is created. When the amount of light scattered exceeds a threshold, a 
set period of time for signal detection commences. The threshold can be set on any 
parameter but in this investigation the threshold was set on forward scatter. When 
a particle is in the centre of the laser light where maximum amount of scatter or 
fluorescence is achieved, the highest level of the pulse is achieved. The pulse 
returns to the baseline as the particle leaves the laser beam. The intensity of light 
scatter or fluorescence determines the height of the peak pulse. The distribution of 
the fluorescence determines the width of the pulse. Therefore, the total 
fluorescence (intensity and distribution) determines the area under the pulse. Cells 
with the same amount of total fluorescence but with different fluorescence 
intensities produce different peak pulses.  
A number of detectors are aligned at the point where the fluid stream passes 
through the beam of light, one detector is in line with the beam of light and several 
detectors are perpendicular to the beam of light. Light scatter is detected at two 
angles; forward scatter measures blue light scattered in the direction of the laser 
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path and gives information regarding bacterial size and shape. The amount of 
forward scatter is proportional to the size of the cell that scattered the laser light. A 
photodiode tube, which can convert light into either a current or a voltage, collects 
the forward scatter signal. Photodiodes are used for strong signals in cases where 
saturation is a potential problem as with forward scatter. 
All side scatter and fluorescence measurements are made at a 90° angle relative to 
the laser beam and each of these is connected to a separate photomultiplier tube. 
Photomultiplier tubes are more sensitive than photodiodes and are used to detect 
small amounts of fluorescence emitted from fluorochromes. Photo detectors have a 
band pass filter in front of them, which only allow a specific bandwidth of light to 
reach the detector (Figure 5.1). Signals can be amplified by applying a voltage to 
the photomultiplier tube that collects or detects the light, or by increasing the 
amplification gain.  
The laser light, which is directed to the side scatter and fluorescence detectors, 
passes through a series of dichroic filters. Dichroic filters can be either long pass of 
short pass and the photons of light which travel down channels are steered and 
split by these dichroic filters. A 488 nm dichroic long pass filter at a 450 angle to the 
incident light reflects light to the side scatter sensor but transmits fluorescent light 
of longer wavelengths. Some of the light is reflected at 900 to the incident light 
while part of the light is transmitted and continues on to the next dichroic filter. 
Side scatter measures blue light that is scattered off the internal components of the 
cell, such as the nucleolus and cytoplasmic granules, being a source of cell 
granularity. A short pass filter will transmit all wavelengths that are less than a 
specified wavelength, for example a 600 short pass filter will transmit all 
wavelengths less than 600 nm. The light the 488 nm long pass filter transmits, 
goes to a 488 nm laserblocking filter. The 488 nm laser blocking filter blocks any 
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remaining laser light and transmits only fluorescent light. The remaining optical 
filters separate the light for the four FL sensors and these are displayed in Table 
5.1.  
Dichroic 
long pass 
filter 
450 angle 
Reflected 
wavelength 
(nm) 
Filter 
type 
Transmitted 
wavelength 
(nm) 
Sensor 
type 
Detector 
name 
Dye  
detected 
None 488 Forward 
scatter 
488 
 
 
Photo 
diode 
FS None 
488  488 Side 
scatter 
N/A 
 
 
PMT SC None 
550  >550 525 Band 
Pass 
505 - 545 FLI FITC Fluorescein 
isothyocyanate  
SYTO® dyes 
600  
 
555 - 600 575 Band 
Pass 
560 – 590 
 
 
FL2 PE Phycoerythrin 
 
 
645  605 - 645 620 Band 
Pass 
605 - 635 FL3 ECD Propidium 
iodide 
ECD (Energy 
coupled dye) 
675  600 - 700 675 Band 
Pass 
660 – 700 
 
 
FL4 PC5 PE Cyanine 5 
Table 5.1 EPICS® XL™ filters and detectors. FS; forward scatter. SC; side scatter. 
PMT; photomultiplier tube 
 
Fluorescent chemicals attached to or within the bacterial cell are excited into 
emitting light of a longer wavelength than the light source and the fluorescent 
detectors pick up these signals. Filters designed to work at 90° to the incident light 
are placed in front of each detector. Light of a particular colour is separated from 
the light beam and directed to each detector using colour filters called dichroic 
filters that work at a 45° angle. These dichroic filters act in part like mirrors and are 
wavelength dependent; for example the first filter is a 488 nm dichroic long pass 
filter so any light up to and including 488 nm is blocked while light of a wavelength 
greater than 488 nm passes through the filter. The second filter is a 550 dichroic 
long pass filter therefore light between 489 and 550 nm is blocked and greater than 
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550nm passes through the filter. The third filter is a 600 nm dichroic long pass 
filter, so only light with a wavelength greater than 600 nm passes through this 
filter. Finally, light with a wavelength greater than 645 nm passes through the 
fourth dichroic long pass filter. The light from the dichroic filter is then directed 
through another filter, a band pass filter, which only permits passage of a very 
narrow beam of light (Table 5.1). There are four band pass filters in the EPICS® 
XL™ flow cytometer, termed FL1, FL2, FL3 and FL4. These bandpass filters are 
located in front of the photomultiplier tubes, or fluorescence detectors, to optimise 
the specificity of the detector for a particular fluorescent dye. This is achieved by 
only allowing a narrow range of wavelengths to reach the detector.  
The photomultiplier tubes generate electrical impulses proportional to the amount 
of incident light striking the detectors. The light signals (photons) reach the 
photomultiplier tube from the band pass filter and side scatter detector or in the 
case of forward scatter a photodiode, and are converted into a proportional number 
of electrons. These electrons are multiplied, hence creating a greater electrical 
current, which travels to the amplifier and is converted to a voltage pulse. Next the 
signals undergo analogue to digital conversion before being transmitted to the 
computer. The voltage pulse is given a digital value by the analogue-to-digital 
converter. The resolution of the data is also dependent on the analogue to digital 
converter; in the EPICS® XL™ the 10-bit analogue to digital converter converts the 
lowest to highest voltage into numbers from 1 to 1024. These numbers are referred 
to as channels. 
5.1.5 Fluorescent dyes 
Various dyes are used in flow cytometry to stain bacterial cells thus allowing the 
examination of the stained bacteria by different detectors. These dyes absorb the 
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laser light energy and emit fluorescence of different colours. Dyes may be bound 
within or on the cell surface; for example, SYTO 9 has a spectrum of excitation at 
420 nm and emission at 580 nm and enters living viable bacterium through specific 
pores and intercalates into DNA. Propidium iodide has an emission spectrum of 
excitation at 488 nm and emission at 640 nm, only diffuses across a damaged cell 
wall and intercalates into DNA (one molecule of propidium iodide binds per 4/5 base 
pairs of DNA). The differences in excitation and emission spectra means that SYTO 
9 will be picked up on FL1 and propidium iodide on FL3.  
When more than one dye is used to stain a bacterial population, colour 
compensation must be utilised. Colour compensation is an electronic subtraction 
method for correcting overlapping fluorescent signals. Each dye must be run 
independently first and parameters optimised before dual stained bacterial 
populations can be accurately separated. Once the colour compensation protocol is 
optimised, the flow cytometer can accurately identify and quantify the proportions 
of live and dead bacteria in a sample. In this investigation the use of both SYTO 9 
and propidium iodide to stain all bacterial samples permitted the simultaneous 
detection of living and dead bacteria. SYTO 9 enters the living and damaged cells 
and intercalates with DNA, however propidium iodide crosses only damaged cell 
walls/cytoplasmic membranes and, due to possessing two positive charges, 
propidium iodide has a higher affinity for DNA and displaces SYTO 9. Propidium 
iodide is excluded from cells with structurally intact cytoplasmic membranes 
because of the size and charge of the propidium molecule. 
5.1.6 Acquisition 
The process by which data is collected from samples in a flow cytometer is termed 
acquisition. A computer is connected to the flow cytometer and the computer 
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software handles the digital interface with the flow cytometer. The discriminator on 
a flow cytometer is a size exclusion bar, which allows particles, debris or cells below 
a certain size to be excluded from the data collection. If the discriminator is set too 
high, viable cells will be excluded and if it is set too low, interference due to debris 
will show up on the plots. Once the protocol is optimised for a particular bacterial 
species, gating the population can isolate the majority of detected cells and only 
data from this gated population will be collected. Clicking an icon on the flow 
cytometer tool bar allows the operator to draw a gate or line around the bacteria of 
interest. Figure 5.3 (a) demonstrates a typical dot plot displaying 2 gated 
populations, A and B; this data was collected on a linear scale; side scatter versus 
forward scatter. A logarithmic scale was used to collect all other flow cytometry 
data in this study.  
 
Figure 5.3 Several graphical representations of the same flow cytometry data: (a) dot plot 
displaying gated populations (b) density plot (c) tomogram plot (d) surface plot. SS Lin is 
Side Scatter Linear scale; FS Lin is Forward Scatter Linear scale 
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5.1.7 Aim of flow cytometry investigation 
Antimicrobials have many different modes of action, some resulting in changes in 
bacterial structure post antimicrobial exposure. Also, changes in the growth 
dynamics of a bacterial culture can occur. Flow cytometry was undertaken on 
treated bacterial populations to give qualitative and quantitative information on 
bacteria once antimicrobial exposure had occurred. During this investigation data 
was collected from 10,000 cells for each test sample at a flow rate of approximately 
500 cells per second.  
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5.2 Methodologies 
5.2.1 Preparation of samples for analysis by flow cytometry 
Samples of bacterial cultures incubated with either triclosan, colistin, NP101 or 
NP108 were prepared as described in Section 2.8.2 
5.2.2 Calibration of flow cytometer 
Prior to analysis of samples by flow cytometery, the instrument was calibrated as 
described in Section 2.8.1. 
5.2.3 Data analysis 
After completion of experiments, data analysis was performed using the EPICS® 
XL™ MCL on-board software provided by Beckman Coulter. 
5.3 Results  
5.3.1 Examination of the effects of triclosan on E. coli and S. 
aureus 
Bacterial cultures containing 1 x 106 cfu/ml of either E. coli or S. aureus were 
incubated with control, 1/20th MIC, MIC and 10xMIC triclosan and samples 
withdrawn for analysis at 24, 72 and 168 hours. Overlay histogram plots of data 
collected on FL1 (SYTO 9 fluorescence) by the flow cytometer of control and test 
bacteria and correlated culture viability are shown in Figures 5.4 and 5.6. For 
comparison purposes Figure 5.5 displays an overlay histogram plot of data collected 
on FL3 (propidium iodide fluorescence) with data gathered on FL1. All subsequent 
overlay histograms displayed in this Chapter will be based on data gathered on FL1 
only. 
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a) Escherichia coli 
 
Figure 5.4 E. coli 1x106 cfu/ml cultures incubated with different concentrations of triclosan 
(control; 1/20th MIC – 0.0035 g/ml; MIC - 0.07 g/ml;10xMIC - 0.7 g/ml) and stained with 
Syto 9 were examined at (a) 24 (b) 72 and (c) 168 hours. Viability of E. coli cultures (d) 
post triclosan incubation at 24, 72 and 168 hours. Data are representative of flow cytometry 
experiments performed in triplicate on three occasions.  
 
The control histogram portrays the normal bacterial size of an E. coli culture with 
bacterial cells continuously multiplying by binary fission, therefore two peaks in a 
control culture would represent the elongated cells prior to binary fission by the 
larger peak and the smaller peak representing the smaller just divided cells. From 
the data depicted in Figure 5.4 it is apparent that E. coli incubated with 10xMIC 
(0.7 g/ml) triclosan could not withstand the effects of this concentration of the 
antibacterial, as witnessed by the absence of a peak at 24, 72 or 168 hours 
incubation. The culture viability data also support this finding, with the 10xMIC 
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culture showing no viable bacteria at any time point. When flow cytometry 
protocols are optimised for each bacterial species, these protocols are based on 
gated populations of untreated control bacteria. Bacterial populations that have 
been exposed to antimicrobials and have been physically altered as a consequence 
may not therefore be detected. For instance bacteria, which have reduced in size, 
may now be below the discriminator. This accounts for the fact that bacterial cells 
that comprise small colony variants (as detailed in Chapter 4), though detected by 
viability checks, do not appear in the flow cytometry histograms.  
The matching overlay of the peaks for the control and 1/20th MIC cultures at all 
time points confirm very similar viability dynamics of these cultures. The presence 
of a single peak after 24 hours incubation indicates one homogenous sized group of 
bacteria within the sub-inhibitory culture with the control population displaying twin 
peaks; thus a heterogeneous bacterial population, with one bacterial group within 
the culture bigger than the other, possibly cells pre and post binary fission. This 
had changed at 72 hours to the appearance of three peaks, indicating the presence 
of three differently sized groups of bacteria within these populations; the minor 
peak closer to the y-axis representing bacteria much smaller in size to those in the 
two major peaks. The cultures at 168 hours incubation show two principal peaks 
therefore two bacterial groups, one larger than the other. That the histograms and 
viability of E. coli incubated with 1/20th MIC triclosan at 24, 72 and 168 hours were 
identical to control, which confirms the fitness cost or stress of incubation with 
1/20th MIC triclosan over 168 hours was insufficient to induce changes in the 
growth dynamics of this culture. From Chapter 3 the exposure of E. coli to sub-
lethal triclosan was shown to induce an additional tolerance to subsequent triclosan 
treatment. Therefore the 1/20th MIC culture would probably have a modified 
phenotype and would be worthwhile examining in future.  
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The MIC treated culture displayed no colonies that were viable after 24 hours 
incubation but had substantially recovered by 72 hours and displayed small colony 
variants as discussed in Chapter 4. The data gathered by the flow cytometer 
support this result, with a very small histogram peak for the MIC incubated bacteria 
visible at 24 hours but this had radically changed at 72 hours with the appearance 
of a much larger histogram equivalent to that of control and 1/20th MIC triclosan 
treated bacteria. The MIC histogram at 24 hours was further along the x-axis than 
the control and sub-inhibitory incubated bacteria, meaning the few detected 
bacteria were slightly larger than the bacteria in the other two cultures. This could 
be due to the detection of longer non-septated E. coli due to the effect of the 
inhibitory MIC concentration (which will be discussed and visualised in scanning 
electron micrographs in Chapter 6). The histogram for E. coli incubated with 
triclosan MIC at 72 hours was co-located with the control and 1/20th MIC peaks; 
therefore the bacteria in all three cultures were of a similar size. However, the MIC 
incubated bacteria at 168 hours, as shown by a very small broad histogram peak, 
identifies the bacteria in the MIC culture as a homogenous group of smaller bacteria 
compared to bacteria in the other cultures.  
The data collected on FL3 and FL1 shows a different location of the histogram peaks 
for all cultures, the FL3 data being closer to the y-axis (Figure 5.4). Data collected 
on FL3 is based on propidium iodide fluorescence (Figure 5.5) and as this 
fluorescent dye stains dead or dying cells and is excluded from living cells, the data 
collected on control and 1/20th MIC cultures does not show the detail on bacterial 
size and culture diversity as shown in the FL1 data; thus, control and sub-inhibitory 
cultures are represented by triple peaks in the 72 hour plot in FL1 data compared 
to a single peak in FL3 data. 
138 
 
 
 
Figure 5.5 E. coli 1x106 cfu/ml cultures incubated with different concentrations of triclosan 
(control; 1/20th MIC – 0.0035 g/ml; MIC - 0.07 g/ml;10xMIC - 0.7 g/ml) and stained with 
propidium iodide were examined at (a) 24 (b) 72 and (c) 168 hours. Viability of E. coli 
cultures (d) post triclosan incubation at 24, 72 and 168 hours. Data are representative of 
flow cytometry experiments performed in triplicate on three occasions.  
 
 
Conversely, the histogram peak for the MIC incubated bacteria is depicted as a 
single histogram peak at 72 hours in the FL1 data as opposed to a triple peaked 
histogram in the FL3 data.  
b) Staphylococcus aureus 
The overlay images of S. aureus incubated with triclosan (Figure 5.6) display single 
peaks representing control, 1/20th MIC (0.00275 µg/ml) and MIC (0.055 µg/ml) 
triclosan incubated bacteria. Very few bacteria were enumerated for 10xMIC (0.55 
µg/ml) triclosan culture at all time points indicating the inability of S. aureus to 
withstand this treatment. 
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Figure 5.6 S. aureus 1x106 cfu/ml incubated with different concentrations of triclosan 
(control; 1/20th MIC – 0.00275 g/ml; MIC - 0.055 g/ml;10xMIC - 0.55 g/ml) and stained 
with Syto 9 were examined at (a) 24 (b) 72 and (c) 168 hours. Viability of S. aureus (d) 
cultures post triclosan incubation at 24, 72 and 168 hours. Data are representative of flow 
cytometry experiments performed in triplicate on three occasions. 
 
 
The overlay histograms after 24 hours incubation reveal similarly placed peaks for 
control and 1/20th MIC triclosan cultures, however the histogram representing the 
sub inhibitory incubated bacteria was broader than control. These sub-inhibitory 
incubated bacteria therefore were similarly sized to control bacteria; however some 
of the sub-inhibitory bacterial cells were larger than those in the control population. 
Few bacteria were enumerated at the MIC concentration, as depicted by the 
appearance of a very small broad peak slightly further along the x-axis than control 
and 1/20th MIC histograms. The viability data after 24 hours triclosan incubation 
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support the flow cytometry data in that no viable cells were produced at this time 
point.  
Histograms of S. aureus at 72 hours display very similar patterns between control 
and sub-inhibitory incubated bacteria, with a single peak representing each culture. 
This suggests that at 72 hours the control and 1/20th MIC incubated bacteria were 
very similar to each other; a single homogeneous sized group of bacteria in each 
culture. The histogram for the MIC culture reveals this culture has recovered 
substantially against triclosan at 72 hours. The single histogram peak for the MIC 
culture is broadly in the same position on the x-axis as the control and 1/20th MIC 
cultures; thus, S. aureus in all three cultures were similar in size to one another. 
The survival and subsequent division of a few persister cells in the culture was most 
likely responsible for the presence of a histogram peak for the MIC concentration at 
72 hours. The 168 hour overlay plot reveals a similar situation with practically no 
variation in histogram breadth or location on the x-axis. Therefore bacteria from 
these three cultures possessed similar size and viability post 168 hour triclosan 
exposure relative to each other.  This is supported by the viability data at 72 and 
168 hours that shows little difference between control, 1/20th MIC and MIC triclosan 
S. aureus incubated bacterial populations.  
5.3.2 Examination of the effects of colistin on E. coli, S. aureus and P. 
aeruginosa 
a) Escherichia coli 
 
The inability of E. coli to withstand the MIC and 10xMIC concentrations of colistin 
(Figure 5.7) is evidenced by the absence of a histogram peak at any experimental 
time point. The viability data show the 10xMIC colistin incubated bacteria produced 
no viable bacteria over the experimental period.  The MIC incubated bacteria 
141 
 
viability had increased substantially at 72 hours but showed a four-log difference to 
control at 168 hours.  
 
 
Figure 5.7 E. coli cultures inoculated with 1x106 cfu/ml, incubated with different 
concentrations of colistin (control; 1/20th MIC – 0.15 g/ml; MIC - 3 g/ml;10xMIC - 30 
g/ml) and stained with Syto 9 were examined at (a) 24 (b) 72 and (c) 168 hours. Viability 
of E. coli cultures (d) inoculated with 1 x 106 cfu/ml, post colistin incubation at 24, 72 and 
168 hours. Data are representative of flow cytometry experiments performed in triplicate on 
three occasions.  
 
The control and 1/20th MIC cultures displayed histograms remarkably similar to 
each other at 24 and 72 hours, each displaying a homogenously sized population at 
24 hours and two differently sized bacterial groups at 72 hours. The control 
histogram at 168 hours showed a triple peaked histogram depicting a population of 
smaller bacteria co-existing with two groups of larger bacteria within the culture. 
Twin histograms were also depicted for the 1/20th MIC culture with small cells 
comprising the majority of bacteria in the culture that also contained a second 
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group of larger bacteria. The viability data also showed a difference between the 
control and sub-inhibitory bacteria, with more than one log-scale difference in 
viability between these two cultures at 168 hours.  
b) Staphylococcus aureus 
The lack of a detectable peak for the 10xMIC colistin incubated S. aureus (Figure 
5.8) verified the inability of the bacterium to withstand this concentration of the 
antibacterial, as confirmed by the viability data.  
 
 
 
Figure 5.8 S. aureus cultures inoculated with 1x106 cfu/ml, incubated with different 
concentrations of colistin (control; 1/20th MIC – 5 g/ml; MIC – 100 g/ml;10xMIC – 1 
mg/ml) and stained with Syto 9 were examined at (a) 24 (b) 72 and (c) 168 hours. Viability 
of S. aureus cultures (d) inoculated with 1 x 106 cfu/ml, post colistin incubation at 24, 72 
and 168 hours. Data are representative of flow cytometry experiments performed in 
triplicate on three occasions.  
 
The absence of a histogram peak for the MIC incubated bacteria at 24 hours is also 
verified by the viability data, as is the appearance of a peak for this culture at 72 
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and 168 hours. The triple peaked MIC histogram at 72 hours appeared further 
along the x-axis than the control and 1/20th MIC histograms, which indicated three 
differently sized groups of bacteria within the culture, the smaller group similarly 
sized to the control and sub-inhibitory bacteria, with the bigger group within the 
MIC culture larger in size compared to the bacteria in the other two cultures. 
The broad MIC histogram peak at 168 hours spanned the 1/20th and control 
histograms; this indicated a great diversity in bacterial size within the MIC culture. 
The histograms representing control and sub-inhibitory treatment were very similar 
at 24 hours, by 72 hours both histograms displayed broad bases indicating diversity 
in the size of bacteria within the cultures, with slightly bigger bacteria present in 
the sub-inhibitory compared to control culture. This situation had reversed at 168 
hours with the control bacteria now larger in size than the 1/20th MIC bacteria. 
c) Pseudomonas aeruginosa 
The data confirm that P. aeruginosa when incubated with 10xMIC colistin was 
unable to withstand exposure to that concentration of colistin due to the lack of a 
histogram peak (Figure 5.9). This is supported by the viability data which shows no 
viable bacteria were produced by P. aeruginosa incubated with 10xMIC colistin at 
24, 72 or 168 hours. P. aeruginosa incubated with MIC colistin displayed no 
histogram at 24 hours but the bacterium had recovered sufficiently by 72 hours to 
produce a single peaked narrow based histogram further along the x-axis than the 
control, indicating the MIC incubated bacteria were a single homogenous group 
larger in size than control or 1/20th MIC incubated bacteria. The MIC culture 
displayed a triple peaked histogram at 168 hours, indicating the presence of a large 
group of very small bacteria (peak close to the y-axis) and two other groups of 
larger bacteria, similar in profile to control and 1/20th MIC bacteria.  
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The broad spread of the control histogram base and twin peaks at 24 hours 
identified diverse bacterial sizes within this culture. The single histogram peak 
representing the 24 hour 1/20th MIC culture was similarly located with the main 
body of the control histogram but without the broad spreading histogram tail which 
reached the y-axis, indicating bacteria within the 1/20th MIC culture were equal in 
size to the majority of the control bacteria.   
 
 
Figure 5.9 P. aeruginosa cultures inoculated with 1x106 cfu/ml, incubated with different 
concentrations of colistin (control; 1/20th MIC – 0.075 g/ml; MIC – 1.5 g/ml;10xMIC – 15 
g/ml) and stained with Syto 9 were examined at (a) 24 (b) 72 and (c) 168 hours. Viability 
of P. aeruginosa cultures (d) inoculated with 1 x 106 cfu/ml, post colistin incubation at 24, 
72 and 168 hours. Data are representative of flow cytometry experiments performed in 
triplicate on three occasions.  
At 72 hours P. aeruginosa incubated with the sub-inhibitory colistin concentration 
exhibited a histogram that was closer to the y-axis than control, which indicated 
the bacteria were smaller in size than control bacteria. 
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The 168 hour histograms for control and 1/20th MIC cultures all displayed triple 
peaked histograms, similarly located on the x-axis, therefore both cultures 
possessed two differently sized groups of bacteria, very small bacteria (very close 
to the y-axis) and much larger bacteria further along the x-axis. 
5.3.3 Effects of NP101 on E. coli, S. aureus and P. aeruginosa 
a) Escherichia coli 
 
E. coli incubated with MIC and 2xMIC of NP101 were not detected by flow 
cytometry at 24 and 72 hours (Figure 5.10), which indicated the inability of the 
bacterium to tolerate the effects of the CAP.  
 
 
Figure 5.10 E. coli cultures inoculated with 1x106 cfu/ml, incubated with different 
concentrations of NP101 (control; 1/20th MIC – 0.025 mg/ml; MIC - 0.5 mg/ml;10xMIC – 5 
mg/ml) and stained with Syto 9 were examined at (a) 24 (b) 72 and (c) 168 hours. Viability 
of E. coli cultures (d) inoculated with 1 x 106 cfu/ml, post NP101 incubation at 24, 72 and 
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168 hours. Data are representative of flow cytometry experiments performed in triplicate on 
three occasions.  
 
At 168 hours a small peak from the MIC culture had appeared, most likely the 
result of tolerance developed by a very small number of E. coli cells to the presence 
of NP101. The viability data support the flow cytometry findings; with a small viable 
population produced by the 168 hour MIC incubated E. coli. The control histogram 
at 24 hours covered more than one log scale in width that revealed one 
heterogeneous population of bacteria of differing sizes. At 72 hours three separate 
peaks appeared on the control histogram, therefore a wide range of bacterial sizes 
were present in the culture. The 1/20th MIC histogram displayed two peaks at both 
24 and 72 hours, but these display a different profile. By 168 hours both control 
and 1/20th MIC cultures displayed very similar twin peaked histograms.  
b) Staphylococcus aureus 
Neither the MIC or 2xMIC S. aureus cultures were able to withstand incubation with 
NP101 as revealed by flow cytometry assessment over the experimental period. 
The viability data revealed the recovery of the MIC culture from 72 hours but these 
persister cells were not detected by the flow cytometry assay, probably due to size 
limitation. 
The control and sub-inhibitory concentrations displayed very similar peak profiles at 
24 hours indicating three groups of differently sized bacteria within the population. 
This changed to a single peak at 72 hours suggesting these bacterial populations 
were matched and similar in size. By 168 hours the control culture histogram was 
spread over several log scales and displayed two separate peaks, so the diversity of 
sizes within this culture was substantial. The sub-inhibitory culture at 168 hours 
also displayed a twin peaked histogram spread over several log scales, with the 
larger histogram peak closer to the y-axis, therefore the greater proportion of 
bacteria in this culture were smaller in size than control bacteria. 
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Figure 5.11 S. aureus cultures inoculated with 1x106 cfu/ml, incubated with different 
concentrations of NP101  (control; 1/20th MIC – 0.0125 mg/ml; MIC - 0.25 mg/ml;10xMIC – 
2.5 mg/ml) and stained with Syto 9 were examined at (a) 24 (b) 72 and (c) 168 hours. 
Viability of S. aureus cultures (d) inoculated with 1 x 106 cfu/ml, post NP101 incubation at 
24, 72 and 168 hours. Data are representative of flow cytometry experiments performed in 
triplicate on three occasions.  
 
Though the viability data revealed a four-log difference between control and 1/20th 
MIC incubated bacteria at 72 and 168 hours, the bacterial size was substantially 
similar between these two cultures. 
c) Pseudomonas aeruginosa 
 
The 2xMIC incubated bacteria were not able to withstand the effects of NP101 and 
no histogram was recorded for this culture at any time point. The MIC incubated 
bacteria were recorded at 24 hours as a small peak but no histograms were 
recorded for the 72 hour and 168 hour cultures. The viability data also supported 
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this evidence while neither the MIC or 2xMIC cultures produced viable bacteria at 
24, 72 or 168 hours.  
 
 
Figure 5.12 P. aeruginosa cultures inoculated with 1x106 cfu/ml, incubated with different 
concentrations of NP101 (control; 1/20th MIC – 0.0125 mg/ml; MIC - 0.25 mg/ml;10xMIC – 
2.5 mg/ml) and stained with Syto 9 were examined at (a) 24 (b) 72 and (c) 168 hours. 
Viability of S. aureus cultures (d) inoculated with 1 x 106 cfu/ml, post NP101 incubation at 
24, 72 and 168 hours. Data are representative of flow cytometry experiments performed in 
triplicate on three occasions.  
 
 
Control and 1/20th MIC histograms were very similar to each other over the 
experimental period. The peak representing a population of small cells had 
disappeared by 72 hours and only two larger groups of bacteria existed within each 
culture. The histograms for control and sub-inhibitory concentrations at 168 hours 
also exhibited two peaks, one peak very close to the y-axis and the other much 
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further along the y-axis, so the dynamics of the bacterial response varied 
substantially under the effect of NP101 over the experimental period.  
5.3.4 Examination of the effects of NP108 on E. coli, S. aureus and P. 
aeruginosa 
a) Escherichia coli 
 
The absence of histogram peaks for E. coli incubated with MIC and 2xMIC NP108 
indicated the inability of E. coli to tolerate the effects of NP108.  
 
 
Figure 5.13 E. coli cultures inoculated with 1x106 cfu/ml, incubated with different 
concentrations of NP108 (control; 1/20th MIC – 0.0125 mg/ml; MIC - 0.25 mg/ml;10xMIC – 
2.5 mg/ml) and stained with Syto 9 were examined at (a) 24 (b) 72 and (c) 168 hours. 
Viability of E. coli cultures (d) inoculated with 1 x 106 cfu/ml, post NP108 incubation at 24, 
72 and 168 hours. Data are representative of flow cytometry experiments performed in 
triplicate on three occasions.  
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This is also supported by the viability data at all time points. At 24 hours the 
control histogram revealed two groups of different sized bacteria within the culture. 
Triple peaks on both control and 1/20th MIC histograms at 72 hours revealed a 
range of bacterial sizes in both cultures, however the sub-inhibitory incubated 
bacterial groups were smaller in size compared to control. The control histogram at 
168 hours was practically identical to the 72 hour profile whereas the 1/20th MIC 
histogram, possessed one peak and a base extending over several log scales down 
to the y-axis, therefore the majority of these bacteria were substantially smaller 
than the control bacteria. 
b) Staphylococcus aureus 
 
S. aureus did not withstand the effects of MIC or 2xMIC NP108 at any time point 
(Figure 5.14), as indicated by the absence of histogram peaks for either of these 
two concentrations, the viability data generally support this finding.  
The histograms of control and 1/20th MIC cultures were very similar to each other 
at all time points assessed. Both cultures displayed single histogram peaks at 24 
hours. At 72 hours the histograms had moved closer to the y-axis, indicating the 
bacteria had decreased in size and each histogram exhibited a second small 
histogram peak further along the x-axis; therefore a small population of larger 
bacteria co-existed within the culture composed mainly of smaller bacteria. 
The control and sub-inhibitory histograms had bases extending down to the y-axis 
at 168 hours and two histogram peaks, so these cultures contained varying sizes of 
small bacterial cells, similarly sized with each other. 
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Figure 5.14 S. aureus cultures inoculated with 1x106 cfu/ml, incubated with different 
concentrations of NP108 (control; 1/20th MIC – 0.0125 mg/ml; MIC - 0.25 mg/ml;10xMIC – 
2.5 mg/ml) and stained with Syto 9 were examined at (a) 24 (b) 72 and (c) 168 hours. 
Viability of S. aureus cultures (d) inoculated with 1 x 106 cfu/ml, post NP108 incubation at 
24, 72 and 168 hours. Data are representative of flow cytometry experiments performed in 
triplicate on three occasions.  
 
c) Pseudomonas aeruginosa 
As previously seen with NP101, P. aeruginosa was unable to tolerate the effects of 
NP108 at either MIC or 2xMIC concentrations, as supported by the viability data. 
The control and 1/20th MIC plots were very similar at 24 hours, with two differently 
sized groups of bacteria within each culture. At 72 hours the histograms that 
represented each culture were very broad and extended right to the y-axis, which 
revealed a wide range of bacterial sizes. Control and sub-inhibitory histograms at 
168 hours both revealed twin histogram peaks very similar in size and location to 
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one another, one peak beside the y-axis and the other histogram peak further 
along the x-axis. 
 
 
Figure 5.15 P. aeruginosa cultures inoculated with 1x106 cfu/ml, incubated with different 
concentrations of NP108  (control; 1/20th MIC – 0.0125 mg/ml; MIC - 0.25 mg/ml;10xMIC – 
2.5 mg/ml) and stained with Syto 9 were examined at (a) 24 (b) 72 and (c) 168 hours. 
Viability of P. aeruginosa cultures (d) inoculated with 1 x 106 cfu/ml, post NP108 incubation 
at 24, 72 and 168 hours. Data are representative of flow cytometry experiments performed 
in triplicate on three occasions.  
 
 The lesser histogram peak represented small bacteria with the presence of the 
larger histogram peak further along the x-axis revealed the presence of a group of 
much larger bacteria within each of these cultures.                    
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5.4 Discussion 
5.4.1 Flow cytometry for analysing antimicrobial activity  
The multiparameter measurements obtained from flow cytometer analysis of a 
bacterial population can be used to measure microbial diversity (Koch, Robertson 
and Button 1996). The flow cytometer permits the individual physical and 
fluorescence properties of each bacterial cell within a sample containing tens of 
thousands bacterial cells to be recorded (Valdivia and Falkow 1998). Early flow 
cytometry studies have shown that the growth of bacterial cells within a culture 
differs substantially from one another (Broger et al. 2011). This lack of growth 
homogeneity may be due to various reasons such as phenotypic changes during the 
cell cycle, spontaneous genetic mutations in some bacteria or differences in 
bacterial microenvironments (Broger et al. 2011)(Hall 1995)(Dien and Srienc 
1991). Flow cytometry however permits the measurement of population 
distributions within bacterial cultures (Broger et al. 2011)(Rieseberg et al. 2001). 
Changes in bacterial cultures exposed to antimicrobials can also be measured to 
analyse the bacterial reactions to stresses induced by incubation with these agents. 
These bacterial responses to antimicrobial exposure can be diverse, ranging from 
morphological and size changes, alteration in bacterial growth rates, to bacterial 
death (Gant, Warnes and Phillips, I. and Savidge, G.F. 1993).   
However there are drawbacks associated with flow cytometry use. Analysis of 
bacterial viability through the utilisation of dyes requires caution as it has been 
shown that the viability of a propidium iodide labelled, heat treated S. aureus 
population detected by flow cytometry was lower than the viability recorded by 
plate count, due to the ability of some bacteria retaining sufficient membrane 
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integrity to exclude propidium iodide despite being non-culturable (Comas and 
Vives-Rego 1998).  
Also, optimised flow cytometry protocols are based on control bacteria with the 
discriminator set to exclude background noise and small sub-cellular particles or 
debris. However when analysing samples incubated with either MIC or supra-
inhibitory concentrations of an antimicrobial, the monitor at the time of data 
acquisition, showed a large component of detected events fell below the 
discriminator level set on forward scatter. Consequently these events representing 
material below 0.2 m were excluded from analysis and are not included in the 
overlay histograms presented in this investigation. Whether these were whole cells 
substantially smaller than those normally found or pieces of sub-cellular debris 
were un-clear.  
Longer acquisition times were also necessary for all MIC and 2/10xMIC cultures due 
to the smaller number of cells present. The maximum acquisition time and level of 
detected events were set at 100 seconds and 10,000 events respectively and while 
data acquisition for the control and 1/20th MIC cultures took 20 seconds to record 
this number of events for every test species analysed, neither the MIC or 2/10xMIC 
cultures, except for E. coli and S. aureus incubated with triclosan MIC (Figure 5.4 
and 5.5) and S. aureus and P. aeruginosa incubated with colistin MIC, (Figures 5.8 
and 5.9) had 10,000 events recorded within the time period set on the flow 
cytometer. While the rate of bacterial viability in these cultures is directly 
attributable to exposure to the cationic antibacterials, analysis of these cultures was 
limited by the detection parameters of the flow cytometer to accurately analyse 
particles below 0.2 m.  
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5.4.2 Effect of triclosan upon E. coli and S. aureus  
a) Escherichia coli 
Homogeneity in viability patterns were not displayed by E.coli control and triclosan 
incubated cultures. The control histograms display fluorescence associated with 
normal healthy bacterial cells to which the triclosan incubated cultures can be 
compared. The presence of viable cells in MIC and 10xMIC incubated bacteria was 
severely retarded through incubation with the bisphenol at 24 hours, resulting in 
insufficient numbers of bacteria being detected.  At 72 and 168 hours the MIC 
culture had recovered sufficiently to be measured, but the 10xMIC culture was 
unable to tolerate exposure to triclosan at this concentration over the experimental 
period. This was also demonstrated in Chapter 3 (Figure 3.3) where severe 
retardation in onset of logarithmic growth coupled with reduction in logarithmic 
growth was shown for the MIC (0.07 g/ml) bacteria and no growth was recorded 
at 10xMIC  (0.7 g/ml) triclosan.  
The presence of viable bacteria in the MIC culture at 72 hours could be attributed to 
the development of tolerance by E. coli to triclosan that has been demonstrated in 
this investigation (Chapter 3) and by other investigators (Russell 2004). The 
substantial increase in the number of bacteria in the MIC culture could also be 
explained by the reduction in triclosan available for interaction with the bacteria at 
72 hours, possibly through binding of the bisphenol to older bacteria within the 
culture, thus allowing cells composing the small colony variants to replicate and 
grow without the restraining influence of triclosan (Levy et al. 1999). The 
susceptibility of E. coli to triclosan concentrations of 0.07 µg/ml (MIC) displayed by 
the reduced growth rate of the bacterium is attributable to the ability of triclosan to 
inhibit fatty acid synthesis, subsequently reducing bacterial growth (Escalada et al. 
2005)(Heath et al. 2000). Up-regulation of efflux pumps in E. coli has also been 
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proposed as a mechanism of decreased susceptibility to triclosan, permitting the 
bacterial cell to expel the bisphenol from within the bacterium as quickly as it 
enters (Suller and Russell 2000). Thus given time, E. coli is far better able to 
tolerate the presence of triclosan. Exposure to the antibacterial results in increased 
production or increased activity of these efflux pumps in the exposed bacteria than 
normal. 
Another factor to be considered in recovery of the MIC culture is that as the 
incubation time increases and the availability of nutrients is reduced, susceptibility 
to antimicrobials decreases due to bacterial gene expression altering the bacterial 
envelope, which either reduces the permeability of the cell to the antimicrobial or 
the availability of fewer binding sites in the bacterium reducing the attachment of 
the agent to the bacterium and subsequent reduced antimicrobial effects (Gant, 
Warnes and Phillips, I. and Savidge, G.F. 1993)(Delcour 2009).  
The result of exposure to triclosan MIC over 168 hours resulted in size reduction in 
E. coli i.e. the MIC culture was composed of small bacteria, compared to normal 
sized bacteria forming the bulk of the control culture.  
b) Staphylococcus aureus 
As with E. coli the 10xMIC triclosan incubated S. aureus was unable to tolerate the 
effects of that concentration of the biocide and the culture did not grow; therefore 
no histograms were recorded for these cultures. Similarly with the MIC incubated E. 
coli culture, the growth at 24 hours had been sufficiently inhibited that only a small 
histogram was registered for this culture. The MIC culture had significantly 
recovered at 72 and 168 hours for histograms to be recorded at these time points, 
most likely as a result of the similar responses observed for E. coli.  
The MIC histogram at 72 and 168 hours were similarly located on the x-axis as the 
control histogram, therefore the MIC culture tolerated the effects of triclosan well 
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and the bacteria were similar in size and number to control. This was possibly due 
to S. aureus altering the permeability of its outer envelope to triclosan and up-
regulation of efflux pumps (Suller and Russell 2000). The effects of the sub-
inhibitory triclosan concentrations were well tolerated by S. aureus and the viability 
dynamics of these bacterial cultures substantially correlated to those of control 
culture. No fitness cost was placed on S. aureus as a result of incubation with the 
1/20th MIC triclosan. 
5.4.3 Effects of colistin on E. coli, S. aureus and P. aeruginosa  
a) Escherichia coli 
 
Incubation with MIC and 10xMIC colistin exerted a bactericidal effect on E. coli over 
the experimental period and E. coli did not develop tolerance as a result of 
exposure to colistin. The viability of MIC incubated bacteria was sufficiently 
inhibited that not enough bacteria were detected at 24, 72 or 168 hour assays to be 
detected. The reputed mode of action of colistin, as described in Chapter 3, is by 
diffusion through bacterial walls to undertake intracellular activity. Unlike the 
irreversible binding of triclosan to bacterial targets reducing the concentration of 
triclosan within the incubated cultures, the concentration of colistin over the 
experimental period appeared to remain constant and E. coli was un-able to 
develop tolerance or acquire resistance to either the MIC or 10xMIC colistin 
concentrations.  
Though the viability data revealed the MIC culture displayed small colony variants 
at 72 and 168 hours, any bacteria detected were too small to be registered as 
events and were registered as sub-cellular particles by the discriminator. The 
growth of the sub-inhibitory incubated bacteria was very similar to control at 24 
and 72 hours so these bacteria matched the control culture for size and rate of 
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growth. The bulk of the 168 hour 1/20th MIC culture however was composed of 
smaller bacteria than the control culture, which indicated this concentration of 
colistin caused a size reduction in E. coli at longer exposure times. 
b) Staphylococcus aureus 
The most significant finding from the exposure of S. aureus to colistin was the 
concentration tolerated by the Gram-positive bacterium. Colistin is a cyclic CAP that 
was first isolated from the Gram positive Bacillus polymyxa (El Solh and 
Alhajhusain 2009) which is not used clinically in the treatment of Gram positive 
infections (Maviglia, Nestorini and Pennisi 2009). This colistin MIC was 33 times 
greater than that tolerated by E. coli and 67 times greater than the concentration 
tolerated by P. aeruginosa. Though bacteria in the 24 hour MIC colistin culture were 
not detected, sufficient bacterial numbers were enumerated in the 72 and 168 hour 
cultures for these cultures to be represented in histogram form. This suggests the 
development of a tolerance by S. aureus to colistin or an alteration of a colistin 
target by S. aureus resulting in decreased susceptibility to the antibacterial. The 
location of the 72 hour MIC histogram registered these bacteria as being larger in 
size than control bacteria. From this data it is perhaps a result of doublets or 
triplets being registered as single large events rather than colistin causing an 
increase in S. aureus size for which some evidence is available (Chapter 6). The 
sub-inhibitory concentration was well tolerated by S. aureus and matched the 
control at 24 hours with slightly larger bacteria registered by the 72 hour culture 
compared to control, probably as a result of the aggregatory effect of colistin on S. 
aureus. Both sub-inhibitory and inhibitory colistin concentrations at 168 hours 
revealed similarly placed histograms closer to the y-axis than the control 
histogram. Therefore as previously seen with E. coli the effect of long term 
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exposure on S. aureus by colistin at these concentrations resulted in a decrease in 
bacterial size compared to control. 
c) Pseudomonas aeruginosa 
Exposure of P. aeruginosa to 10xMIC colistin recorded a bactericidal effect at all 
assay times, as was previously shown in Chapter 3 (Figure 3.14). As described for 
S. aureus, the inhibitory effects of the MIC concentration on P. aeruginosa resulted 
in a loss of a detectable population after 24 hours exposure, although the organism 
was detected at 72 and 168 hours. As such P. aeruginosa is more able to deal with 
colistin than E. coli, as evidenced by the presence of detectable cells by flow 
cytometry. The 72 hour histogram was further along the x-axis compared to control 
but as with S. aureus it is plausible to suggest that doublet or triplet cells were 
recorded as large singlet events rather than colistin causing a size increase in P. 
aeruginosa.  
The sub-inhibitory concentration was very similar to control at 24 hours but the 
viability dynamics had changed by 72 hours to reveal smaller bacteria within this 
culture. The data from control, sub-inhibitory and inhibitory concentrations were 
similar by 168 hours, revealing two group sizes of bacteria within each culture. 
However, as the un-treated control depicted the normal viability of this bacterium, 
neither of these colistin concentrations at this time point exerted a fitness cost on 
P. aeruginosa as both bacterial size and growth rate matched that of the untreated 
control.  
5.4.4 Effects of NP101 on E. coli, S. aureus and P. aeruginosa  
Exposure of E. coli to 2xMIC NP101 exerted a bactericidal effect on the bacterium, 
as previously revealed in Chapter 3 (Figure 3.16). The growth of MIC incubated 
bacteria was sufficiently inhibited that no cells were detected at either 24 or 72 
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hour assays; however, by 168 hours E. coli survivors had either developed a 
tolerance to or alteration of a target site such that a small histogram peak was 
recorded at this time point. Further investigation to elucidate whether this tolerance 
was stable or reversible upon de-sensitisation to NP101 would be worthwhile, as 
this would have serious implications as to whether CAPs could be used as 
therapeutic agents. Incubation with sub-inhibitory concentrations of NP101 caused 
changes in bacterial size over the experimental period, with bacterial size at 24 
hours similar to control, changing to smaller bacteria at 72 hours and reverting to 
normal bacterial size, as depicted by the control culture, by 168 hours. 
b) Staphylococcus aureus 
Both MIC and 2xMIC NP101 concentrations affected bacterial viability to such an 
extent that no histograms were recorded for either of these cultures at any time 
point. However, viability data showed a limited presence of some small colony 
variants in the MIC culture.  
Incubation of S. aureus with 1/20th MIC NP101 revealed histograms similar to 
control at 24 and 72 hours, while the viability data at 24 hours revealed viability of 
this culture being less than 1x102 cfu/ml. This could be due to variations 
experienced in cultivating S. aureus colonies on agar plates from planktonic 
cultures, as sufficient bacteria were present in this culture for enumeration in flow 
cytometry samples i.e. viable but not culturable (Trevors 2011). The 168 hour 
histogram revealed NP101 caused a reduction in size of the majority of the sub-
inhibitory incubated bacteria compared to control. 
c) Pseudomonas aeruginosa 
Tolerance to NP101 was not developed by P. aeruginosa to the MIC or 2xMIC 
concentration. A small histogram was displayed by the MIC culture at 24 hours, but 
by 72 hours insufficient bacteria were detected in this culture for a histogram to be 
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displayed. The 1/20th MIC culture revealed viability and bacterial size similar to 
control with no reduction in size after extended exposure to the CAP. 
5.4.5 Effects of NP108 on E. coli, S. aureus and P. aeruginosa  
Incubation with MIC and 2xMIC concentration of NP108 did not result in the 
development of tolerance by E. coli, S. aureus or P. aeruginosa to the antibacterial. 
Insufficient bacterial numbers were detected in all three bacterial species for peaks 
to be present in overlay histograms. 
As seen with NP101 exposure to the sub-inhibitory concentration of NP108 resulted 
in a reduction in bacterial size of E. coli over long term exposure to this peptide. 
However no size reduction was detected in Staphylococcus aureus after extended 
exposure to the sub-inhibitory concentration of NP108, whereas extended exposure 
of Pseudomonas aeruginosa to 1/20th MIC NP108 concentration resulted in slightly 
larger bacteria compared to control.  
5.5 Conclusion 
The sub-inhibitory triclosan concentration was well tolerated by both E. coli and S. 
aureus with neither culture exhibiting any apparent physiological stress. As with 
triclosan the supra-inhibitory 10xMIC colistin concentration was bactericidal against 
all three test species. E. coli alone of the test species did not develop a tolerance to 
the effects of the MIC colistin concentration. The reduction in size of S. aureus after 
prolonged exposure to the inhibitory colistin concentration was not detected in P. 
aeruginosa; however the colistin concentration tolerated by S. aureus was 67 times 
higher than that withstood by P. aeruginosa.  
Exposure of E. coli to the inhibitory concentration of NP101 resulted in what 
appeared to be tolerance to the CAP by 168 hours, requiring further investigation. 
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Tolerance to either MIC or 2xMIC NP108 did not develop in E. coli, S. aureus or P. 
aeruginosa over the experimental period.  
163 
 
Chapter Six 
Examination of the influence of cationic antibacterials 
upon test bacteria using scanning electron microscopy 
6.1 Introduction 
Scanning electron microscopy was used to examine any morphological or 
population changes in E. coli, S. aureus and P. aeruginosa incubated with sub-
inhibitory, inhibitory and supra-inhibitory concentrations of four antimicrobial 
agents; triclosan, colistin, NP101 and NP108. 
6.1.1 Electron Microscope  
The prototype of the electron microscope was developed in 1931 by Ernst Ruska 
and Max Knoll with the capacity for a 400 fold magnification. Instruments today are 
capable of magnifications in excess of one million fold and Figure 6.1 shows the 
internal components of a scanning electron microscope.  
 
Figure 6.1 Components of a scanning electron microscope 
An electron microscope uses a particle beam of electrons to illuminate a sample and 
obtain a magnified image. Within the electron microscope, electrostatic and 
electromagnetic lenses are used to control the electron beam and focus them to 
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form an image. The 50 picometre resolution of the electron microscope is due to 
electrons possessing wavelengths approximately 100,000 times shorter than visible 
light, permitting sample magnification by up to 10,000,000 times. 
6.1.2 Scanning Electron Microscope 
The scanning electron microscope (SEM) produces an image by scanning a very 
small spot on a sample with a focussed electron beam. This electron beam is in turn 
moved over every part of the sample being examined. At each point on the 
specimen, the incident electron beam loses some energy and this energy is 
converted into the emission of low-energy secondary electrons and heat. The 
electron current leaving the sample is collected and amplified and is then used to 
modulate the brightness of a cathode-ray tube (CRT). The movement of the CRT on 
the display screen exactly corresponds to the motion of the electron beam over the 
object. Any feature on a sample causing the electron current to change from point 
to point upon leaving, is recorded on the picture generated by the CRT. Thus 
variations in any property of the scanned area of the sample are recorded.  
6.1.3 Bacterial responses to incubation with antibacterial 
agents 
Investigation of bacterial responses to incubation with various concentrations of 
test antibacterials was undertaken via SEM. All test agents were cationic 
antibacterials with reputed known effects on bacterial membranes. However CAPs 
are reported to have several mechanisms of action (Hale and Hancock 2007)(Zhang 
and Falla 2006) and the exact mode of colistin activity remains to be identified 
(Clausell et al. 2003), while many groups have attributed direct activity on lipid 
synthesis by triclosan (Escalada et al. 2005)(McMurray, Oethinger and Levy 1998). 
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Therefore the effect of incubation with antibacterials possessing varied modes of 
action on the gross morphology of each test bacterium was undertaken in this 
investigation.  
Bacterial responses to incubation with increasing antibacterial concentrations were 
also investigated. Sub-inhibitory antibacterial concentrations can inhibit normal 
cellular functions without death ensuing (Dynes et al. 2009) so investigations were 
undertaken to determine whether bacterial morphology displayed by such treated 
bacteria proved different to that of bacteria incubated with growth inhibitory MIC or 
multiples of the MIC concentration. 
The response of bacteria reported to be resistant to or unaffected by some of the 
selected antimicrobials; such as P. aeruginosa to triclosan (Chuanchuen, Karkhoff-
Schweizer and Schweizer 2003) and S. aureus to colistin (Clausell et al. 2003), 
were also examined and results obtained compared with the effects displayed by 
susceptible bacteria.  
6.1.4 Morphology of test species 
Escherichia coli, family Enterobacteriaceae, is reported as being a blunt ended rod 
shaped Gram-negative bacterium 0.3-1 x 1–6 m in length, peritrichously 
flagellate, naturally existing as a pair of two bacteria or as single cells (Furchtgott, 
Wingreen and Huang 2011)(Singleton 1999). Staphylococcus aureus (Genus 
Staphylococcus) is a round or ellipsoidal non-motile Gram positive bacterium, 
approximately 1 m in diameter, naturally occurring as irregular clusters of 
bacteria, resembling bunches of grapes, from whence their name is derived. (Salton 
and Kim 1996)(Singleton 1999). Pseudomonas aeruginosa is a Gram-negative rod 
shaped bacterium 0.5-1 x 1.5 - 5 m in length, belonging to the family 
Pseudomonadacaea, occurring as single cells or groups of two/three cells, with 
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one/several un-sheathed typically polar flagella per bacterium (El Solh and 
Alhajhusain 2009)(Singleton 1999). 
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6.2 Methodologies 
6.2.1 Preparation of bacterial cultures for Scanning Electron 
Microscopy analysis 
All bacterial cultures were prepared for SEM examination as described in Section 
2.9. The images presented are representative of several similar images obtained 
across the field of view. Attempts have been made to ensure that operator 
subjectivity have been minimised.  
6.2.2 Scanning Electron Microscope data collection 
SEM micrographs in this investigation were collected at a magnification of 20,000 
and 50/100,000 and at a working distance of 7 - 8 mm. As triclosan incubated 
bacteria were the first to be examined, the magnification employed to capture 
these SEM images are not consistent as protocols were being optimised. However, 
the magnifications at which subsequent SEM images of colistin and CAP incubated 
bacteria were recorded, are identical.  
6.2.3 Selection of suitable bacterial density 
Initial SEM experiments employed a density of 1x106 cfu/ml, which proved a 
sufficient initial bacterial density for experiments of 24-hours duration and longer. 
However this bacterial density was insufficient when SEM analysis of cultures 
incubated for less than 24 hours was undertaken and as triclosan was examined 
initially, a cell density of 1x108 cfu/ml was selected. However, this concentration 
was revised downwards to 1x107 cfu/ml for all subsequent bacterial analysis when 
examination of this bacterial density proved suitable. The SEM images of NP101 
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and NP108 displayed here were prepared from the same bacterial cultures used for 
the flow cytometry experiments described in Chapter 5, Sections 5.3.3 and 5.3.4. 
6.3 Results  
6.3.1 SEM images of E. coli, S. aureus and P. aeruginosa 
incubated with triclosan 
a) Escherichia coli 
 
The morphology of E. coli control and triclosan incubated bacteria can be seen in 
Figure 6.2. The control micrographs revealed a normal morphological pattern; 
bacterial length being 2-3 µm and rod shaped cells of an E. coli culture under 
optimum conditions.  This served as a reference to which triclosan incubated 
bacteria could be compared. It can be clearly seen from the SEM images below that 
the reaction of E. coli to the presence of triclosan was swift. Within one hour‘s 
incubation with sub, MIC and supra-inhibitory triclosan concentrations, the effect of 
triclosan was manifest by the rounding of individual cells and inhibition of normal 
septation in the bacterium at all three triclosan concentrations. 
Bacterial size in the sub-inhibitory triclosan concentration was 1.5 µm in length; the 
non-septated chain in the MIC culture was 11.8 µm in length, with individual 
bacteria measuring just over 1 µm in length. The reduction in bacterial size due to 
incubation of E. coli with triclosan is inversely proportional to the increasing 
triclosan concentrations.  
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Figure 6.2 Scanning electron micrograph of 1x108 cfu/ml E. coli exposed to triclosan for 1 
hour: (a) control (b) 0.9 g/ml (1/20th MIC) (c) 18 g/ml (MIC) and (d) 180 g/ml (10xMIC) 
 
 
 
Figure 6.3 Scanning electron micrograph of 1x108 cfu/ml E. coli exposed to triclosan for 3 
hours: (a) control (b) 0.9 g/ml (1/20th MIC) (c) 18 g/ml (MIC) and (d) 180 g/ml 
(10xMIC).  
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At three hours incubation (Figure 6.3) with the agent, the long co-joined E. coli 
were more apparent especially at MIC concentration, where few single bacteria 
were now visible. Control bacteria were 1.3 µm in length, with 1/20th MIC bacteria 
measuring 6.5 µm for non-septated bacteria and 1.6 µm for individual bacteria. The 
visualized co-joined bacterial chain in the MIC culture was 18 µm long, while the 
bacteria visualised in the 10xMIC micrograph measured 1.2 µm and 2.5 µm 
respectively.  
Control bacteria were 1µm long at 6 hours (Figure 6.4) compared to 0.9µm for 
1/20th MIC bacteria.  
 
Figure 6.4 Scanning electron micrograph of 1x108 cfu/ml E. coli exposed to triclosan for 6 
hours: (a) control (b) 0.9 g/ml (1/20th MIC) (c) 18 g/ml (MIC) and (d) 180 g/ml 
(10xMIC). Viability after 6 hours; E. coli control 1.55x1011 cfu/ml; E. coli incubated with 
1/20th MIC triclosan 4.5x109 cfu/ml; MIC and 10xMIC triclosan incubated bacteria was < 10 
cfu/ml  
 
The inhibitory triclosan concentration still displayed aberrant septation behaviour 
with the presence of long chains of attached bacteria 9 µm in length, which also 
displayed a budding propensity (Figure 6.4 (c)). This budding effect suggested 
growth in E. coli was now occurring not only longitudinally but also in other 
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dimensions to the co-joined chain. The supra-inhibitory concentration continued to 
reveal co-joined bacteria. 
Incubation at 24 hours (Figure 6.5) revealed the normal size and typical blunt 
ended shape of E. coli control bacteria. A clumping effect of the sub-inhibitory 
triclosan concentration was more apparent at 24 hours; however bacterial length 
was equivalent to control. Flow cytometry data presented in Chapter 5 (Figure 5.4 
(a)) revealed control and 1/20th MIC bacteria were very similarly sized to one 
another, while the MIC treated bacteria that were detected were larger in size than 
these two cultures. The inhibition of normal bacterial septation was now displayed 
by the entire MIC incubated culture with cross-linked bacteria visible throughout 
this culture, which would account for the identification of larger bacteria in this 
culture by flow cytometry. 
 
Figure 6.5 Scanning electron micrograph of 1x106 cfu/ml E. coli exposed to triclosan for 24 
hours: (a) control (b) 0.0035 g/ml (1/20th MIC) (c) 0.07 g/ml (MIC) and (d) 0.7 g/ml 
(10xMIC). Viability after 24 hours; E. coli control 7.75x108 cfu/ml; E. coli incubated with 
1/20th MIC triclosan 7.5x108 cfu/ml; MIC and 10xMIC triclosan incubated bacteria was < 10 
cfu/ml  
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The 10xMIC culture was now displaying a gelling effect, previously reported for 
biocides on bacteria by other researchers (Barrett-Bee, Newboult and Edwards 
1994). This would explain why insufficient bacteria were detected by flow cytometry 
in the supra-inhibitory culture, as bacterial features employed in flow cytometry to 
identify bacteria within a culture, include forward scatter for size and bacterial 
shape and side scatter for granularity. 
The varied effects of triclosan on E. coli revealed in the 24 hour SEM images had 
intensified by 72 hours (Figure 6.6); namely aggregation in the sub-inhibitory 
concentration, non-septation at inhibitory concentration and gelling at the supra-
inhibitory concentration.  
 
Figure 6.6 Scanning electron micrograph of 1x106 cfu/ml E. coli exposed to triclosan for 72 
hours: (a) control (b) 0.0035 g/ml (1/20th MIC) (c) 0.07 g/ml (MIC) and (d) 0.7 g/ml 
(10xMIC). Viability after 72 hours; E. coli control 1.5x1010 cfu/ml; E. coli incubated with 
1/20th MIC triclosan 1.3x1010 cfu/ml; E. coli incubated with MIC triclosan 7.7x109 cfu/ml ; 
10xMIC triclosan incubated bacteria was < 10 cfu/ml 
 
The inhibitory concentration revealed the re-appearance of single bacteria, co-
existing with the non-septated bacteria. Flow cytometry data in (Figure 5.4 (b)) 
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revealed the re-appearance of normal sized cells in the MIC culture in the 72-hour 
overlay plot, which were absent from the overlay plot describing the 24-hour 
cultures. The viability of E. coli exposed to the inhibitory triclosan concentration had 
recovered substantially (Figure 5.4 (D)) and the bacteria were exhibiting a 
tolerance to triclosan gained through exposure to the bisphenol for 72 hours.  
After 168 hours incubation normal E. coli bacteria 1 µm long can be seen in the 
control culture (Figure 6.7 (a)).  
 
Figure 6.7 Scanning electron micrograph of 1x106 cfu/ml E. coli exposed to triclosan for 
168 hours: (a) control (b) 0.0035 g/ml (1/20th MIC) (c) 0.07 g/ml (MIC) and (d) 0.7 
g/ml (10xMIC). Viability after 168 hours; E. coli control 6.3x1010 cfu/ml; E. coli incubated 
with 1/20th MIC triclosan 5.5x1010 cfu/ml; E. coli incubated with MIC triclosan 7.6x109 cfu/ml 
; 10xMIC triclosan incubated bacteria was < 10 cfu/ml  
 
 
The 1/20th MIC incubated culture revealed large aggregated bodies of bacterial 
cells.  Whilst bacterial viability was not affected by 1/20th MIC triclosan, the degree 
of bacterial aggregation was. Incubation with the MIC concentration for 168 hours, 
revealed co-joined E. coli as well as individual bacterial cells, smaller in size than 
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control cells. It is important to note that after both 72 and 168 hours incubation 
with triclosan, the MIC treated culture displayed a viable population. 
At 168 hours the bacteria in the 10xMIC culture revealed barely discernible 
bacterial outlines clumped in a gelled mass, in keeping with the loss of a viable 
population. This is supported by flow cytometry data (Figure 5.4 (c)) where the MIC 
culture revealed bacteria smaller in size than control cells and few bacteria were 
acquired in the 10xMIC culture.  
b) Staphylococcus aureus 
S. aureus cultures were examined after incubation with triclosan for one hour 
(Figure 6.8).  
 
 
Figure 6.8 Scanning electron micrograph of 1x108 cfu/ml S. aureus exposed to triclosan for 
1 hour: (a) control (b) 0.7 g/ml (1/20th MIC) (c) 14 g/ml (MIC) and (d) 140 g/ml 
(10xMIC) (b) S. aureus 1x106 cfu/ml culture.  
 
The control culture displayed clusters of bacteria between 0.7 – 1 µm in diameter. 
Incubation in the sub-inhibitory triclosan concentration caused S. aureus cells to 
form spherical aggregates approximately 16 µm in diameter. Spherical aggregates 
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were also observed in the MIC and 10xMIC culture but were imperfectly formed in 
the 10xMIC culture. 
Images obtained for 3 hours exposure (Figure 6.9) revealed bacteria of a normal 
size in the control culture, whilst single and aggregated bacteria were visualised in 
the 1/20th MIC culture, although the larger spherical entities from one hour were 
missing. The MIC and 10xMIC cultures continued to display spherical cellular 
aggregates, with larger aggregates observed in the MIC culture, and no normal 
clusters of two to three bacterial cells.  
 
Figure 6.9 Scanning electron micrograph of 1x108 cfu/ml S. aureus exposed to triclosan for 
3 hours: (a) control (b) 0.7 g/ml (1/20th MIC) (c) 14 g/ml (MIC) and (d) 140 g/ml 
(10xMIC).  
 
By 6 hours incubation (Figure 6.10) bacterial sizes in all the cultures were similarly 
sized and the aggregatory effect of triclosan on S. aureus was more apparent as 
the concentration of triclosan increased. However in both MIC and 10xMIC 
populations there was a lack of the larger spherical structures observed at one and 
three hours. These must have disassembled. 
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Figure 6.10 Scanning electron micrograph of 1x108 cfu/ml S. aureus exposed to triclosan 
for 6 hours: (a) control (b) 0.7 g/ml (1/20th MIC) (c) 14 g/ml (MIC) and (d) 140 g/ml 
(10xMIC). Viability after 6 hours; S. aureus control 5.6x109 cfu/ml; S. aureus incubated 
with 1/20th MIC triclosan 3.8x108 cfu/ml; MIC and 10xMIC triclosan incubated bacteria was 
< 10 cfu/ml  
 
 
After 24 hours incubation (Figure 6.11) the control culture revealed the normal 
staphylococcal morphology and size. The presence of aggregates in the sub-
inhibitory culture was universal on the sample surface, which also revealed single 
cells. Large, well formed and regular spherical structures of dimensions varying 
from 2 – 19 µm were observed in both MIC and 10xMIC cultures with no single cells 
visible in either culture. Results presented in Figure 5.6 (a) after 24 hours 
incubation with triclosan, revealed the absence of cells in the MIC and 10xMIC 
cultures at this time point; examination of the SEM data for both these cultures 
revealed the presence of far fewer bacteria (single or aggregated), compared to 
control and sub-inhibitory cultures.  
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Figure 6.11 Scanning electron micrograph of 1x106 cfu/ml S. aureus exposed to triclosan 
for 24 hours: (a) control (b) 0.7 g/ml (1/20th MIC) (c) 14 g/ml (MIC) and (d) 140 g/ml 
(10xMIC). Viability after 24 hours; S. aureus control 1.4x109 cfu/ml; S. aureus incubated 
with 1/20th MIC triclosan 1.4x109 cfu/ml; MIC and 10xMIC triclosan incubated bacteria was 
< 10 cfu/ml 
 
It is worth noting at this stage that SEM samples were prepared by concentrating a 
10 ml culture sample to 2.5 ml final volume by brief centrigugation, with one ml 
passed through a 0.2 m filter; whereas samples for flow cytometry analysis 
employed 10 l of culture. Therefore while the quantities of bacterial aggregates 
would suggest the both these cultures possessed enough bacteria at 24 hours to be 
observed in flow cytometry, in reality there was a 1000-fold difference in the 
volume of culture employed to prepare samples for SEM and flow cytometry. This 
being the case, density of cells on the SEM samples is important; there are far 
more bacteria present on control and 1/20th MIC samples than on MIC and 10xMIC 
samples. Thus enumeration of too few bacterial cells for these cultures resulted in 
their non-representation in the 24-hour overlay images in flow cytometry. 
By 72 hours (Figure 6.12), the presence of spherical aggregates were still apparent 
at all three triclosan concentrations, however the MIC culture now revealed both 
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individual and spherical aggregated cells, which correlated with the data presented 
in Chapter 5 (Figure 5.6 (b)) where the viability of S. aureus incubated with MIC of 
triclosan had recovered by 72 hours. The individual cells were probably viable, with 
the aggregates containing non-viable cell remnants.  
 
Figure 6.12 Scanning electron micrograph of 1x106 cfu/ml S. aureus exposed to triclosan 
for 72 hours: (a) control (b) 0.7 g/ml (1/20th MIC) (c) 14 g/ml (MIC) and (d) 140 g/ml 
(10xMIC). Viability after 72 hours; S. aureus control 6.5x109 cfu/ml; S. aureus incubated 
with 1/20th MIC triclosan 5.0x109 cfu/ml; S. aureus incubated with triclosan MIC 2.95x1010 
cfu/ml; 10xMIC triclosan incubated bacteria was < 10 cfu/ml 
 
 
This recovery of the MIC culture by 72-hours meant the re-appearance of cells in 
the inhibitory culture, with bacterial size similar to control, as revealed by the SEM 
micrographs. 
Investigation of all bacterial cultures at 168 hours (Figure 6.13) showed the normal 
size and shape of S. aureus, whilst the aggregatory effect of triclosan on the 
bacterium was still visible in all three test triclosan concentrations. Both sub-
inhibitory and inhibitory concentrations also possessed individual cells co-existing 
with aggregated spherical entities, which indicated S. aureus developed a tolerance 
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or resistance to triclosan, manifested as the de-aggregation of the majority of the 
visualised bacterial cells. 
 
 
Figure 6.13 Scanning electron micrograph of 1x106 cfu/ml S. aureus exposed to triclosan 
for 168 hours: (a) control (b) 0.7 g/ml (1/20th MIC) (c) 14 g/ml (MIC) and (d) 140 g/ml 
(10xMIC). Viability after 168 hours; S. aureus control 2.9x1010 cfu/ml; S. aureus incubated 
with 1/20th MIC triclosan 5.9x1010 cfu/ml; S. aureus incubated with triclosan MIC 2.9x1010 
cfu/ml; 10xMIC triclosan incubated bacteria was < 10 cfu/ml 
 
c) Pseudomonas aeruginosa 
Flow cytometry was not performed on P. aeruginosa as the bacterium was reported 
to be resistant to triclosan and determination of an MIC for triclosan against P. 
aeruginosa in this investigation (Figure 3.9) only resulted in an MIC being 
determined for a time period of 32 hours. This time period permitted the monitoring 
of morphological responses by P. aeruginosa to the presence of triclosan.  
Different time points were selected for SEM analysis compared to E. coli and S. 
aureus as preliminary experiments revealed longer exposure times to triclosan were 
necessary for effects of the antibacterial on the bacterium to be visualised. 
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Figure 6.14 Scanning electron micrograph of 1x106 cfu/ml P. aeruginosa exposed to 
triclosan for 4 hours: (a) control (b) 18 g/ml (1/20th MIC) and (c) 360 g/ml (MIC). 
Viability after 4 hours; P. aeruginosa control 1.2x108 cfu/ml; P. aeruginosa incubated with 
1/20th MIC triclosan 8.5x107 cfu/ml; P. aeruginosa incubated with triclosan MIC < 10cfu/ml 
 
After four hours incubation (Figure 6.14) control bacteria displayed bacteria of 
normal shape and size. P. aeruginosa incubated with 1/20th MIC triclosan were 
longer at 2.5 µm, while the inhibitory concentration contained bacteria from 1.3 to 
7 µm long. A number of spherical shaped entities were also visualised in the MIC 
culture.  
After eight hours incubation (Figure 6.15) the control sample revealed normal 
bacteria, with the sub-inhibitory culture containing bacteria ranging in size from 1.3 
to 7.3 µm in length. The spherical shaped entities had disappeared from the 
inhibitory culture but the length of single bacteria varied in size from 1.3 –5 µm. 
The sparse number of bacteria visualised in the MIC sample was in stark contrast to 
the control and 1/20th MIC cultures. 
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Figure 6.15 Scanning electron micrograph of 1x106 cfu/ml P. aeruginosa exposed to 
triclosan for 8 hours: (a) control (b) 18 g/ml (1/20th MIC) and (c) 360 g/ml (MIC). 
Viability after 8 hours; P. aeruginosa control 1.2x109 cfu/ml; P. aeruginosa incubated with 
1/20th MIC triclosan 9.2x108  cfu/ml; P. aeruginosa incubated with triclosan MIC < 10cfu/ml 
 
 
 
Figure 6.16 Scanning electron micrograph of 1x106 cfu/ml P. aeruginosa exposed to 
triclosan for 24 hours: (a) control (b) 18 g/ml (1/20th MIC) and (c) 360 g/ml (MIC). 
Viability after 24 hours; P. aeruginosa control 5.6x1010 cfu/ml; P. aeruginosa incubated with 
1/20th MIC triclosan 3.5x1010 cfu/ml; P. aeruginosa incubated with triclosan MIC < 10cfu/ml 
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After 24 hours incubation (Figure 6.16) the difference between the control and 
triclosan incubated bacteria was substantial. Sub-inhibitory incubated bacteria 
displayed a variety of bacterial sizes that appeared to be interconnected by a fine 
thread like substance, possibly fimbriae. This culture also demonstrated some 
aggregation of the bacteria compared to control cells. The MIC culture displayed no 
familiar rod-shaped bacteria but had transformed into spherical shaped entities 
bearing a roughened exterior in response to exposure to this concentration of 
triclosan.  
The last time point sampled was 32 hours (Figure 6.17) as P. aeruginosa had 
developed sufficient tolerance to triclosan after this time, most likely due to the up-
regulation of MDR efflux pumps (Chuanchuen, Karkhoff-Schweizer and Schweizer 
2003), that an MIC could not be determined, due to the limitations of the solubility 
of triclosan. 
 
 
Figure 6.17 Scanning electron micrograph of 1x106 cfu/ml P. aeruginosa exposed to 
triclosan for 32 hours: (a) control (b) 18 g/ml (1/20th MIC) and (c) 360 g/ml (MIC). 
Viability after 32 hours; P. aeruginosa control 7.8x1010 cfu/ml; P. aeruginosa incubated with 
1/20th MIC triclosan 6.3x1010 cfu/ml; P. aeruginosa incubated with triclosan MIC < 10cfu/ml 
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P. aeruginosa incubated with 1/20th MIC triclosan displayed bacterial sizes from 1.7 
to 9 µm in length and some of the extracellular material interconnecting the 
bacteria was still evident. The MIC culture displayed spherical shapes approximately 
1.5 µm in diameter. Thus P. aeruginosa displayed a number of morphological 
changes in response to triclosan exposure. The sub-inhibitory concentration 
revealed no visible effects at four hours exposure; that had changed to non-
septated bacterial cells co-existing with bacteria of normal length after eight hours 
triclosan exposure. Incubation of 24 hours and longer revealed fine strands of 
cellular material were interconnecting the bacteria, with the 24 and 32 hour 
incubated cultures revealing aggregation of cells compared to control. 
6.3.2 SEM images of E. coli, S. aureus and P. aeruginosa 
incubated with colistin 
a) Escherichia coli  
 
The control bacteria after one hour incubation (Figure 6.18) exhibited cells of 
normal shape and size between 1.5 – 2.5 µm. Large, spherical cellular aggregates 
were present throughout the sub-inhibitory culture, with clearly visible E. coli cells 
approximately 1.3 µm in length on the aggregate surface. Single cells were also 
visible in the sub-inhibitory, inhibitory and supra-inhibitory concentrations, similarly 
sized to control bacteria. Aggregated cells were seen in the MIC and 10xMIC 
concentrations, however, the structures in the 10xMIC concentration were half the 
size of those visualised in the MIC culture. 
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Figure 6.18 Scanning electron micrograph of 1x107 cfu/ml E. coli exposed to colistin for 1 
hour: (a) control (b) 0.49 g/ml (1/20th MIC), (c) 9.8 g/ml (MIC) and (d) 98 g/ml 
(10xMIC)  
 
 
Figure 6.19 Scanning electron micrograph of 1x107 cfu/ml E. coli exposed to colistin for 3 
hours: (a) control (b) 0.49 g/ml (1/20th MIC), (c) 9.8 g/ml (MIC) and (d) 98 g/ml 
(10xMIC)  
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After three hours incubation with colistin (Figure 6.19) the 1/20th MIC incubated 
bacteria resembled the control culture far more than at 1 hour, with single cells co-
existing with aggregated cells. The MIC culture also displayed single misshapen 
bacteria and spherical structures. No single rod shaped E. coli were visible in the 
10xMIC sample, which contained variously sized spherical structures. 
The appearance of un-treated E. coli bacteria (Figure 6.20) was substantially 
different to exposed bacteria at 6 hours. The sub-inhibitory and inhibitory 
concentrations displayed large and small spherical structures with only large 
spherical structures approximately 15 µm in diameter observed in the 10xMIC 
sample.   
 
Figure 6.20 Scanning electron micrograph of 1x107 cfu/ml E. coli exposed to colistin for 6 
hours: (a) control (b) 0.49 g/ml (1/20th MIC), (c) 9.8 g/ml (MIC) and (d) 98 g/ml 
(10xMIC). Viability after 6 hours; E. coli control 3.2x109 cfu/ml; E. coli incubated with 1/20th 
MIC colistin 1.1x109  cfu/ml; E. coli incubated with colistin MIC and 10xMIC < 10cfu/ml 
 
After 24 hours incubation (Figure 6.21), E. coli control exhibited shape and sizes 
typical of the bacterium. The micrographs of bacteria in all three colistin incubated 
cultures continued to reveal spherical aggregates.  The outline of E. coli cells can be 
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detected as the component parts of these spherical structures. The composition of 
the material connecting these cells appears to have been extruded from within the 
bacterial interiors as a defence mechanism in the formation of spherical entities to 
improve bacterial survival due to incubation with colistin. 
Results from flow cytometry (Figure 5.7 (a)) revealed control and sub-inhibitory 
cultures were similar in size to one another, which agree with the SEM micrographs. 
Insufficient numbers of bacteria were enumerated – limit was set for 10,000 
bacteria within 100 seconds - for the MIC and 10xMIC cultures to be represented by 
flow cytometry. 
 
Figure 6.21 Scanning electron micrograph of 1x107 cfu/ml E. coli exposed to colistin for 24 
hours: (a) control (b) 0.49 g/ml (1/20th MIC), (c) 9.8 g/ml (MIC) and (d) 98 g/ml 
(10xMIC). Viability after 24 hours; E. coli control 3.6x1010 cfu/ml; E. coli incubated with 
1/20th MIC colistin 1.13x1010 cfu/ml; E. coli incubated with colistin MIC and 10xMIC < 
10cfu/ml 
 
SEM images of colistin incubated bacteria at 72 hours, displayed the de-aggregation 
of the sub-inhibitory incubated E. coli, though morphological distortion of bacterial 
cells from rod to round shaped cells was apparent. The MIC and 10xMIC samples 
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only contained spherical structures, the density of which was very low compared to 
control and 1/20th MIC samples. 
 
Figure 6.22 Scanning electron micrograph of 1x107 cfu/ml E. coli exposed to colistin for 72 
hours: (a) control (b) 0.49 g/ml (1/20th MIC), (c) 9.8 g/ml (MIC) and (d) 98 g/ml 
(10xMIC). Viability after 72 hours; E. coli control 3.7x109 cfu/ml; E. coli incubated with 
1/20th MIC colistin 1.1x109 cfu/ml; E. coli incubated with colistin MIC 7.0x107 cfu/ml; E. coli 
incubated with 10xMIC colistin < 10cfu/ml 
 
Incubation of E. coli for 168 hours (Figure 6.23) revealed rod shaped control 
bacteria approximately 2 µm in length, with the 1/20th MIC culture displayed both 
single as well as bacterial aggregates. The exposure to the sub-inhibitory colistin 
concentration had not only caused a rounding in E. coli cells, they were 
substantially smaller than control bacteria. Flow cytometry data (Figure 5.7 (c)) 
had previously revealed a smaller bacterial size in the 1/20th MIC culture compared 
to control. Sparse clusters of aggregated cells were visualised in the MIC and 
10xMIC samples, explaining the absence of histograms in the flow cytometry 
overlay images due to insufficient bacterial numbers in these cultures. Bacterial 
replication through binary fission was visible over the experimental period in un-
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treated bacteria. This phenomenon was also identified in the 1/20th MIC incubated 
bacteria but was not observed at any point in either the MIC or 10xMIC incubated 
bacteria. 
 
Figure 6.23 Scanning electron micrograph of 1x107 cfu/ml E. coli exposed to colistin for 
168 hours: (a) control (b) 0.49 g/ml (1/20th MIC), (c) 9.8 g/ml (MIC) and (d) 98 g/ml 
(10xMIC). Viability after 168 hours; E. coli control 1.3x1010 cfu/ml; E. coli incubated with 
1/20th MIC colistin 5.3x108 cfu/ml; E. coli incubated with colistin MIC 6.3x106 cfu/ml; E. coli 
incubated with 10xMIC colistin < 10cfu/ml 
 
b) Staphylococcus aureus  
A different time scale was selected for the S. aureus SEM micrographs (Figure 6.24 
a)), to highlight the incredibly swift reaction of this bacterium when incubated with 
a very high colistin concentration of 156 µm/ml. Colistin is not used clinically in the 
treatment of Gram-positive infections. Control bacteria at 30 minutes were 
ellipsoidal in shape and approximately 1 µm in diameter. Incubation with the sub-
inhibitory, inhibitory and supra-inhibitory colistin concentrations for merely 30 
minutes (Figure 6.24) resulted in the formation of cellular spheres. The structure of 
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the spheres became more developed as the concentration of colistin increased; with 
the least well-developed spherical aggregates in the 1/20th MIC culture. 
 
Figure 6.24 Scanning electron micrograph of 1x107 cfu/ml S. aureus exposed to colistin for 
30 minutes: (a) control (b) 7.8125 g/ml (1/20th MIC) (c) 156 g/ml (MIC) and (d) 1560 
g/ml (10xMIC)  
 
Figure 6.25 Scanning electron micrograph of 1x107 cfu/ml S. aureus exposed to colistin for 
1 hour: (a) control (b) 7.8125 g/ml (1/20th MIC) (c) 156 g/ml (MIC) and (d) 1560 g/ml 
(10xMIC) 
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The micrographs at one hour (Figure 6.25) exhibited the substantial difference 
between the control and exposed bacteria. A great proportion of bacteria in the 
three colistin incubated cultures had formed large spherical structures with few 
single bacteria visible. 
 
Figure 6.26 Scanning electron micrograph of 1x107 cfu/ml S. aureus exposed to colistin for 
3 hours: (a) control (b) 7.8125 g/ml (1/20th MIC) (c) 156 g/ml (MIC) and (d) 1560 g/ml 
(10xMIC) 
 
Micrographs of S. aureus incubated with colistin for three hours (Figure 6.26) 
revealed control and sub-inhibitory bacteria similar in size and shape. However the 
1/20th MIC incubated bacteria displayed blebbed bacterial membranes. Spheres 
populated the MIC and 10xMIC sample surface, with a higher density present on 
the inhibitory sample compared to 10xMIC sample surface.  
Incubation for 24 hours resulted in the un-treated and sub-inhibitory incubated 
bacteria substantially similar in size and shape (Figure 6.27). Few bacteria were 
present in the MIC micrograph, however the clusters of bacteria present resembled 
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normal S. aureus groupings compared to structures visualised at earlier time 
points. 
 
Figure 6.27 Scanning electron micrograph of 1x107 cfu/ml S. aureus exposed to colistin for 
24 hours: (a) control (b) 7.8125 g/ml (1/20th MIC) (c) 156 g/ml (MIC) and (d) 1560 
g/ml (10xMIC). Viability after 24 hours; S. aureus control 7.8x109 cfu/ml; S. aureus 
incubated with 1/20th MIC colistin 7.0x109 cfu/ml; MIC and 10xMIC colistin incubated 
bacteria was < 10 cfu/ml 
 
Micrographs of the 10xMIC culture revealed sparse spherical entities. Examination 
of S. aureus incubated with colistin by flow cytometry (Figure 5.8 (a)) support what 
is shown in the SEM images; control and sub-inhibitory cultures similar to each 
other, while neither MIC nor 10xMIC colistin cultures were detected due to 
insufficient bacterial numbers detected in these cultures. 
S. aureus control and 1/20th MIC cultures bore great similarity to each other at 72 
hours (Figure 6.28). Normal size and shaped bacteria were also visualised in the 
MIC culture, which also contained some larger spherical cellular aggregates. Few 
bacteria were identified in the 10xMIC micrograph, the majority of which appeared 
as spherical structures. 
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Figure 6.28 Scanning electron micrograph of 1x107 cfu/ml S. aureus exposed to colistin for 
72 hours: (a) control (b) 7.8125 g/ml (1/20th MIC) (c) 156 g/ml (MIC) and (d) 1560 
g/ml (10xMIC). Viability after 72 hours; S. aureus control 3.6x1010 cfu/ml; S. aureus 
incubated with 1/20th MIC colistin 6.3x1010 cfu/ml; S. aureus incubated with MIC colistin 
5.6x1010 cfu/ml and 10xMIC colistin incubated bacteria was < 10 cfu/ml 
 
Data presented in Figure 5.8 (b) revealed bacterial size in control and 1/20th MIC 
cultures very similar to each other, while bacteria incubated with MIC colistin 
appeared larger in size. The presence of some aggregated cellular structures in 
conjunction with the normal S. aureus clusters depicted in the SEM images could 
explain this result. 
Bacteria in 1/20th MIC and MIC cultures at 168 hours (Figure 6.29) were smaller in 
size compared to control. The MIC incubated bacteria, while not aggregated were 
different in appearance to that of control, while the 10xMIC culture continued to 
display a few aggregated structures. Overlay flow cytometry data support the SEM 
data (Figure 5.8 (c)); with histograms for sub-inhibitory and inhibitory cultures 
193 
 
smaller in size compared to control bacteria and a lack of bacteria in the 10xMIC 
colistin incubated culture.  
 
Figure 6.29 Scanning electron micrograph of 1x107 cfu/ml S. aureus exposed to colistin for 
168 hours: (a) control (b) 7.8125 g/ml (1/20th MIC) (c) 156 g/ml (MIC) and (d) 1560 
g/ml (10xMIC). Viability after 168 hours; S. aureus control 1.7x1010 cfu/ml; S. aureus 
incubated with 1/20th MIC colistin 2.3x1010 cfu/ml; S. aureus incubated with MIC colistin 
2.1x1010 cfu/ml and 10xMIC colistin incubated bacteria was < 10 cfu/ml 
 
Actively dividing bacteria were observed in all cultures over the experimental period 
except the 10xMIC culture. It is likely that the bactericidal ability of colistin is due in 
part to inhibition of bacterial reproduction. 
c) Pseudomonas aeruginosa 
Incubation with colistin produced no effect on the morphology of P. aeruginosa at 
or less than 90 minutes; therefore the SEM images presented here were taken at 
different time intervals to E. coli and S. aureus. SEM micrographs of P. aeruginosa 
incubated with colistin for two hours (Figure 6.30) revealed aggregation in the 
incubated bacteria proportional to the concentration of colistin present. 
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Figure 6.30 Scanning electron micrograph of 1x107 cfu/ml P. aeruginosa exposed to 
colistin for 2 hours: (a) control (b) 0.245 g/ml (1/20th MIC), (c) 4.9 g/ml (MIC) and (d) 
49 g/ml (10xMIC) colistin 
 
The aggregation did not result in spherical cellular structures as seen with E. coli 
and S. aureus but in the formation of layers of attached bacteria, interlinked by 
strands of extracellular material. Changes in P. aeruginosa shape were observed at 
all colistin concentrations at this time point. 
Four hours incubation of P. aeruginosa with colistin (Figure 6.31) resulted in 
substantial differences between the appearances of un-treated and treated 
bacteria. The sub-inhibitory incubated bacteria were rod-shaped in appearance, 
with some long P. aeruginosa cells visualised in the aggregated bacterial layers. The 
MIC incubated bacteria were more tightly interwoven into layers, with the supra-
inhibitory culture displaying a more spherical than rod-shaped appearance of 
individual cells. Also, a clear presence of an extracellular matrix of what appeared 
to be thin fibres is seen in all the treated cultures. 
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Figure 6.31 Scanning electron micrograph of 1x107 cfu/ml P. aeruginosa exposed to 
colistin for 4 hours: (a) control (b) 0.245 g/ml (1/20th MIC), (c) 4.9 g/ml (MIC) and (d) 
49 g/ml (10xMIC) colistin  
 
 
Figure 6.32 Scanning electron micrograph of 1x107 cfu/ml P. aeruginosa exposed to 
colistin for 8 hours: (a) control (b) 0.245 g/ml (1/20th MIC), (c) 4.9 g/ml (MIC) and (d) 
49 g/ml (10xMIC) colistin. Viability after 8 hours; P. aeruginosa control 3.1x109 cfu/ml; P. 
aeruginosa incubated with 1/20th MIC colistin 3.1x109 cfu/ml; P. aeruginosa incubated with 
MIC colistin 1.5x1011 cfu/ml; P. aeruginosa incubated with 10xMIC colistin < 10 cfu/ml 
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P. aeruginosa appeared to have developed a tolerance to the antimicrobial, after 
eight hours incubation (Figure 6.32) with 1/20th MIC colistin.  These sub- inhibitory 
exposed bacteria had reverted from the aggregated bacterial layers seen at 4 hours 
and now closely resembled the control bacteria in size, shape and bacterial 
groupings. The MIC incubated bacteria had also abandoned the layered bacterial 
structures at eight hours incubation and were beginning to assemble spherical 
cellular structures. Blebs were apparent on the surface of MIC incubated bacteria as 
were distorted bacterial shapes. Few bacteria incubated with 10xMIC colistin were 
visualised in the eight-hour micrograph, with these bacteria also spherical in shape.  
 
Figure 6.33 Scanning electron micrograph of 1x107 cfu/ml P. aeruginosa exposed to 
colistin for 24 hours: (a) control (b) 0.245 g/ml (1/20th MIC), (c) 4.9 g/ml (MIC) and (d) 
49 g/ml (10xMIC) colistin. Viability after 24 hours; P. aeruginosa control 6.8x1010 cfu/ml; 
P. aeruginosa incubated with 1/20th MIC colistin 6.2x1010 cfu/ml; P. aeruginosa incubated 
with MIC 7.6x1010 cfu/ml; P. aeruginosa incubated with 10xMIC colistin < 10 cfu/ml 
 
After 24-hours incubation P. aeruginosa control and 1/20th MIC cells were similar in 
size and structure. Bacteria in the MIC and 10xMIC incubated cultures had formed 
spherical aggregates, slightly larger in the MIC culture than the 10xMIC culture. 
Very few of these aggregated structures were visualised on the MIC sample surface 
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but considerable cellular debris was present on the surface of the 10xMIC sample. 
Flow cytometry results in Figure 5.9 (a) revealed the control and sub-inhibitory 
bacteria at 24 hours being very similar to each other, with insufficient bacteria 
enumerated in the MIC and 10xMIC cultures to be analysed at this time point, all of 
which is supported by the SEM images.    
 
Figure 6.34 Scanning electron micrograph of 1x107 cfu/ml P. aeruginosa exposed to 
colistin for 72 hours: (a) control (b) 0.245 g/ml (1/20th MIC), (c) 4.9 g/ml (MIC) and (d) 
49 g/ml (10xMIC) colistin. Viability after 72 hours; P. aeruginosa control 6.8x1010 cfu/ml; 
P. aeruginosa incubated with 1/20th MIC colistin 6.2x1010 cfu/ml; P. aeruginosa incubated 
with MIC 7.6x1010 cfu/ml; P. aeruginosa incubated with 10xMIC colistin < 10 cfu/ml 
 
P. aeruginosa incubated with 1/20th MIC colistin for 72 hours were similar in size to 
control bacteria (Figure 6.34). The bacterial density in the MIC culture had 
improved substantially in keeping with the viability data, with some of the 
visualised bacteria in clusters. Very few bacteria were captured on the 10xMIC 
sample, with those present bearing altered shapes. Flow cytometry results at 72 
hours (Figure 5.9 (b)) identified that the MIC culture had recovered substantially at 
this time point and was represented by a histogram peak indicating bacteria larger 
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than control. This could be as a result of aggregates visualised in the MIC SEM 
images.  
 
Figure 6.35 (a) Scanning electron micrograph of 1x107 cfu/ml P. aeruginosa exposed to 
colistin for 168 hours: (a) control (b) 0.245 g/ml (1/20th MIC), (c) 4.9 g/ml (MIC) and (d) 
49 g/ml (10xMIC) colistin. Viability after 168 hours; P. aeruginosa control 4.5x109 cfu/ml; 
P. aeruginosa incubated with 1/20th MIC colistin 3.2x109 cfu/ml; P. aeruginosa incubated 
with MIC 3.0x109 cfu/ml; P. aeruginosa incubated with 10xMIC colistin < 10 cfu/ml 
 
Incubation for 168 hours (Figure 6.35 a)) displayed control, 1/20th MIC and MIC 
incubated bacteria all similar in size and shape. However the MIC culture has once 
again started to reveal extracellular strands or fibres connecting the bacteria into 
layers (Figure 6.35 b)). Some bacteria were visualised in the 10xMIC culture, with 
misshapen exteriors. Flow cytometry data in (5.9 (c)) supports the SEM findings 
with control, 1/20th MIC and MIC cultures revealed as similar in size to each other, 
with no detection of the 10xMIC culture due to lack of normal bacterial cells in this 
culture. 
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Figure 6.35 (b) High magnification scanning electron micrograph of 1x106 cfu/ml P. 
aeruginosa exposed to MIC colistin for 168 hours 
 
6.3.3 SEM images of E. coli, S. aureus and P. aeruginosa 
incubated with NP101 
a) Escherichia coli 
 
Incubation of E. coli with increasing concentrations of NP101 (Figure 6.36) resulted 
in substantial changes to bacterial size and shape after exposure to the CAP for one 
hour, when compared to the normal size and shape of the un-treated bacteria. 
Non-septated E. coli cells were visualised in the sub-inhibitory and inhibitory 
concentrations, while shorter and rounder cells were visible in the supra-inhibitory 
concentration. What appears to be extrusion of cellular contents and presence of 
extracellular fibres forming a matrix can also be seen in the 1/20th, MIC and 2xMIC 
images.  
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Figure 6.36 Scanning electron micrograph of 1x107 cfu/ml E. coli exposed to NP101 for 1 
hour: (a) control (b) 0.0155 mg/ml (1/20th MIC) (c) 0.31 mg/ml (MIC) and (d) 0.62 mg/ml 
(2xMIC) 
 
 
Figure 6.37 Scanning electron micrograph of 1x107 cfu/ml E. coli exposed to NP101 for 3 
hours: (a) control (b) 0.0155 mg/ml (1/20th MIC) (c) 0.31 mg/ml (MIC) and (d) 0.62 mg/ml 
(2xMIC).  
 
Three hours incubation with NP101 (Figure 6.37) revealed bacteria in the 1/20th 
MIC culture appeared to be linked to each other. Extrusion of fibrous material from 
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bacterial cells was also visible. Bacteria in the inhibitory culture displayed 
misshapen exteriors in some cells, extrusion of what appeared to be intracellular 
contents from some bacteria, as well as spherical cellular aggregates. Grossly 
deformed bacterial exteriors were exhibited by cells incubated with 2xMIC NP101 in 
conjunction with misshapen spherical bacterial cells or their remnants. 
 
Figure 6.38 a) Scanning electron micrograph of 1x107 cfu/ml E. coli exposed to NP101 for 
6 hours: (a) control (b) 0.0155 mg/ml (1/20th MIC) (c) 0.31 mg/ml (MIC) and (d) 0.62 
mg/ml (2xMIC). Viability after 6 hours; E. coli control 6.6x108 cfu/ml; E. coli incubated with 
1/20th MIC NP101 7.8x106 cfu/ml; MIC and 2xMIC NP101 incubated bacteria was < 10 
cfu/ml 
 
By six hours incubation with NP101 (Figure 6.38 a)) E. coli incubated with 1/20th 
MIC were reverting to the size and shape displayed by the control bacteria. Bacteria 
with deformed exteriors were visible in the MIC culture, together with spherical 
structures that appeared to be linked by extruded cellular contents. An SEM image 
at higher magnification of the spherical structures and connecting material is shown 
in Figure 6.38 b). The 10xMIC incubated bacteria revealed non-septation, blebbing, 
spheronisation and deformation of gross morphology of bacterial cells. 
202 
 
 
Figure 6.38 b) High magnification scanning electron micrograph of 1x107 cfu/ml E. coli 
exposed to MIC NP101 for 6 hours 
 
 
Figure 6.39 Scanning electron micrograph of 1x106 cfu/ml E. coli exposed to NP101 for 24 
hours: (a) control (b) 0.025 mg/ml (1/20th MIC) (c) 0.5 mg/ml (MIC) and (d) 1.0 mg/ml 
(2xMIC). Viability after 24 hours; E. coli control 3.5x109 cfu/ml; E. coli incubated with 1/20th 
MIC NP101 4.9x109 cfu/ml and E. coli incubated with MIC and 2xMIC NP101 was < 10 
cfu/ml 
 
Typical blunt ended bacteria comprised the control culture at 24 hours (Figure 
6.39).  Some non-septated bacteria were present in the 1/20th MIC culture, co-
existing with E. coli of normal shape and size. This could account for the flow 
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cytometry data (Figure 5.10) revealing the 1/20th MIC incubated bacteria being 
larger than control at 24 hours. Very few cells were visualised in the MIC culture, 
those present revealed non-septation and cell spheronisation. E. coli incubated with 
2xMIC NP101 only displayed one cluster of aggregated cells on the entire sample 
surface as well as some spherical entities.  
 
Figure 6.40 Scanning electron micrograph of 1x106 cfu/ml E. coli exposed to NP101 for 72 
hours: (a) control (b) 0.025 mg/ml (1/20th MIC) (c) 0.5 mg/ml (MIC) and (d) 1.0 mg/ml 
(2xMIC). Viability after 72 hours; E. coli control 3.1x108 cfu/ml; E. coli incubated with 1/20th 
MIC NP101 3.2x108 cfu/ml and E. coli incubated with MIC and 2xMIC NP101 was < 10 
cfu/ml 
 
After seventy two hours incubation (Figure 6.40), NP101 continued to inhibit proper 
septation of bacterial cells in the sub-inhibitory concentration. Single bacterial cells 
in this culture were smaller in size than control cells. The inhibitory concentration 
produced spherical cellular structures up to 4 µm in diameter, with the 2xMIC 
culture revealed a gelling of bacterial cells similar to that previously seen with E. 
coli incubated with 10xMIC triclosan (Figure 6.5 (d)). Flow cytometry data at 72 
hours (Figure 5.10 (b)) showed the greater proportion of control bacteria slightly 
larger in size to 1/20th MIC incubated bacteria.  
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Incubation with NP101 for 168 hours resulted in substantial changes to the size and 
shape of the incubated bacteria (Figure 6.41 a)).  
 
Figure 6.41 a) Scanning electron micrograph of 1x106 cfu/ml E. coli exposed to NP101 for 
168 hours: (a) control (b) 0.025 mg/ml (1/20th MIC) (c) 0.5 mg/ml (MIC) and (d) 1.0 
mg/ml (2xMIC). Viability after 168 hours; E. coli control 3.1x108 cfu/ml; E. coli incubated 
with 1/20th MIC NP101 6.7x107 cfu/ml and E. coli incubated with MIC and 2xMIC NP101 was 
< 10 cfu/ml  
 
Non-septated bacteria were present in the sub-inhibitory culture, a higher 
magnification SEM micrograph showing the unusual elongation in cell length can be 
seen in Figure 6.41 b). However, the majority of bacteria in the 1/20th MIC and MIC 
cultures were similar in size and shape to control bacteria. The inhibitory culture 
also revealed a degree of cellular aggregation but single cells were also visible. The 
density of cells in the MIC culture had also increased significantly by 168 hours 
although no viable cells were detected by plate counts. The supra-inhibitory culture 
revealed irregular spherical cellular structures of varying sizes, which appeared to 
be interconnected by cellular debris. Results presented in Figure 5.10 displayed 
what appeared to be the development of tolerance to the effects of NP101 by E. 
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coli, in the re-appearance of cellular peaks for both MIC and 2xMIC cultures at 168 
hours, having been absent from both 24 and 72 hour histograms.  
 
Figure 6.41 b) High magnification scanning electron micrograph of 1x106 cfu/ml E. coli 
exposed to MIC NP101 for 168 hours 
 
b) Staphylococcus aureus 
 
 
Figure 6.42 Scanning electron micrograph of 1x107 cfu/ml S. aureus exposed to NP101 for 
1 hour: (a) control (b) 0.0155 mg/ml (1/20th MIC) (c) 0.31 mg/ml (MIC) and (d) 0.62 
mg/ml (2xMIC)  
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The effects of incubation with NP101 for one hour on S. aureus are revealed in 
Figure 6.42. Aggregation of cells was visible in all three treated cultures. Bacteria in 
the control, 1/20th MIC and MIC culture were similar in size and shape, whereas 
slightly smaller bacteria were visualised in the 2xMIC culture. 
 
 
Figure 6.43 Scanning electron micrograph of 1x107 cfu/ml S. aureus exposed to NP101 for 
3 hours: (a) control (b) 0.0155 mg/ml (1/20th MIC) (c) 0.31 mg/ml (MIC) and (d) 0.62 
mg/ml (2xMIC)  
 
 
Cell aggregation could be seen in the sub and inhibitory cultures at 3 hours (Figure 
6.43), while spherical structures of varying diameter were visualised in the 2xMIC 
culture, different in appearance to control bacteria. NP101 appeared to have lost its 
aggregatory effect on S. aureus at the sub-inhibitory concentration after 6 hours 
incubation (Figure 6.44). A low bacterial density was revealed in the MIC and 
2xMIC samples, with both cultures displaying spherical cellular aggregates as well 
as single cells. 
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Figure 6.44 Scanning electron micrograph of 1x107 cfu/ml S. aureus exposed to NP101 for 
6 hours: (a) control (b) 0.0155 mg/ml (1/20th MIC) (c) 0.31 mg/ml (MIC) and (d) 0.62 
mg/ml (2xMIC). Viability after 6 hours; S. aureus control 1.5x109 cfu/ml; S. aureus 
incubated with 1/20th MIC NP101 1.17x109 cfu/ml; S. aureus incubated with MIC and 2xMIC 
was < 10 cfu/ml 
 
 
Figure 6.45 Scanning electron micrograph of 1x106 cfu/ml S. aureus exposed to NP101 for 
24 hours: (a) control (b) 0.0125 mg/ml (1/20th MIC) (c) 0.25 mg/ml (MIC) and (d) 0.5 
mg/ml (2xMIC). Viability after 24 hours; S. aureus control 5.6x1011 cfu/ml; S. aureus 
incubated with 1/20th MIC NP101 5.6x1011 cfu/ml; S. aureus incubated with MIC NP101 
1.0x102 cfu/ml; S. aureus incubated with 2xMIC NP101 1.0x102 cfu/ml  
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Great similarity in size and shape of control and sub-inhibitory bacteria existed at 
24 hours (Figure 6.45). Clearly visible bacterial aggregates were present in the MIC 
and 2xMIC samples, which also revealed a much reduced bacterial density 
compared to control. 
 
 
Figure 6.46 Scanning electron micrograph of 1x106 cfu/ml S. aureus exposed to NP101 for 
72 hours: (a) control (b) 0.0125 mg/ml (1/20th MIC) (c) 0.25 mg/ml (MIC) and (d) 0.5 
mg/ml (2xMIC). Viability after 72 hours; S. aureus control 2.9x109 cfu/ml; S. aureus 
incubated with 1/20th MIC NP101 5.6x105 cfu/ml; S. aureus incubated with MIC NP101 
1.0x102 cfu/ml; S. aureus incubated with 2xMIC NP101 1.0x102 cfu/ml 
 
Micrographs of S. aureus after 72 hours incubation (Figure 6.46) disclosed similar 
bacterial size and shaped cells in the control and sub-inhibitory cultures. Large 
spherical bacterial aggregates or clusters were visible in the MIC and 2xMIC NP101 
cultures.   
Control bacteria were slightly larger than sub-inhibitory incubated bacteria after 
168 hours incubation with NP101 (Figure 6.47). A single cluster of slightly gelled 
looking aggregated cells was present on the MIC sample surface. Bacteria present 
on the 2xMIC sample, were slightly smaller in size than control cells. Low bacterial 
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density of the MIC and 2xMIC cultures was most probably responsible for the 
absence of detectable cells from both these cultures at any sampled time point in 
the flow cytometry experiments (Figure 5.11). Control and 1/20th MIC incubated 
bacteria were identified as similar in size and shape by flow cytometry and 
confirmed by the SEM images.  
 
Figure 6.47 Scanning electron micrograph of 1x106 cfu/ml S. aureus exposed to NP101 for 
168 hours: (a) control (b) 0.0125 mg/ml (1/20th MIC) (c) 0.25 mg/ml (MIC) and (d) 0.5 
mg/ml (2xMIC). Viability after 168 hours; S. aureus control 4.5x108 cfu/ml; S. aureus 
incubated with 1/20th MIC NP101 2.1x105 cfu/ml; S. aureus incubated with MIC NP101 
1.0x102 cfu/ml; S. aureus incubated with 2xMIC NP101 1.0x102 cfu/ml 
 
c) Pseudomonas aeruginosa 
Spherical structures were present in the sub-inhibitory culture, though bacterial 
size and shape were similar to control after incubation for one hour with NP101 
(Figure 6.48). The reaction of P. aeruginosa to incubation with the MIC and 2xMIC 
concentration was to form bacterial layers interconnected with what appeared to be 
extruded fibrous cellular material; similar to the response of P. aeruginosa to 
incubation with colistin at both two and four hours (Figure 6.30/6.31). As with the 
210 
 
sub-inhibitory culture, spherical structures were also apparent in the inhibitory and 
supra-inhibitory cultures.  
 
Figure 6.48 Scanning electron micrograph of 1x107 cfu/ml P. aeruginosa exposed to NP101 
for 1 hour: (a) control (b) 0.0155 mg/ml (1/20th MIC), (c) 0.31 mg/ml (MIC) and (d) 0.62 
mg/ml (2xMIC) NP101 
 
Figure 6.49 Scanning electron micrograph of 1x107 cfu/ml P. aeruginosa exposed to NP101 
for 3 hours: (a) control (b) 0.0155 mg/ml (1/20th MIC), (c) 0.31 mg/ml (MIC) and (d) 0.62 
mg/ml (2xMIC) NP101 
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Three hours incubation with NP101 (Figure 6.49) resulted in the appearance of non-
septated bacteria in the sub-inhibitory culture, while the formation of bacterial 
sheets in the MIC and 2xMIC incubated cultures was even more pronounced than 
when visualised after incubation for one hour with these NP101 concentrations.  
SEM images revealing the effects of six hours incubation with NP101 (Figure 6.50) 
on P. aeruginosa disclosed inhibition of normal bacterial septation in the 1/20th MIC 
culture. However, layered bacterial aggregation was absent from the MIC and 
2xMIC cultures at six hours, though some aggregated bacterial clumps were visible 
in both these cultures. Gelling of some bacteria was also visualised in bacteria in 
the MIC sample. 
 
Figure 6.50 Scanning electron micrograph of 1x107 cfu/ml P. aeruginosa exposed to NP101 
for 6 hours: (a) control (b) 0.0155 mg/ml (1/20th MIC), (c) 0.31 mg/ml (MIC) and (d) 0.62 
mg/ml (2xMIC) NP101. Viability after 6 hours; P. aeruginosa control 5.1x1010 cfu/ml; P. 
aeruginosa incubated with 1/20th MIC NP101 5.0x1010 cfu/ml; P. aeruginosa incubated with 
MIC NP101 2.0x103 cfu/ml; P. aeruginosa incubated with 2xMIC NP101 1.0x102 cfu/ml 
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Figure 6.51 a) Scanning electron micrograph of 1x106 cfu/ml P. aeruginosa exposed to 
NP101 for 24 hours: (a) control (b) 0.0125 mg/ml (1/20th MIC), (c) 0.25 mg/ml (MIC) and 
(d) 0.5 mg/ml (2xMIC) NP101. Viability after 24 hours; P. aeruginosa control 6.6x1010 
cfu/ml; P. aeruginosa incubated with 1/20th MIC NP101 6.6x1010 cfu/ml; P. aeruginosa 
incubated with MIC NP101 1.0x102 cfu/ml; P. aeruginosa incubated with 2xMIC NP101 
1.0x102 cfu/ml 
 
The appearances of the three NP101 cultures were very different to control at 24 
hours (Figure 6.51 a)). Though size and bacterial shape of control and 1/20th MIC 
cultures was very similar, the sub-inhibitory incubated bacteria were interconnected 
by what appeared to be thin filaments of an extracellular nature (Figure 6.51 b)). 
Bacterial clumping in the inhibitory and supra-inhibitory cultures was visualised, 
with some gelling of bacteria in the MIC culture. The flow cytometry data (Figure 
5.12) revealed both control and 1/20th MIC cultures were similar is size. The MIC 
and 2xMIC cultures were not detected at any time point due to reduced bacterial 
density, which is apparent from the SEM micrographs.  The examination of viability 
demonstrated 99.99% reduction at six hours and non-viability of P. aeruginosa in 
both MIC and 2xMIC cultures at 24, 72 and 168 hours. 
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Figure 6.51 b) High magnification scanning electron micrograph of 1x106 cfu/ml P. 
aeruginosa exposed to 1/20th MIC NP101 for 24 hours 
 
SEM images of P. aeruginosa incubated with NP101 for seventy two hours (Figure 
6.52) revealed similar size and shaped control and sub-inhibitory bacteria. The 
density of bacteria in the inhibitory and supra-inhibitory cultures was very low, with 
the visualised bacteria forming aggregated clumps. 
 
Figure 6.52 Scanning electron micrograph of 1x106 cfu/ml P. aeruginosa exposed to NP101 
for 72 hours: (a) control (b) 0.0125 mg/ml (1/20th MIC), (c) 0.25 mg/ml (MIC) and (d) 0.5 
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mg/ml (2xMIC) NP101. Viability after 72 hours; P. aeruginosa control 1.2x1010 cfu/ml; P. 
aeruginosa incubated with 1/20th MIC colistin 7.9x109 cfu/ml; P. aeruginosa incubated with 
MIC NP101 1.0x102 cfu/ml; P. aeruginosa incubated with 2xMIC NP101 1.0x102 cfu/ml 
 
After 168 hours incubation (Figure 6.53) bacteria incubated with 1/20th MIC NP101 
displayed inhibition of normal bacterial septation. Bacterial density in MIC and 
2xMIC cultures was again very low, with these bacteria forming spherical cellular 
aggregated structures with some gelling in 2xMIC apparent.  
 
Figure 6.53 Scanning electron micrograph of 1x106 cfu/ml P. aeruginosa exposed to NP101 
for 168 hours: (a) control (b) 0.0125 mg/ml (1/20th MIC), (c) 0.25 mg/ml (MIC) and (d) 0.5 
mg/ml (2xMIC) NP101. Viability after 168 hours; P. aeruginosa control 7.8x108 cfu/ml; P. 
aeruginosa incubated with 1/20th MIC colistin 5.6x108 cfu/ml; P. aeruginosa incubated with 
MIC NP101 1.0x102 cfu/ml; P. aeruginosa incubated with 2xMIC NP101 1.0x102 cfu/ml 
 
6.3.4 SEM images of E. coli, S. aureus and P. aeruginosa 
incubated with NP108 
a) Escherichia coli 
 
Incubation of E. coli with NP108 for one hour (Figure 6.54) led to dramatic 
differences in the appearance of all incubated cultures compared to control. E. coli 
incubated with 1/20th MIC NP108 revealed bacteria similar in size and shape to 
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control, as well as bacteria with clearly visible blebbed exteriors. The sample also 
contained a wide film of material to which spherical and normal bacterial cells were 
attached. This film was probably formed from extruded cellular material. The MIC 
culture revealed a number of spherical cellular entities of varying dimensions. The 
2xMIC culture revealed a similar film of material to that observed in the sub-
inhibitory sample; to which the cells were attached. Some of the bacteria in the 
sample also exhibited blebbed outer membranes as well as distorted external 
morphologies. 
 
Figure 6.54 Scanning electron micrograph of 1x107 cfu/ml E. coli exposed to NP108 for 1 
hour: (a) control (b) 0.025 mg/ml (1/20th MIC) (c) 0.5 mg/ml (MIC) and (d) 1.0 mg/ml 
(2xMIC)  
 
Incubation for three hours incubation with NP108 resulted in the sub-inhibitory 
incubated bacteria displaying inhibition of normal septation, and bacterial 
aggregation. Bacterial aggregation was also visible in the MIC culture, while the 
supra-inhibitory bacteria revealed distorted and blebbed cellular exteriors.  
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Figure 6.55 Scanning electron micrograph of 1x107 cfu/ml E. coli exposed to NP108 for 3 
hours: (a) control (b) 0.025 mg/ml (1/20th MIC) (c) 0.5 mg/ml (MIC) and (d) 1.0 mg/ml 
(2xMIC) 
 
 
Figure 6.56 Scanning electron micrograph of 1x107 cfu/ml E. coli exposed to NP108 for 6 
hours: (a) control (b) 0.025 mg/ml (1/20th MIC) (c) 0.5 mg/ml (MIC) and (d) 1.0 mg/ml 
(2xMIC). Viability after 6 hours; E. coli control 4.0x1010 cfu/ml; E. coli incubated with 1/20th 
MIC NP101 3.6x109 cfu/ml; E. coli incubated with MIC and 2xMIC NP101 was < 10 cfu/ml 
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Six hours incubation (Figure 6.56) with 1/20th MIC NP108 continued to disrupt 
normal bacterial septation and cause bacterial aggregation. The bacteria visualised 
in the MIC sample were aggregated into one large cluster, which was slightly gelled 
in appearance. Nothing could be seen on the very clean 2xMIC sample surface 
except for a few spherical structures, most probably of cellular debris. 
Sub-inhibitory and inhibitory concentrations after 24-hours incubation with NP108 
(Figure 6.57) revealed non-septated E. coli. Small spherical structures, probably 
cellular remnants, were also visualised in the MIC sample along with bacteria 
displaying blebbed and distorted exteriors.  
 
Figure 6.57 Scanning electron micrograph of 1x106 cfu/ml E. coli exposed to NP108 for 24 
hours: (a) control (b) 0.0125 mg/ml (1/20th MIC) (c) 0.25 mg/ml (MIC) and (d) 0.5 mg/ml 
(2xMIC). Viability after 24 hours; E. coli control 5.1x109 cfu/ml; E. coli incubated with 1/20th 
MIC NP101 5.0x109 cfu/ml; E. coli incubated with MIC and 2xMIC NP101 was < 10 cfu/ml 
 
A single aggregated bacterial group, slightly gelled in appearance was revealed in 
the SEM micrograph for the 2xMIC culture. Data presented in Figure 5.13 
demonstrated the 1/20th MIC bacteria as being larger than control bacteria, this can 
now be explained by the non-septated bacterial cells co-existing with single 
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bacteria. Neither the MIC nor 2xMIC treated cultures were detected by flow 
cytometry as insufficient bacteria were present in these cultures at all the time 
points assayed. The low bacterial density in both MIC and 2xMIC cultures visualised 
by SEM is the most likely explanation for this occurrence.  
The 1/20th MIC treated bacteria were still exhibiting long, non-septated cells after 
72 hours incubation with NP108 (Figure 6.58).  
 
Figure 6.58 Scanning electron micrograph of 1x106 cfu/ml E. coli exposed to NP108 for 72 
hours: (a) control (b) 0.0125 mg/ml (1/20th MIC) (c) 0.25 mg/ml (MIC) and (d) 0.5 mg/ml 
(2xMIC). Viability after 72 hours; E. coli control 1.8x109 cfu/ml; E. coli incubated with 1/20th 
MIC NP101 1.4x109 cfu/ml; E. coli incubated with MIC and 2xMIC NP101 incubated bacteria 
was < 10 cfu/ml 
 
The sub-inhibitory culture contained a variety of bacterial sizes at this time point; 
however, this was not un-usual as the control sample also contained bacterial cells 
ranging from less than 1 m up to nearly 3 m at this time. The MIC culture 
contained only one aggregated clump of distorted E. coli bacteria. The 2xMIC 
culture sample revealed an aggregated clump of small, distorted cells that 
appeared to have extruded some cellular material. Smaller spherical entities were 
also visualised in the 2xMIC sample. Sub-inhibitory incubated cells were revealed 
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as larger than control bacteria by flow cytometry (Figure 6.58), which is supported 
by the SEM data with the presence of long co-joined bacteria in this culture. 
The inhibitory effect of NP108 on normal bacterial septation in E. coli was still 
visible in the sub-inhibitory incubated bacteria at 168 hours (Figure 6.59 a)).  
 
Figure 6.59 a) Scanning electron micrograph of 1x106 cfu/ml E. coli exposed to NP108 for 
168 hours: (a) control (b) 0.0125 mg/ml (1/20th MIC) (c) 0.25 mg/ml (MIC) and (d) 0.5 
mg/ml (2xMIC). Viability after 168 hours; E. coli control 1.0x109 cfu/ml; E. coli incubated 
with 1/20th MIC NP101 6.0x108 cfu/ml; E. coli incubated with MIC NP101 1.0x103 cfu/ml and 
E. coli incubated with 2xMIC NP101 was < 10 cfu/ml 
 
Blebbing of the cell surfaces of these 1/20th MIC bacteria was apparent (higher 
magnification images Figure 6.59 b)) in conjunction with indented cell exteriors and 
what appeared to be leakage of intracellular material from some bacterial cells. 
Initiation of cross wall formation in E. coli can be clearly seen in the higher 
magnification SEM image, which was never completed. Though cross wall formation 
was inhibited, peripheral wall growth occurred, suggesting two separate processes 
may control such synthesis and only the cross wall formation is affected by NP108.  
An aggregated mass of bacteria exhibiting a gelled appearance was displayed on 
both the MIC and 2xMIC sample surface. The MIC bacteria were still replicating at 
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six hours but from that experimental sample time, no MIC bacteria exhibited active 
division for the remaining experimental period.  
 
 
Figure 6.59 b) High magnification scanning electron micrograph of 1x106 cfu/ml E. coli 
exposed to 1/20th MIC NP108 for 168 hours 
 
b) Staphylococcus aureus 
 
 
Figure 6.60 Scanning electron micrograph of 1x107 cfu/ml S. aureus exposed to NP108 for 
1 hour: (a) control (b) 0.0125 mg/ml (1/20th MIC) (c) 0.25 mg/ml (MIC) and (d) 0.5 mg/ml 
(2xMIC).  
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Exposure of S. aureus to NP108 for one hour (Figure 6.60) produced aggregated 
bacterial groups in the 1/20th MIC culture, while the MIC and 2xMIC incubated 
bacteria exhibited spherical cellular structures of different dimensions. 
Aggregation of bacterial cells was visualised with S. aureus after three hours 
incubation with NP108 (Figure 6.61).  
 
Figure 6.61 Scanning electron micrograph of 1x107 cfu/ml S. aureus exposed to NP108 for 
3 hours: (a) control (b) 0.0125 mg/ml (1/20th MIC) (c) 0.25 mg/ml (MIC) and (d) 0.5 
mg/ml (2xMIC).  
 
This aggregation was similar for all three test concentrations, with S. aureus 
exposed to the sub-inhibitory NP108 concentration retaining some degree of normal 
morphology.  
The effects of the longer incubation time of six hours on S. aureus (Figure 6.62 a)) 
were more severe. Blebbed and distorted bacterial membranes together with 
aggregation were visible in the 1/20th MIC NP108 culture. Bacteria in the MIC 
culture formed one cohesive group, from which appeared to have extruded 
intracellular material (Figure 6.62 b)). In addition to this extruded material the 
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spherical cellular structures present had diameters ranging in size between 200 – 
900 nm. Bacteria in the 2xMIC concentration displayed gelled spherical structures. 
 
Figure 6.62 a) Scanning electron micrograph of 1x107 cfu/ml S. aureus exposed to NP108 
for 6 hours: (a) control (b) 0.0125 mg/ml (1/20th MIC) (c) 0.25 mg/ml (MIC) and (d) 0.5 
mg/ml (2xMIC). Viability after 6 hours; S. aureus control 2.8x109 cfu/ml; S. aureus 
incubated with 1/20th MIC NP108 1.8x108 cfu/ml; S. aureus incubated with MIC NP108 
2.3x106 cfu/ml; S. aureus incubated with 2xMIC was < 10 cfu/ml 
 
 
Figure 6.62 b) High magnification scanning electron micrograph of 1x107 cfu/ml S. aureus 
exposed to MIC NP108 for 6 hours 
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S. aureus control and sub-inhibitory incubated bacteria were similar in size and 
shape at 24 hours (Figure 6.63). The bacteria revealed in the MIC SEM micrographs 
had formed into a large group of cells, each cell similar in size to control bacteria. S 
aureus in the 2xMIC culture adopted two forms, one as part of a gelled bacterial 
mass, while smaller spherical structures with a roughened exterior, different to the 
smooth exterior of control cells, were also present. 
 
Figure 6.63 Scanning electron micrograph of 1x107 cfu/ml S. aureus exposed to NP108 for 
24 hours: (a) control (b) 0.0125 mg/ml (1/20th MIC) (c) 0.25 mg/ml (MIC) and (d) 0.5 
mg/ml (2xMIC). Viability after 24 hours; S. aureus control 5.5x1011 cfu/ml; S. aureus 
incubated with 1/20th MIC NP108 3.0x1011 cfu/ml; S. aureus incubated with MIC NP108 
6.2x103 cfu/ml; S. aureus incubated with 2xMIC was < 10 cfu/ml 
 
Data gathered by flow cytometry regarding these cultures and presented in Chapter 
5 (Figure 5.14) had identified the control and sub-inhibitory incubated bacteria as 
similar in size and shape. However, neither MIC nor 2xMIC cultures were detected 
due to low bacterial density in these cultures, which is certainly obvious from the 
2xMIC SEM data.  Bacterial density in the MIC culture had improved from the six-
hour sample, which is in accordance with the viability data described in Figure 5.14 
(d).  
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SEM images at 72 hours display similarity between control, 1/20th MIC and MIC 
incubated bacteria (Figure 6.64). The MIC incubated bacteria had reverted from one 
aggregated mass to the more normal sized and evenly distributed S. aureus. Very 
few bacteria were revealed in the supra-inhibitory concentration and those that 
were present expressed slightly gelled exteriors. 
 
Figure 6.64 Scanning electron micrograph of 1x107 cfu/ml S. aureus exposed to NP108 for 
72 hours: (a) control (b) 0.0125 mg/ml (1/20th MIC) (c) 0.25 mg/ml (MIC) and (d) 0.5 
mg/ml (2xMIC). Viability after 72 hours; S. aureus control 4.2x1010 cfu/ml; S. aureus 
incubated with 1/20th MIC NP108 8.0x109 cfu/ml; S. aureus incubated with MIC NP108 
1.14x105 cfu/ml; S. aureus incubated with 2xMIC was < 10 cfu/ml 
 
SEM micrographs at 168 hours exposed partial aggregation in the 1/20th MIC 
cultures (Figure 6.65) but size and bacterial shape were similar to control. Bacterial 
density in the MIC culture had fallen dramatically from the 24 and 72 hour levels 
and only spherical cellular aggregates were visible via SEM. A few spherical entities 
were also present in the 2xMIC sample surface. Viability and flow cytometry results 
(Figure 5.14) support this SEM data which identified similarity between control and 
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sub-inhibitory incubated bacterial cultures, with very low density in the inhibitory 
and supra-inhibitory concentrations. 
 
Figure 6.65 Scanning electron micrograph of 1x107 cfu/ml S. aureus exposed to NP108 for 
168 hours: (a) control (b) 0.0125 mg/ml (1/20th MIC) (c) 0.25 mg/ml (MIC) and (d) 0.5 
mg/ml (2xMIC). Viability after 168 hours; S. aureus control 1.0x1011 cfu/ml; S. aureus 
incubated with 1/20th MIC NP108 7.8x1010 cfu/ml; S. aureus incubated with MIC NP108 
1.0x103 cfu/ml; S. aureus incubated with 2xMIC was < 10 cfu/ml 
 
 
c) Pseudomonas aeruginosa 
 
NP108 caused partial aggregation of P. aeruginosa when incubated at the sub-
inhibitory and inhibitory concentrations for one hour (Figure 6.66). Exposure to 
2xMIC concentration for the same time period resulted in spherical structures, 
probably forming from cellular debris 
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Figure 6.66 Scanning electron micrograph of 1x107 cfu/ml P. aerugionsa exposed to NP108 
for 1 hour: (a) control (b) 0.025 mg/ml (1/20th MIC) (c) 0.5 mg/ml (MIC) and (d) 1.0 
mg/ml (2xMIC). 
 
 
Figure 6.67 Scanning electron micrograph of 1x107 cfu/ml P. aerugionsa exposed to NP108 
for 3 hours: (a) control (b) 0.025 mg/ml (1/20th MIC) (c) 0.5 mg/ml (MIC) and (d) 1.0 
mg/ml (2xMIC).  
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Bacterial aggregation had increased in the 1/20TH MIC and MIC cultures with the 
longer incubation of three hours (Figure 6.67). The shape and size of P. aeruginosa 
exposed to the sub-inhibitory concentration were similar to control, with bacteria in 
the inhibitory culture substantially shorter and rounder than control cells. Spherical 
structures of varying diameter continued to be present in the 2xMIC sample.  
 
Figure 6.68 Scanning electron micrograph of 1x107 cfu/ml P. aerugionsa exposed to NP108 
for 6 hours: (a) control (b) 0.025 mg/ml (1/20th MIC) (c) 0.5 mg/ml (MIC) and (d) 1.0 
mg/ml (2xMIC). Viability after 6 hours; P. aeruginosa control 5.6x1010 cfu/ml; P. aeruginosa 
incubated with 1/20th MIC NP108 5.0x1010 cfu/ml; P. aeruginosa incubated with MIC NP108 
4.0x102 cfu/ml; P. aeruginosa incubated with 2xMIC was < 10 cfu/ml 
 
At six hours, bacteria treated with 1/20th MIC concentration, revealed a more 
rounded exterior, some spherical cellular entities and elongated groups of 
aggregated bacteria. The MIC and 2xMIC cultures displayed smaller spherical 
entities rather than one large structure, with the cell density of the 2xMIC culture 
radically reduced. 
Surprisingly incubation of P. aeruginosa with NP108 for twenty-four hours (Figure 
6.69), revealed a reversion to normal bacterial shape for the MIC and 2xMIC 
cultures. The 1/20th MIC incubated bacteria continued to exhibit a more rounded 
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bacterial shape. As with the 6-hour culture a long fibrous entity of possibly cellular 
material, with attached cells, was displayed by the sub-inhibitory culture. 
 
Figure 6.69 Scanning electron micrograph of 1x107 cfu/ml P. aerugionsa exposed to NP108 
for 24 hours: (a) control (b) 0.0125 mg/ml (1/20th MIC) (c) 0.25 mg/ml (MIC) and (d) 0.5 
mg/ml (2xMIC). Viability after 24 hours; P. aeruginosa control 5.0x1011 cfu/ml; P. 
aeruginosa incubated with 1/20th MIC NP108 5.0x1011 cfu/ml; P. aeruginosa incubated with 
MIC NP108 6.0x102 cfu/ml; P. aeruginosa incubated with 2xMIC was < 10 cfu/ml 
 
 
The SEM micrographs after 72 hours incubation with NP108 (Figure 6.70), showed 
the now familiar strand of material with attached bacteria in the sub-inhibitory 
concentration. Non-septation and spheronisation of cells were two other effects of 
the 1/20th MIC NP108 on P. aeruginosa. Both inhibitory and supra-inhibitory 
incubated bacteria contained spherical cellular aggregated, with a much lower 
bacterial density in the higher NP108 concentration. 
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Figure 6.70 Scanning electron micrograph of 1x107 cfu/ml P. aerugionsa exposed to NP108 
for 72 hours: (a) control (b) 0.0125 mg/ml (1/20th MIC) (c) 0.25 mg/ml (MIC) and (d) 0.5 
mg/ml (2xMIC). Viability after 72 hours; P. aeruginosa control 5.0x1011 cfu/ml; P. 
aeruginosa incubated with 1/20th MIC NP108 5.0x1011cfu/ml; P. aeruginosa incubated with 
MIC NP108 1.0x105cfu/ml; P. aeruginosa incubated with 2xMIC was < 10 cfu/ml 
 
The effects of incubation for 168 hours with NP108 on P. aeruginosa were 
dependent on the concentration employed (Figure 6.71 a)). The 1/20th MIC bacteria 
possessed significantly distorted, dented and blebbed exteriors (SEM Figure 6.71 
b)). Only spherical cellular structures were visible in the MIC and 2xMIC cultures. 
Flow cytometry data for P. aeruginosa incubated with NP108 (Figure 5.15) supports 
the SEM images showing control and 1/20th MIC cultures to be similar in size and 
shape over the 168 hour period. The MIC and 2xMIC cultures due to low bacterial 
density, were not detected by flow cytometry; supported by the low bacterial 
density of these cultures revealed by the SEM micrographs. 
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Figure 6.71 a) Scanning electron micrograph of 1x107 cfu/ml P. aerugionsa exposed to 
NP108 for 168 hours: (a) control (b) 0.0125 mg/ml (1/20th MIC) (c) 0.25 mg/ml (MIC) and 
(d) 0.5 mg/ml (2xMIC). Viability after 168 hours; P. aeruginosa control 5.0x1011 cfu/ml; P. 
aeruginosa incubated with 1/20th MIC NP108 2.9x1010cfu/ml; P. aeruginosa incubated with 
MIC NP108 1.14x105cfu/ml; P. aeruginosa incubated with 2xMIC was < 10 cfu/ml 
 
 
 
Figure 6.71 b) High magnification scanning electron micrograph of 1x106 cfu/ml P. 
aeruginosa exposed to MIC NP108 for 168 hours 
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6.4 Discussion 
6.4.1 Introduction 
Bacteria respond to environmental stresses through alteration of their genetics, 
physiology, biochemistry that probably lead to changes in cellular morphology to 
permit continued cell growth and division (Dynes et al. 2009). This was apparent 
from the responses of the test bacteria upon their exposure to cationic antibacterial 
agents used in this investigation. Some of the most surprising results collected, 
were those bacterial reactions to incubation with sub-inhibitory antibacterial 
concentrations. The inhibition of normal septation in S. aureus and S. bovis 
exposed to sub-inhibitory concentrations of penicillin had been reported by Lorain 
et al (Lorian 1975). In this investigation results of incubation with sub-inhibitory 
concentrations of cationic antibacterials have included; non-septation, bacterial 
aggregation; the probable release of cellular filaments to form extracellular fibres, 
filaments or films linking cells; blebbing; deformation; and formation of large 
spherical structures, probably aggregates of viable or non-viable cells or debris 
derived from such cells. This is to some extent surprising in view of the growth 
inhibition data shown in Chapter 3, when the 1/20th MIC revealed no adverse effect 
on the rate or extent of growth. 
The reactions of P. aeruginosa to the presence of triclosan, to which the bacterium 
is continuously referred to being resistant, were un-expected as they matched the 
responses observed in E. coli, which is not triclosan resistant. The normal rod-
shaped P. aeruginosa cells have been shown to adopt a smaller coccoid shape 
during under nutritionally challenging conditions (Dynes et al. 2009). In the SEM 
images presented here the response of P. aeruginosa from four hours incubation 
with the inhibitory triclosan concentration has also been to adopt a coccoid shape. 
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Responses of bacteria such as E. coli and other un-related bacterial species to 
transition into stationary-phase conditions by size reduction and the subsequent 
exhibition of spherical or ovoid exteriors, through induction of expression of the 
alternative sigma factor S that controls the morphological phenotype, is well 
reported (Lange and Hengge-Aronis 1991). The SEM images of E. coli incubated 
with various colistin concentrations from one to 168 hours presented here, has also 
shown reduction in bacterial size and exhibition of spheroid exteriors as a result of 
exposure to this antibacterial. 
The reaction of S. aureus within 30 minutes exposure to the presence of colistin, by 
the adoption of an aggregated spherical structure was also un-expected (Figure 
6.24). Little information exists on the effect of colistin on Gram-positive bacteria 
such as S. aureus, as a consequence of this antibacterial agent not being used 
clinically to treat Gram-positive infections, so these results were intriguing.  
As NP101 and NP108 are novel antibacterials, bacterial reaction to incubation with 
these agents through morphological alteration was un-known. However SEM 
micrographs revealed alterations in outer bacterial morphology, similar to those 
reported for other CAPs such as inhibition of normal bacterial septation and 
membrane blebbing (Hale and Hancock 2007)(Zhang and Falla 2006). 
6.4.2 Changes in morphology of E. coli, S. aureus and P. 
aeuginosa induced by triclosan 
6.4.2.1 Sub-inhibitory concentration 
Incubation with 1/20th MIC triclosan produced different effects upon the Gram-
positive and Gram-negative bacteria. Effects visualised in E. coli and P. aeruginosa 
was a rounding of the normal rod-shaped exterior and inhibition of normal bacterial 
septation. Aggregation combined with non-septation was present in E.coli incubated 
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with the sub-inhibitory triclosan concentration from 24 hours onwards. A longer 
exposure time of eight hours, to the presence of 1/20th MIC triclosan, was required 
before non-septated P. aeruginosa became apparent. Limiting factors such as the 
solubility of triclosan and high level triclosan resistance possessed by P. aeruginosa 
as a result of its MDR efflux pumps which actively extrudes triclosan from the 
bacterium, meant an MIC could only be determined for a maximum of 32 hours 
(Chuanchuen, Karkhoff-Schweizer and Schweizer 2003). However, by 24 hours 
incubation and again at 32 hours incubation with the sub-inhibitory triclosan 
concentration, P. aeruginosa had begun to form bacterial sheets interlinked with 
what appeared to be fine extracellular strands or fibres as well as distinct long co-
joined bacterial cells. 
The response of the Gram-positive S. aureus to incubation with sub-inhibitory 
triclosan concentration from one to 168-hours was shown to be bacterial 
aggregation. The most striking example of this phenomenon was displayed by S. 
aureus after 24 hours incubation (Figure 6.11), when co-joined S. aureus chains 
were visualised at this concentration  
6.4.2.2 Inhibitory concentration 
In E. coli, elongation or non-septation was apparent in MIC incubated bacteria from 
one hour onwards. By six hours, this phenomenon of non-septation had developed 
a further dimension as the non-septated bacteria now exhibited a budding or 
blebbing effect, that suggested growth in E. coli was now occurring not only 
longitudinally but also in other dimensions to the bacterial chain, indicative of an 
adverse impact upon peptidoglycan synthesis (Figure 6.4). Non-septated P. 
aeruginosa were visible in the MIC concentration after four hours incubation, with 
the 24/32 hour samples also populated with spherical aggregates bearing a 
corrugated appearance. S. aureus response to incubation with the inhibitory 
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triclosan concentration was shown to be bacterial aggregation. Elaborate, large 
apparently hollow spherical structures were produced by S. aureus after 24 hours 
incubation with triclosan (Figure 6.11).  
6.4.2.3 Supra-inhibitory concentration 
The supra-inhibitory triclosan concentration produced a gelling of E. coli cells after 
incubation times of 24 to 168 hours; a phenomenon observed in bacteria exposed 
to biocides that have been reported by other researchers (Barrett-Bee, Newboult 
and Edwards 1994). Exposure of S. aureus to 10xMIC triclosan concentration also 
resulted in production of spherical cellular or acellular structures of varying 
dimensions.  
6.4.2.4 Summary of bacterial responses to triclosan 
A similar response by all three test bacteria to treatment with triclosan was the 
inability to undergo normal bacterial septation. Non-septation in coccoid and rod-
shaped bacteria resulting from exposure to an antibacterial agent has been 
reported by other researchers (Lorian 1975). Well established antibacterial effects 
of triclosan effects are the inhibition of both membrane biogenesis and fatty acid 
synthesis (Escalada et al. 2005)(Rock and Jackowski 2002)(Levy et al. 1999). The 
SEM images presented tend to support the results of both these reported inhibitory 
effects in all three test species. 
A reduction in size of E. coli incubated with the inhibitory triclosan concentration 
and a change in shape of P. aeruginosa from rod to spheroid shape after incubation 
with the inhibitory triclosan concentration for 32 hours was also noted. It has 
already been mentioned that induction of alternative sigma factor S responsible for 
controlling bacterial phenotypes is induced by depletion of available nutrients and 
results in smaller bacterial size and shape changes (Lange and Hengge-Aronis 
1991). It is possible that this factor is also triggered by the stress of incubation with 
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an antibacterial agent such as triclosan as both smaller bacterial size and changes 
in bacterial structure were visualised in the SEM images presented here (Lange and 
Hengge-Aronis 1991). A common response by S. aureus observed with all triclosan 
concentrations at most time points was demonstrated to be bacterial aggregation. 
Whether this aggregatory effect on S. aureus was as a result of the inability of S. 
aureus bacteria to septate normally and therefore forced to remain co-joined and 
form larger and larger structures of aggregated cells remains to be elucidated. 
However it is probable that aggregation was the reason, as the appearance of large 
aggregates occurred within one hour of incubation with triclosan. 
6.4.3 Changes in morphology of E. coli, S. aureus and P. 
aeuginosa induced by colistin 
6.4.3.1 Sub-inhibitory concentration 
Spherical cellular aggregates of E. coli were present in the sub-inhibitory culture 
after incubation from one to 72 hours with colistin. SEM images at 72 hours 
revealed the de-aggregation of these spherical structures into smaller groups. 
Rounding of E. coli cell shape as well as smaller bacterial size was noted at 72 and 
168-hours incubation. 
The response of S. aureus to the presence of sub-inhibitory colistin was the rapid 
formation of spherical structures, regressing at three hours into normal sized S. 
aureus groups displaying blebbed membranes. Subsequent SEM images at 24, 72 
and 168 hours revealed bacterial exteriors similar to un-treated bacteria.  
Reactions by P. aeruginosa to this colistin concentration produced interlinked 
bacterial sheets until eight hours with the bacteria reverting to normal control-like 
bacterial appearance at that time. Inhibition of bacterial septation was also 
observed in P. aeruginosa at 72 and 168 hours. 
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6.4.3.2 Inhibitory concentration 
Incubation with the inhibitory (and supra-inhibitory) colistin concentrations resulted 
in a similar reaction to both concentrations by E. coli in the formation of spherical 
structures throughout the experimental period. A very low bacterial density was 
also noticed in all SEM samples for both these concentrations. Whilst incubated with 
MIC and 10xMIC colistin E. coli was not observed to undergo binary fission, though 
bacterial division was noted in un-treated and sub-inhibitory incubated E. coli.   
Incubation of S. aureus with MIC colistin produced spherical structures until 24 
hours whereupon reversion to control-type bacterial groupings occurred. 
Recognisable S. aureus groups persisted until 168 hours at which point S. aureus 
cells were visualized as one cohesive mass. 
P. aeruginosa produced interlinked bacterial sheets in reaction to the stress of the 
inhibitory colistin concentration up to eight hours, then appearing to exist as single, 
smaller bacteria with blebbed and indented exteriors observed at eight hours. 
Spherical structures were observed in the 24 hour SEM image, with cellular 
aggregation at 72 hours. By 168 hours incubation P. aeruginosa had formed a mat 
of interconnected bacteria, interwoven with what appeared to be filaments or fibres 
almost certainly of bacterial origin. 
6.4.3.3 Supra-inhibitory concentration 
Supra-inhibitory colistin concentrations resulted in the formation of spherical 
structures by S. aureus over the experimental period. The density of bacteria in all 
the SEM images was very low but as binary fission was not observed in the supra-
inhibitory incubated S. aureus, inhibition of cell replication would in part be 
responsible for this. 
Individual P. aeruginosa cells had adopted a spherical shape in response to the 
presence of 10xMIC colistin at two, four and eight hours, producing an aggregated 
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spherical structure at 24-hours. Very few P. aeruginosa cells were identified in the 
72 and 168 hour cultures, with these revealing deformed exteriors. Bacterial 
replication was not observed in the inhibitory or supra-inhibitory colistin 
concentrations during the experiment. However, as the density of the MIC culture 
had increased dramatically between 24 and 168 hours, binary fission must have 
occurred. Failure to replicate could account for the low bacterial density observed in 
the supra-inhibitory cultures throughout these experiments.  
6.4.3.4 Summary of bacterial responses to colistin 
The production of spherical aggregates, rounding of bacterial cells, blebbing of 
bacterial membranes and non-septation were the effects of sub-inhibitory colistin 
concentration on the test bacteria. Colistin is attributed as being a membrane 
active agent, yet the examination of two Gram-negative and one Gram-positive 
bacterium at concentrations ranging from 1/20th MIC to 10xMIC has not disclosed 
burst or ruptures bacterial cells. Blebbing of bacterial membranes, distortion of cell 
shapes and indentation of bacterial surfaces are all effects visualised by SEM. It has 
been postulated (Clausell et al. 2003) that colistin acts in a different way on the 
bacterial membrane at the MIC concentration, probably through effects on the lipid 
bilayer surrounding the periplasmic space.  
Incubation with the inhibitory and supra-inhibitory colistin concentrations resulted 
in spherical aggregation, blebbing of bacterial membranes, reduced bacterial size 
and low bacterial density. This is in agreement with a report by Mortensen et al that 
the bacterial surface of P. aeruginosa had changed to a wrinkled phenotype after 3 
hours incubation and cell length had decreased after exposure to 10 g/ml colistin 
(Mortensen et al. 2009). A concentration of 10 g/ml colistin is equivalent to 7xMIC 
used in the current investigation of P. aeruginosa. Clauselle et al revealed colistin 
has more than one mechanism of action; at high concentrations several times the 
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MIC value the mechanism of action has been reported to be through membrane 
permeability, although no significant K+ loss was observed when P. aeruginosa was 
treated with 10xMIC in this study (Clausell et al. 2003).  
Binary fission was not observed in E. coli either at inhibitory or sub-inhibitory 
concentrations, or in S. aureus or P. aeruginosa at the supra-inhibitory 
concentrations. This agrees with Mortensen et al who reported colistin reduced the 
rate of bacterial cell division five–fold in P. aeruginosa incubated for one hour with 
10 g/ml colistin compared to P. aeruginosa untreated cultures. The bactericidal 
effect of colistin is likely due in part to prevention of normal bacterial replication 
above certain concentrations. Mortensen et al suggested colistin incubated P. 
aeruginosa were arrested in proliferation after septum formation, preventing 
elongation in mother and daughter cells (Mortensen et al. 2009).  
6.4.4 Changes in morphology of E. coli, S. aureus and P. 
aeuginosa induced by CAPs 
6.4.4.1 Sub-inhibitory concentration 
Bacterial responses to incubation with NP101 and NP108 were very similar and 
these novel CAPs will therefore be considered together. Incubation with the sub-
inhibitory CAP concentrations produced the following myriad effects in E. coli and P. 
aeruginosa cells: shortening and rounding of cells; extrusion of intracellular 
contents; and non-septation. Filaments or fibres of possible cellular origin were 
observed to interlink P. aeruginosa cells after 24 hours incubation with 1/20th MIC 
NP101 and after 72 hours incubation with 1/20th MIC NP108. Whether these 
materials were extruded intracellular matter or specifically produced by the 
bacterium in response to the antibacterial stress of incubation with NP101 or NP108 
remains to be determined.  
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6.4.4.2 Inhibitory and supra-inhibitory concentrations 
Similar responses to those exhibited by the test bacteria incubated with sub-
inhibitory CAP concentration were also seen at the MIC and 2xMIC concentrations, 
but to a more severe degree. Specifically the effects were indentation, corrugated 
and misshapen bacterial exteriors, interruption in bacterial septation, blebbing of 
bacterial membranes, extrusion of intracellular material and formation of spherical 
structures. The production of aggregated bacterial layers was noted in P. 
aeruginosa in response to incubation with NP101. Gelling of E. coli cells by 
inhibitory and supra-inhibitory NP108 concentrations and S. aureus by supra-
inhibitory NP108 concentration were also observed. As with the supra-inhibitory 
colistin concentration, binary fission was not observed in the test bacteria in either 
2xMIC NP101 or NP108 concentrations, (except for P. aeruginosa incubated with 
2xMIC NP101 up to six hours, but absent thereafter). Significantly different to 
colistin, E. coli incubated with MIC NP108 underwent binary fission at 6 hours but 
not subsequently, while dividing P. aeruginosa cells were seen after 24 hours 
incubation with MIC NP108 but no cell division in this culture was observed 
afterwards.  The low bacterial density of these cultures was most likely due to 
prevention of cell replication by NP101 and NP108.  
6.4.4.3 Summary of bacterial responses to CAPs 
Responses of test bacteria to incubation with either NP101 or NP108 were similar to 
those observed for colistin; changes to bacterial shape and size, extrusion of 
intracellular material, blebbing of bacterial membranes, inhibition of septation and 
prevention of binary fission. CAPs are primarily reported in literature as membrane 
active agents; regardless of whether they act on intracellular targets, CAPs still 
have to interact with the bacterial membrane to reach their intracellular target 
(Reddy, Yedery and Aranha 2004)(Brogden 2005). Many of the visualised reactions 
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of the test bacteria to NP101 and NP108 are typical of bacterial responses to the 
presence of a cationic antimicrobial peptide (Hancock and Chapple 1999)(Hale and 
Hancock 2007)(Zhang and Falla 2006)(Hancock and Sahl 2006). 
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Chapter Seven  
The production of lyophilised wafers as a formulation 
vehicle for the topical delivery of CAPs 
7.1 Introduction 
Human skin is a complex organ possessing many in-built protective mechanisms. 
(Supp and Neely 2008)(Martin and Dodds 2006) These protective mechanisms 
include desquamation of the outer skin layers with subsequent microbial shedding 
and secretion of antimicrobial peptides in response to organisms that have 
penetrated the epithelium (Zaiou 2007)(Martin and Dodds 2006). Skin components 
such as lipids also possess substantial antimicrobial activity (Martin and Dodds 
2006). Skin therefore is not a passive barrier but is constantly vigilant against 
microbial attack with continuous monitoring systems and excellent rapid responses 
to ensure an infection free status (Schauber and Gallo 2008)(Martin and Dodds 
2006). 
Human skin is colonised by commensal organisms, including amongst others S. 
aureus and S. epidermidis that do not cause infection unless the physical barrier of 
the skin is breached, whereupon these organisms can cause opportunistic infections 
(Martin and Dodds 2006). 
7.1.2 Wounded and burned skin 
Normal human interaction with the environment occasionally results in damage to 
the skin and underlying dermis; in the US alone more than a million skin burns 
occur annually (Supp and Neely 2008). One main factor is responsible for deaths 
resulting from burns, being infection developing in the wound environment (Bhat 
and Milner 2007). A severe burn destroys the skin‘s protective barrier and the 
burn‘s protein rich environment is ideal for bacterial colonization (Bhat and Milner 
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2007)(Supp and Neely 2008). Immediately after the burn has occurred the wound 
surface is sterile but quickly becomes colonized by commensal bacteria from sweat 
glands and hair follicles from intact skin (Bhat and Milner 2007). 
Apart from burns, chronic wounds are extended in duration for many reasons; the 
patient may be immuno-compromised, malnourished or suffer from other long-term 
medical conditions such as diabetes mellitus that reduce normal healing processes 
(Supp and Neely 2008). The microorganisms that colonise chronic wounds are also 
found in burn environments, with a recent US study identifying S. aureus as the 
most commonly isolated wound organism, closely followed by P. aeruginosa (Supp 
and Neely 2008). The current cost of treating chronic wounds in the US, where over 
2 million people are treated for chronic wounds annually, is $1 billion per year 
(Supp and Neely 2008). The current gold standard in burn and chronic wound 
treatment is by skin graft, however if these wounds are large, locating donor sites 
can be difficult and further complicated by being painful or un-successful due to 
poor patient healing (Supp and Neely 2008). 
7.1.3 Application of CAPs as topical therapeutic agents 
The ever-increasing rise in bacterial resistance to current antimicrobial agents is 
cause for concern (Shukla et al. 2010). MRSA has now become widespread in 
community as well as hospital settings despite efforts to limit the spread of the 
superbug from hospital environments (Shukla et al. 2010). Also adding to the 
problems of bacterial resistance within individual countries; injured soldiers 
returning from conflict situations in other countries are regularly diagnosed with 
multidrug resistant infections (Shukla et al. 2010). New therapeutic agents as well 
as innovative methods in treating bacterial infections are urgently required and an 
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area being investigated for new therapeutic options is antimicrobial peptides (Hale 
and Hancock 2007).  
CAPs have been shown to be effective against Gram-positive and negative bacteria, 
viruses, fungi as well as multi-drug resistant bacteria (Shukla et al. 2010). A recent 
investigation examined the role of multidrug resistance efflux pumps in mediating 
resistance to innate antimicrobial peptides in E. coli, S. aureus and P. aeruginosa 
(Rieg et al. 2009). Neither the RND efflux pumps of E. coli, the MexAB-OprM pumps 
of P. aeruginosa, nor the MF family member NorA in S. aureus conferred resistance 
to the endogenous peptides tested (Rieg et al. 2009). This demonstrated that 
differences in secondary peptide structure, net charge, amphipathicity or 
mechanism of action are not determinants of efflux-mediated CAP resistance in 
these bacterial multidrug resistance pumps.  
Another positive factor possessed by CAPs relate to recent reports that have shown 
the ability of antimicrobials peptides such as lactoferrin to effectively block biofilm 
formation (Shukla et al. 2010). Dead tissue supports the development of sessile 
bacterial communities, leading to further tissue damage and resulting in the 
shedding of planktonic bacteria and the spread of infection (Shukla et al. 2010). 
The most effective method in treating these biofilms is to successfully prevent initial 
bacterial attachment to either the dead tissue or to medical device surfaces (Shukla 
et al. 2010). Current methods in the development of CAPs as therapeutic agents 
are their inclusion in polyelectrolyte multilayer films permitting time controlled drug 
release from various substrates with several potential applications (Shukla et al. 
2010).  
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7.1.4 Lyophilised wafers as topical drug delivery systems 
Traditionally, treatment of small burns and chronic wounds has been delivered 
through the use of systemic or topical agents or via occlusive dressings, which may 
or may not contain antimicrobial compounds (Supp and Neely 2008). Lyophilised 
wafers offer a new topical delivery system in wound treatment, allowing the 
sustained release of an incorporated antibacterial agent thus assuring a steady-
state concentration of the selected agent in the wound environment (Matthews et 
al. 2005). The wafer can be applied directly to the wound necessitating minimum 
human contact, thus the use of lyophilised wafers in wound healing offers several 
advantages over conventional topical treatments (Matthews et al. 2008). 
Lyophilised wafers absorb water when applied to the wound surface, changing state 
from glassy, porous solids to viscous gels (Matthews et al. 2005). Release of the 
antimicrobial agent from lyophilised wafers occurs through diffusion when the 
glassy polymer absorbs water, thereby producing a gel and releasing the active 
agent (Boateng et al. 2009)(Boateng et al. 2010). The diffusion rate of the water-
soluble antimicrobial agent into the wound environment has been shown to be time 
dependent (Boateng et al. 2009). The lyophilised wafers in this investigation were 
produced by freeze-drying the polymeric carrier, guar gum (Table 7.1) with NP101 
and NP108.  
7.1.5 Freeze-drying process 
The three stages in the lyophilisation process are freezing, primary drying followed 
by secondary drying. During freezing, the gel mixture undergoing lyophilisation is 
cooled and the water forms ice, freeze concentrating the polymer vehicle and 
peptide in a separate phase.  Some non-freezing water remains in this freeze-
concentrated phase. The pressure is reduced and the primary drying cycle 
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commences. The shelf temperature is slowly increased in a series of thermal ramps 
over a period of 14 hours from -80 to +20°C. There is thermal lag attributable to 
the polystyrene tray used as a mould for wafers. At some point in this thermal 
cycle, all of the ice has been removed and only residual amounts of non-freezing 
water remain in the glassy polymer structure. Continued low pressure (vacuum) 
causes desorption of this water to the gas phase. This is the secondary drying 
cycle.  
7.1.6 Chemical nature of NP101 and NP108 
NP101 is a 25.2 KDalton peptide while NP108 is half the molecular weight of NP101 
at 10.5 KDalton. The components of NP101 are unknown; however, NP108 is a 
poly-L-lysine cationic antimicrobial peptide.  
7.1.7 Selection of polymeric carrier 
As NP101 and NP108 are cationic antimicrobial peptides, potential interaction 
between gel and CAPs required the exclusion of a number of gels as appropriate 
bases, as illustrated in Table 7.1.   
 
Polymer 
type 
Overall 
chemical 
charge 
Source Molecular 
weight 
(Daltons) 
Guar gum Non-ionic Guar gum bean  
Cyamopsis tetragonolobus 
 
220,000 – 
250,000 
Xanthan gum Anionic Polysaccharide from 
Xanthomonas campestris 
250,000+ 
depending on 
grade used 
Karaya gum Anionic Acetylated polysaccharide 
(composed of galactose, 
rhamnose, glucuronic and 
galacturonic acids) 
5,000,000 – 
8,000,000 
Chitosan Cationic Derived from the exoskeleton 
of shellfish 
3,800 – 
20,000 
 
Table 7.1 Chemical nature and source of polymers 
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Figure 7.1 Chemical structure of guar gum 
The non-ionic guar gum (Figure 7.1) was selected as the most suitable polymer 
type to use as the carrier for the freeze dried wafers, as the weakest and lowest 
level of bonding between CAP and carrier was expected from this combination. It 
was appreciated that as a natural gum, guar could be contaminated with 
native/natural bacterial flora, necessitating the sterilisation of the lyophilised wafers 
by gamma radiation prior to use as a wound therapy (Matthews et al. 2006). In this 
investigation the lyophilised wafers were not gamma-irradiated, however, only the 
presence of test bacteria was detected on examination.  
7.1.7 Objective of current investigation 
The antimicrobial potencies of NP101 and NP108 were established in Chapter 3. 
However the development of a safe, effective formulation vehicle for topical 
delivery to the wound environment, to avoid systemic problems such as stability 
and antigenicity of CAPs, would be very beneficial. The purpose of this area of 
investigation was to formulate cohesive, non-friable lyophilised antimicrobial wafers 
as CAP topical delivery vehicles to aid wound healing.  
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7.2 Methodologies 
7.2.1 Preparation of guar gum gel 
Control and antimicrobial batches of gel were prepared as described in Section 
2.10.1.  
7.2.2 Freeze drying process 
After formulation of gels, the freeze-drying process to prepare lyophilised wafers 
was undertaken as described in Section 2.10.2. 
7.2.3 Rheological analysis of gels 
Analysis of control and antimicrobial gels were performed as described in Section 
2.10.3 
7.2.4 Preparation of agarose plates 
Agarose plates were prepared according to Section 2.3.6.1 and 2.3.6.2, to 
determine activity through a disc diffusion assay and measurement of resulting 
zones of growth inhibition of NP101 and NP108 against the test bacterial species. 
7.2.5 Determination of zones of inhibition 
Analysis of zones of inhibition of NP101 and NP108 were determined as described in 
Section 2.3.6.3. 
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7.3 Results 
7.3.1 Rheological analysis of pre-lyophilised gels 
The rheological properties of the polymeric carrier with and without CAPs were 
examined prior to lyophilisation for comparison with the behaviour in physical state 
post hydration from lyophilised wafers into gel form. 
 
Polymer η’ 
(Pa.s) 
 σo 
(Pa) 
Rate 
Index 
Standard 
error 
2% Guar gum 
control 
51.56 
±5.89 
77.67 
±3.19 
0.10 5.58 
2% Guar gum 
+ NP101 
52.86 
±3.80 
87.37 
± 6.73 
0.11 6.02 
2% Guar gum 
+ NP108 
72.61 
±9.14 
89.69 
± 4.09 
0.09 6.73 
Table 7.2 Viscosity coefficient (consistency) η‘ (Pa.s), yield stress σo (Pa), rate 
index for control, NP101 and NP108 polymers in aqueous solution as analysed by 
the Herschel-Bulkley model 
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Figure 7.2 Rheological analysis of pre-lyophilised gels; ascending and descending flow 
curves of 2% guar gum control      2% guar gum + NP101     2% guar gum + NP108 
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Analysis of the rheological properties of guar gum with and without CAPs was 
undertaken, under controlled conditions and temperature (Table 7.2). The variation 
in the initial part of the ascending flow curve was due to the uneven dissolution of 
the guar gum in water, which was more apparent when either NP101 or NP108 was 
added to the gel solution. Each of the three gels displayed shear thinning with 
pseudoplastic (verging on classic plastic flow) type flow curves. None of the three 
curves intersected the origin, revealing significantly high yield stresses, as 
displayed in Figure 7.2. The yield stress increased as the CAPs were added to guar 
gum (Table 7.2), with the 2% control gel exhibiting the lowest yield stress, followed 
by NP101 and then NP108.  
 
Figure 7.3 Determination of log shear stress against log shear rate 
 
Plots of log shear stress against log shear rate were linear (Figure 7.3) indicating 
that under the shear rates experienced, the behaviour of all three gels can be 
represented by the Herschel-Bulkley equation as stated in Section 2.10.3. The 
viscosity coefficient (η‘) increased from control to NP101 with the highest value 
recorded for NP108 (Table 7.2). The rate index was highest for the control gel, 
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followed by NP101 with NP108 recording the lowest value, as is normal for gels with 
increasing consistency.   
Small differences in the ascending and descending flow curves were attributed to 
very mild thixotropic properties. Thixotropy is a time dependent change in 
consistency displayed by certain gels; for example gels that are viscous under 
normal conditions can become more viscous over time. It can be seen from Figure 
7.2 that NP108 is improving the gel properties of guar gum and giving more 
structure to guar gum than NP101.  
7.3.2 Freeze dried lyophilised wafers 
The temperature profile of the freeze-drying process of the guar gum and CAP 
mixture is highlighted in Figure 7.4. The total time taken for the freeze-drying 
process from start to finish was 24 hours. 
 
 
 
Figure 7.4 Temperature profile of freeze-drying process 
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7.3.3 Determination of expansion and inhibition ratios of 
lyophilised 2% guar gum wafers via spread plates 
 
 
Figure 7.5 Expansion (a) and inhibition (b) ratios of lyophilised wafers. * indicates a 
statistically significant difference between the zone of inhibition recorded for NP101 and 
NP108 against a bacterial species: * indicates p-value < 0.05, ** indicates p-values < 0.01, 
*** indicates p-value < 0.001. # indicates a statistically significant difference between the 
zones of inhibition recorded for NP101 against the test bacteria: # indicates p-value < 0.05, 
## indicates p-values < 0.01, ### indicates p-value < 0.001 
(a) Expansion ratios of 2% guar gum lyophilised wafers; control, 2xMIC NP101, 2xMIC 
NP108, determined on spread plates 
(b) Inhibition ratios of 2% guar gum lyophilised wafers; control, 2xMIC NP101, 2xMIC 
NP108, determined on spread plates 
 
Neither Guar gum control, NP101 nor NP108 wafers experienced expansion (Figure 
7.5 (a)) after 24 hours contact with the agarose plate. Therefore the swollen 
polymer, due to the significantly high polymer yield stress, did not exhibit flow. If 
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the polymer yield stress were lower, when the wafer absorbed water from the 
agarose plate, the polymer would flow causing expansion. Diffusion of both NP101 
and NP108 from the lyophilised wafers occurred and clear zones of inhibition 
against all three test bacterial species were observed surrounding the lyophilised 
wafers after incubation. 
The inhibition zone recorded for NP101 against E. coli, S aureus and P. aeruginosa 
was statistically significantly higher than the zone of inhibition achieved by NP108 
against E. coli, S. aureus and P. aeruginosa. A statistically significant difference was 
also recorded in the zones of inhibition achieved by NP101 against S. aureus 
compared to those recorded against E. coli and P. aeruginosa. Given that the MIC of 
NP101 against E. coli (0.5 mg/ml) was twice that of NP101 against S. aureus (0.25 
mg/ml), it was not un-expected that a smaller zone of inhibition was recorded for E. 
coli than S. aureus.  
The MIC of NP108 recorded against all three test bacteria was 0.25 mg/ml and this 
was reflected by the non-statistically significant difference recorded in the zones of 
inhibition against all three bacterial species. Due to possessing a lower molecular 
weight, NP108 was anticipated to migrate more easily from the gel matrix and 
exhibit a larger zone of inhibition against the test bacteria as a result of the higher 
concentration of NP108 in the agarose gel. This did not occur and a smaller 
inhibition zone was recorded for NP108 compared to NP101 against the three test 
bacteria. As only limited information was available for both NP101 and NP108, 
which did not include the chemical structures, it can only be surmised that NP108 
bound more strongly to guar gum and therefore dissolution of NP108 from the 
lyophilised wafer was retarded resulting in the recording of a smaller zone of 
inhibition against the test bacteria.  
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7.3.3 Determination of expansion and inhibition ratios of guar 
gum 2% lyophilised wafers via pour plates 
As previously described for spread plates, no expansion ratios were determined for 
control, NP101 or NP108 wafers after 24 hours incubation on pour plates (Figure 
7.6 (a)).  
 
 
Figure 7.6 Expansion (a) and Inhibition (b) ratios of lyophilised wafers. * indicates a 
statistically significant difference between the zone of inhibition recorded for NP101 and 
NP108 against a bacterial species: * indicates p-value < 0.05, ** indicates p-values < 0.01, 
*** indicates p-value < 0.001. 
 (a) Expansion ratios of 2% guar gum lyophilised wafers; control, 2xMIC NP101, 2xMIC 
NP108, determined on pour plates 
(b) Inhibition ratios of 2% guar gum lyophilised wafers; control, 2xMIC NP101, 2xMIC 
NP108, determined on pour plates 
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As with the spread plates, a smaller zone of inhibition was recorded for NP101 
against E. coli than for S. aureus and P. aeruginosa, which was not un-expected as 
the MIC for NP101 against E. coli, is twice that of the other two bacteria. A 
statistically significant zone of inhibition (Figure 7.6 (b)) was recorded between the 
zones of inhibition recorded for NP101 and NP108 against each test bacterial 
species. As previously mentioned, NP108 appeared to bind far more strongly to 
guar gum than NP101, thus lower zones of inhibition against all bacteria tested 
were recorded for this CAP. 
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7.4 Discussion 
7.4.1 Determination of inhibition ratios 
The inhibition ratios determined by pour plate against all three test bacterial 
species were higher than those determined by spread plate. There are a number of 
factors that could have contributed to this result being obtained. Firstly, pour plates 
are prepared by introducing the required bacterial density into an empty Petri dish 
and adding the molten agarose at a temperature of approximately 50 0C. Due to 
thermal lysis, a proportion of these bacteria are killed, therefore a lower bacterial 
density may be present within pour plates compared to spread plates, thus a larger 
zone of inhibition will be recorded for the agent being tested against the bacteria. 
Secondly, as pour plates have the bacteria present throughout the agar plate, a 
lower bacterial density per unit volume is present in pour plates than in spread 
plates, where the required bacterial density is spread over the agarose surface.  
Smaller zones of inhibition are regularly recorded in our laboratory for spread plates 
compared to pour plates for reasons outlined above. (A. Lamb, 2011, personal 
communication) 
7.4.2 Lyophilised wafers as topical formulations 
From the results reported in Sections 7.3.2 and 7.3.3. lyophilised wafers of 2% 
Guar gum are effective formulations for the topical delivery of CAPs in vitro. 
Dissolution of NP101 and NP108 from the wafers occurred and zones of inhibition 
were recorded for both CAPs against the three test bacteria. Having a molecular 
weight half that of NP101, a greater concentration of NP108 would be expected to 
diffuse from the wafer into the agarose gel. However, tighter binding of NP108 to 
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guar gum, resulted in less NP108 released over the incubation time, with resultant 
recording of lower zones of incubation compared to NP101. 
7.4.3 CAP cell selectivity 
The current view amongst researchers is that CAPs exhibit cell selectivity 
(Matsuzaki 2009). Based on numerous reports of the non-haemolytic activity of 
CAPs at concentrations several times higher than MIC values determined against 
numerous microorganisms, CAPs selectively kill bacterial cells without exerting 
significant toxicity against host cells (Matsuzaki 2009). This cell selectivity of CAPs 
is partly due to their cationicity; the surfaces of bacterial membranes are more 
highly negatively charged than mammalian membranes (Matsuzaki 2009). The in-
vitro binding of the antimicrobial peptide magainin to S. aureus but not to 
surrounding epithelium has previously been demonstrated (Matsuzaki 2009). CAPs 
have been also been shown to act synergistically with other CAPs and conventional 
antibacterials to induce bacterial death (Marr, Gooderham and Hancock 2006). 
Randomised double-blind Phase III trials were conducted in 1991/2 examining the 
effect of 1% pexiganan acetate (synthetic analogue of the antimicrobial peptide 
magainin 2) and oral ofloxacin on infected diabetic foot ulcers, which reported a 
90% cure rate (Zhang and Falla 2006)(Zheng, Sohn and Kim 2009). The 
development of a topical formulation containing pexiganan for the treatment of 
diabetic ulcers is on-going (Zhang and Falla 2006).  
In the search for new therapeutic agents one of the essential requirements is that 
the antimicrobial under development displays cell selectivity as continued 
development of a therapeutic agent is curtailed if, in addressing microbial infection, 
damage is also inflicted by the agent on host cells. 
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7.4.4 Factors controlling drug residence in tissues 
Before an antimicrobial agent can be effective, it must first be released from the 
formulation vehicle, bind to and remain in the target site at sufficient concentration 
to elicit an effect, also have a long half-life before being excreted by the host (Lu 
and Tonge 2010). The efficacy of any medicament is linked with the length of time 
the active agent is present in the area under treatment (Lu and Tonge 2010). In 
this investigation the incorporation of two novel antimicrobial peptides into 
lyophilised wafers has been shown to be effective against the most commonly 
found bacteria in human wounds, namely, S. aureus and P. aeruginosa. These 
lyophilised wafers deliver the antibacterial agent directly to the treatment area; 
allow the controlled release of the incorporated antimicrobial over time directly into 
the wound environment, therefore assuring sufficient drug/target residence time 
(Matthews et al. 2005). Resistance to these CAPs is not mediated by the efflux 
systems of the test bacteria and CAPs have been shown to exhibit cell selectivity. 
Further investigation is now required to examine the in vivo efficacy of the 
combination of CAPs and lyophilised wafers in the treatment of topical wounds.  
 7.5 Conclusion 
Guar gum is a suitable polymer for the preparation of lyophilised wafers containing 
NP101 and NP108 for use as topical preparations in the treatment of wounds. 
Release of both NP101 and NP108 occurred from the lyophilised wafers, with 
substantial zones of inhibition recorded against E. coli, S. aureus and P. aeruginosa, 
each of which are commonly found in wounded and burned skin.  
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Chapter Eight  
Discussion 
8.1 Introduction 
Excessive use of antibiotics in clinical practice since their discovery, without due 
consideration for inevitable ensuing bacterial resistance, coupled with the dearth in 
development of new antibacterials over the past few decades, has resulted in a 
world wide increase in bacterial resistance, closely correlating antibiotic usage 
(Carlet et al. 2011). Many factors have contributed and continue to add to the 
escalating bacterial resistance including; ageing immuno-suppressed populations in 
the developed world and poor sanitation, malnutrition and freely available generic 
antibacterials in the developing countries (Projan 2002). There is an urgent 
immediate global need for alternatives to classic antibiotics, (Fernebro 2011) which 
CAPs as a class provide a viable alternative to conventional antibacterial agents 
(Lohner and Blondelle 2005). 
8.2 Measures to reduce antibacterial resistance 
The focus of the WHO‘s World Health Day in 2011 was antimicrobial resistance 
(Carlet et al. 2011). This has helped to highlight the level of bacterial resistance 
globally and to promote wiser prescribing strategies for the effective antibacterials 
remaining to humans. Recognition that increased use of an antibacterial agent is 
swiftly followed by increased bacterial resistance to that agent is being actively 
promoted worldwide. One consequence of increased antibacterial resistance to 
existing therapeutic agents is that the empirical use of carbapenems has been 
adopted (Carlet et al. 2011). Carbapenems are currently the last effective class of 
antibacterials against most Gram-negative bacteria, a resource that must be 
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husbanded or resistance to this agent will surely occur if standard first–line therapy 
is adopted worldwide (Carlet et al. 2011).  
However, the development of new agents while critical is not the only measure that 
must be adopted worldwide: informed use of existing agents must be promoted, 
strategies implemented to address the development of bacterial resistance by 
methods other than the use of antimicrobials must be investigated and more 
responsible prescribing policies must be encouraged in all health practitioners. 
Consideration of all these factors leads to the current investigation. Triclosan 
though in clinical use for many decades has recently come under FDA scrutiny due 
to reports of hormone effects in humans and fears of furthering antimicrobial 
resistance. Colistin was abandoned clinically from 1970-2000 due to adverse 
neurotoxic and nephrotoxic effects and is now used as a last resort treatment for 
multidrug resistant bacteria. However there is a great lack of information about the 
effects of colistin on bacteria as it was licensed in an era when existing regulatory 
requirements were not necessary for products and due to being discarded, as a 
therapeutic agent studies into the activity of colistin were not undertaken. NP101 
and NP108 are novel cationic antimicrobial peptides, with the potential for 
development as therapeutic agents.  
Therefore, this investigation examined triclosan, colistin, NP101 and NP108 in order 
to gain more information as to the bacteriostatic/bactericidal effects of these 
antimicrobials. Each agent has been shown to be effective against E. coli, S, aureus 
and P. aeruginosa. Though triclosan has been used clinically for many years it has 
retained its anbacterial efficacy. The abandonment of colistin from clinical practice 
from 1970s–2000 due to safety concerns has contained the development of 
resistance to this antibacterial, which currently remains the only active therapeutic 
agent against several multi-drug resistant bacteria.  
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8.2 Membrane active agents 
Triclosan, colistin and CAPs are each attributed as being membrane active agents. 
Membrane active agents can exert their activity on bacterial membranes through 
alteration of the membrane potential, effects on membrane associated enzymes or 
activity on membrane structure and/or permeability (Denyer and Russell 2004) 
(Singleton 1999). Thus, the ranges of activities through which membrane active 
agents can exert bactericidal or bacteriostatic effects are extensive. 
8.2.1 Membrane potential 
The bacterial membrane is impermeable to protons, the extrusion of which from the 
cell interior forms the proton-motive force (PMF). This PMF drives the energy-
requiring activities of the cell, including adenosine triphosphate synthesis (Denyer 
and Russell 2004)(Singleton 1999). The PMF also controls the up-take and 
metabolism of cellular components such as amino acids and sugars within the 
bacterium. Therefore, membrane active agents, by affecting the membrane 
potential, can un-couple bacterial metabolism from the energy processes which fuel 
catabolic activity essential for bacterial survival, resulting in bacterial death (Denyer 
and Russell 2004)(Singleton 1999).  
8.2.2 Membrane enzymes 
In aerobic bacteria, action on the electron transport chain by membrane active 
agents causes the inhibition of all metabolic processes, followed by bacterial death. 
These agents can also cause inhibition of ATPase and therefore inhibit metabolic 
processes in anaerobic bacteria. Membrane and cytoplasmic enzymes containing 
thiol groups such as the dehydrogenases (which are involved in redox reactions) 
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are also targeted by membrane active agents, with lethal results (Denyer and 
Russell 2004). 
8.2.3 Membrane permeability 
Effects on membrane permeability can produce bacteriostatic or bactericidal results 
depending on the concentration of antibacterial employed or the length of time to 
which the bacterium is exposed to the antimicrobial agent. Bacterial reactions 
therefore, can vary from slight leakage of intracellular components such as 
potassium ions to total cell lysis and bacterial death (Denyer and Russell 2004). 
8.3 Quorum sensing 
The phenomenon of quorum sensing is achieved through all the cells in a bacterial 
population secreting signal molecules; upon attainment of a certain cell density 
(quorum) these molecules accumulate until a level is reached where certain genes 
are activated within bacterial cells (Denyer and Russell 2004)(Singleton 1999). As 
previously detailed, homoserine lactones act as autoinducers in Gram–negative 
bacteria; once a certain concentration is reached they diffuse into bacterial cells, 
bind to a cytoplasmic protein and induce transcription of a specific gene. Thus, 
quorum sensing regulates gene expression in response to increased cell density 
(Otto 2004). Changes in gene expression and reduced growth rate occur in E. coli 
when the bacterium is exposed to the stress of an antimicrobial agent, to ensure 
survival (Rand et al. 2002). Biofilm formation by S. aureus has been shown to 
increase in response to inhibition of quorum sensing (Otto 2004). The acquisition of 
multidrug resistance genes by P. aeruginosa is also thought to affect the quorum 
sensing control of gene expression and release of virulence factors (Deptula and 
Gospodarek 2010). During P. aeruginosa colonization, quorum-sensing mutants 
benefit from molecules produced by wild-type isolates by rapid multiplication, 
262 
 
without any metabolic cost to these bacteria, which therefore have a fitness 
advantage (Kohler et al. 2010). A macrolide antibiotic, azithromycin exerts its 
antibacterial activity through interference with the quorum-sensing circuit, 
inhibiting expression of several extracellular virulence factors (Kohler et al. 2010). 
8.4 Small colony variants and persister cells 
S. aureus small colony variants result from exposure of planktonic cells to 
antimicrobials and amass as a drug-resistant sub-population, reducing sensitivity to 
antimicrobials through slow growth, reduced intake of cationic antibacterials and 
increased survival rates (Seaman, Ochs and Day 2006). The phenotype of small 
colony variants is due to defects in the electron transport chain, which can prove 
genetically inheritable or a transient colony type (Singh et al. 2009). S. aureus 
small colony variants have been shown to arise from antibacterial exposure, in 
particular exposure to aminoglycosides and Seaman et al have also reported the 
development of small colony variants in S. aureus as a result of exposure to 1 
µg/ml triclosan (eighteen times higher than the MIC determined for S. aureus 
exposed to triclosan in this study) (Seaman, Ochs and Day 2006). These small 
colony variants displayed substantially increased resistance to triclosan, tolerating a 
concentration of 7.5 µg/ml triclosan for two hours while wild-type S. aureus were 
killed in less than 20 minutes. Subsequent analysis proved this triclosan resistance 
possessed by small colony variants was not due to mutation of fabI, clearly 
inferring fabI is not the only target affected by triclosan.  
Persister cells are small populations of bacterial cells possessing a highly protected 
phenotype (Lai, Tremblay and Deziel 2009). Persisters do not possess specific 
resistance mechanisms and yet survive exposure to lethal concentrations of 
antimicrobials (Singh et al. 2009). Resistance in these persister cells is as a result 
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of a transient phenotypic switch, which reverts on re-culture to wild-type with new 
persister cells arising within this population (Singh et al. 2009). Persisters are not 
the result of antimicrobial exposure nor are they formed in response to quorum 
sensing but pre-exist in bacterial populations (Singh et al. 2009). Large numbers of 
persister cells are found in biofilms but small numbers of these cells have also been 
reported in planktonic cultures.  
8.5 Antibacterial mechanism of action of triclosan 
The responses of all three test species to incubation with triclosan were longer 
replication times and reduced metabolic activity. The growth inhibitory ability of 
triclosan against E. coli and S. aureus is due to blocking lipid synthesis by inhibiting 
FabI (Russell 2003). McMurray et al demonstrated blockage of lipid synthesis in E. 
coli within two hours incubation in 0.15 µg/ml triclosan (twice the MIC determined 
for E. coli in this study), directly inhibiting the bacterial growth rate by 50% 
(McMurray, Oethinger and Levy 1998). Triclosan has also been credited with having 
multiple target sites in the cytoplasmic membrane inhibiting not only lipid but also 
RNA and protein synthesis, resulting in membrane damage and bacterial death 
(Suller and Russell 2000).  
The growth pattern of un-treated S. aureus was also revealed to be different to that 
displayed by S. aureus incubated with triclosan. Onset of a more rapid second 
phase of exponential bacterial growth was visible in S. aureus several hours after 
logarithmic bacterial growth had already commenced in the bacterium. This onset 
of a second phase of logarithmic bacterial growth was absent from S. aureus 
incubated with triclosan. This further onset of exponential growth in un-treated 
bacteria could perhaps be attributed to quorum sensing; once the bacterial 
population has assessed that adequate nutritional supplies and optimum growing 
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conditions are available to the community, a trigger is lifted and already occurring 
exponential bacterial growth proceeds at a faster rate. Exposure to sub-lethal 
triclosan prevents this trigger being lifted and a single phase of significantly 
reduced exponential growth occurs.  
Assessment of membrane permeability in bacteria incubated with triclosan showed 
that a statistically significant K+ loss linked to concentration and length of exposure 
to the bisphenol was detected from E. coli incubated with inhibitory or supra-
inhibitory triclosan concentrations. McMurray et al demonstrated incubation with 8 
µg/ml triclosan induced lysis in E. coli within two hours incubation (McMurray, 
Oethinger and Levy 1998). This is equivalent to 115xMIC determined for E. coli 
against triclosan in this study. Triclosan is adsorbed into bacterial cells by a Z 
adsorption pattern; the entry of triclosan into cells commences, a sudden cessation 
in triclosan adsorption follows after which adsorption resumes at a faster rate 
(Russell 2003). This type of adsorption indicates triclosan causes the structural 
breakdown of the bacterial cell wall/membrane and generates new sites through 
which it can then access within the bacterial cell (Russell 2003). In contrast to E. 
coli, K+ loss from S. aureus exposed to triclosan was un-affected by concentration 
and exposure time and was not statistically significant. Villalaín et al demonstrated 
triclosan destabilizes structures in bacterial cells, compromising cell membrane 
integrity but not resulting in bacterial lysis (Villalaín et al. 2001). Examination of 
the effects of triclosan on bacterial populations by flow cytometry revealed different 
responses in control and triclosan incubated cultures. Exposure of both these 
bacterial species to sub-inhibitory triclosan concentrations was well tolerated; 
viability patterns and bacterial size of sub-inhibitory and un-treated bacteria were 
very similar, indicating exposure to this triclosan concentration exerted minimal 
stress and limited fitness cost on the bacteria. As 99.999% of E. coli and S. aureus 
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die when incubated with the inhibitory triclosan concentration; the remaining 
0.001% slowly grow and after a long period their progeny cells are detected by flow 
cytometry at 72 hours. Contrary to the inhibitory triclosan concentration, E. coli or 
S. aureus cells do not survive exposure to the supra-inhibitory triclosan 
concentration. Changes in morphology of these test bacteria by SEM examination 
revealed a similar response to incubation with triclosan causing interference with 
the ability of cells to undergo normal septation. Interrupted cell division in S. 
aureus incubated with triclosan has been demonstrated by Seaman et al (Seaman, 
Ochs and Day 2006). Aggregation of S. aureus cells was seen in all triclosan 
concentrations over the experimental period, probably attributable to the inability 
of bacteria to separate properly. 
8.5 Antibacterial mechanism of action of colistin 
A concentration dependent retardation in onset of logarithmic bacterial growth with 
little or no reduction in final bacterial density was seen with all three test bacteria 
incubated with colistin. In contrast to triclosan, onset of the second phase of 
logarithmic bacterial growth was observed in both un-treated and colistin incubated 
S. aureus cells. This highlights the clear distinction between the effects that colistin 
and triclosan exerted on the growth kinetics of S. aureus.  
A concentration dependent, significant K+ loss was observed in S. aureus and E. coli 
when incubated with colistin. However, the concentration of colistin required 
inducing this K+ loss in S. aureus was thirty-three times higher than that used to 
treat E. coli. Importantly incubation of P. aeruginosa with colistin did not result in 
leakage of K+ as no difference in the quantity of K+ lost was detected between un-
treated and treated cells. Therefore the fact that colistin is active against P. 
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aeruginosa, but no loss of K+ is observed, this suggests that K+ loss in the other test 
species are a secondary consequence of the primary action of this agent. 
Exposure to the supra-inhibitory colistin concentration proved bactericidal for all 
three test bacteria. P. aeruginosa and S. aureus but not E. coli, displayed tolerance 
to the presence of the inhibitory colistin concentration between 24 and 72 hours. 
Small colony variants observed to permit bacterial survival were detected during 
viability counts with P. aeruginosa exposed to colistin at inhibitory and supra-
inhibitory concentrations. Neither E. coli nor S. aureus in response to incubation 
with colistin produced these small colony variants.  
Changes in bacterial morphology over 168 hours revealed by SEM, disclosed 
incubation of E. coli, S. aureus and P. aeruginosa with sub-inhibitory colistin 
concentrations produced spherical cellular aggregates, rounding of rod-shaped 
bacteria, interference with normal bacterial septation and membrane blebbing. 
Adaptive resistance to the presence of colistin has been shown previously for P. 
aeruginosa and other Gram-negative bacteria (Skiada et al.). Adaptive resistance is 
a self-regulated bacterial phenomenon, where resistance to an antibacterial through 
phenotypic alterations is displayed by the bacterium in the presence of the 
antibacterial, lost when the antibacterial compound is removed (Skiada et al.). The 
effect underpinning such resistance are changes in bacterial cell surface, alteration 
in outer membrane architecture and lipid composition and reduction in Mg++ and 
Ca++ content of LPS, all of which decreases outer membrane permeability and result 
in reduced binding of colistin (Skiada et al.). Exposure of P. aeruginosa to sub-
inhibitory colistin concentrations activates the two-component regulatory system, 
triggering adoption of adaptive resistance and LPS alterations. MexAB-OprM efflux 
systems, which are overexpressed in P. aeruginosa biofilms, have also been shown 
to confer an adaptive resistant phenotype to colistin (Skiada et al.).  
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Alterations upon bacterial morphology in response to sub-inhibitory colistin 
concentrations were also visualised at the inhibitory and supra-inhibitory 
concentrations; specifically the presence of spherical aggregated cells, membrane 
blebbing and non-septation in conjunction with very low bacterial density at these 
colistin concentrations. 
8.6 Antibacterial mechanism of action of NP101 and NP108 
The effects exerted by NP101 and NP108 were different and depended not on the 
bacterial species with which they were incubated but on the density of the bacterial 
culture. At a lower density an all or nothing effect was seen with all test species; 
this changed to delayed onset of logarithmic growth coupled with reduced final 
bacterial densities when a higher bacterial innoculum was employed. The ability of 
CAPs to inhibit planktonic growth in bacteria has been shown to be linked to the 
peptide length; with hexa and octameric peptides successfully inhibiting E. coli 
growth whereas tetrameric peptides did not (Hou et al. 2010). Until recently it was 
believed there were no specific receptors for cationic peptides on the surfaces of 
micro-organisms. However this viewpoint requires revision since it appears that 
histatins bind specifically to Ssa1/2 proteins on the surface of Candida albicans 
(Pereira 2006). Vylkova et al demonstrated in 2006 that salivary histatin 5 (Hst 5) 
kills Candida albicans by a multi step process involving binding to Ssa 1/2 proteins 
on the cell surface requiring the Trk1 potassium transporter as an essential tool 
(Vylkova et al. 2006). 
As previously observed with S. aureus incubated with triclosan, the second onset of 
logarithmic bacterial growth displayed by un-treated bacteria was not present in the 
growth of S. aureus exposed to either of the CAPs.  
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Being membrane active agents, assessment on changes to membrane permeability 
through detection of K+ loss resulting from exposure to NP108, resulted in swift and 
statistically significant K+ loss in all three test species. The concentration dependent 
K+ loss recorded was greatest for E. coli, with P. aeruginosa requiring a higher 
concentration of NP108 before K+ loss was significant. Low outer membrane 
permeability forms the basis of the reduced susceptibility of P. aeruginosa to most 
antibacterials (Breidenstein, de la Fuente-Núñez and Hancock 2011). This low 
membrane permeability is 12-100 times less than that of E. coli (Breidenstein, de la 
Fuente-Núñez and Hancock 2011). Exposure of P. aeruginosa to sub-inhibitory 
concentrations of antibiotics has resulted in the subsequent development of 
resistance to that antibacterial, through overexpression of genes encoding efflux 
pumps. In chronic cystic fibrosis infections P. aeruginosa switches to a biofilm 
lifestyle with resistance to conventional antibacterials (Breidenstein, de la Fuente-
Núñez and Hancock 2011). E. coli revealed what looked like development of 
tolerance to the inhibitory concentration of NP101 but not to NP108. Neither P. 
aeruginosa nor S. aureus tolerated the inhibitory or supra-inhibitory NP101 or 
NP108 concentrations. To illustrate the diversity of CAPs, there appears to be no 
general peptide cross-resistance mechanism whereby bacteria are resistant to 
every single peptide (Marr, Gooderham and Hancock 2006). S. aureus and Ps. 
aeruginosa have evolved a degree of generalised CAP resistance by increasing the 
amount of positively charged protein in their membranes. S. aureus transports D-
alanine from the cytoplasm to the surface teichoic acid to reduce the net negative 
charge by introducing basic amino groups (Brogden 2005). Another method by 
which bacteria develop resistance to CAPs is by production of proteolytic enzymes; 
for example, LL-37 is cleaved and inactivated by a S. aureus metalloproteinase, 
aureolysin (Brogden 2005). A two-component system ParR-ParS is significant in the 
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adaptive resistance of P. aeruginosa to cationic peptides, through activation of the 
lipopolysaccharide modification operon. Small colony variants were produced by all 
test bacterial species in response to CAP incubation, to increase bacterial survival. 
Changes in bacterial morphology as elucidated by SEM revealed bacterial size and 
shape alterations: extrusion of intracellular material: blebbed bacterial membranes: 
inhibition of bacterial septation and interruption of binary fission. Other proposed 
mechanisms of action include activity on intracellular targets after membrane 
permeabilization, such as activation of autolytic enzymes and inhibition of DNA and 
protein synthesis. For example; attacins block synthesis of integral membrane 
proteins, pyrrhocoricin (insect peptide) has been demonstrated to kill bacteria by 
binding to a protein target called DnaK, preventing DnaK from performing its 
protein repair function resulting in death (Zaiou 2007).  
During this investigation, the statistically significant in vitro efficacy of two novel 
CAPs against the microorganisms most commonly found contaminating chronic 
wounds and burns has been demonstrated. One of the principal factors limiting the 
use of CAPs as clinical therapeutics is their short systemic half-life owing to 
proteolytic degradation (Marr, Gooderham and Hancock 2006). Research is on 
going in the development of protease resistant CAPs; Marsh et al have shown that 
fluorination of naturally existing peptides increases their resistance to proteolytic 
degradation to twenty times longer than their non-fluorinated counterparts (Ritter 
2007). However, there are no known topical toxicities, which make topical delivery 
the most suitable current application for the antibacterial action of CAPs (Marr, 
Gooderham and Hancock 2006).  
Utilisation of antimicrobial peptides to promote wound healing is well established 
since manuka honey was introduced into topical therapy (Ratcliffe et al. 2011). The 
antibacterial activity and re-granulation effect of manuka honey can be attributed in 
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part to the constituents of honey, including the insect antimicrobial peptide bee 
defensin-1. (Ratcliffe et al. 2011) Delivery of these antimicrobials directly into the 
wound bed was possible by incorporating the CAPs into lyophilised wafers. 
Lyophilised wafers are being developed as novel topical therapeutic delivery 
formulations, delivering sustained release, with resultant constant concentration of 
the therapeutic agent in the wound environment. 
8.7 Future work 
A transcriptional analysis of E. coli, S. aureus and P. aeruginosa is now required to 
determine the individual cellular genetic responses of these bacteria to triclosan, 
colistin, NP101 and NP108. This will greatly add to the information already gathered 
during this study. 
While SEM has elucidated several effects of all the test agents against the bacteria 
used in this investigation, analysis by TEM is the logical progression in further 
analysis of individual bacterial responses to these cationic antimicrobial agents. 
During this investigation of the effects of the inhibitory concentration of NP101 on 
E. coli, the appearance of what appeared to be a tolerance to the effects of the 
inhibitory concentration of the CAP was revealed. Further investigation of this effect 
is required and if tolerance to NP101 is revealed, whether de-sensitisation to the 
peptide would result in the return of sensitivity to the agent.  
8.8 Conclusions 
The conclusions that can be drawn from the current investigation are; 
a) Triclosan 
Triclosan exerts a concentration dependent retardation in onset of logarithmic 
growth coupled with reduction in bacterial growth in all three test bacteria. 
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The inhibition of onset of second-phase logarithmic growth in S. aureus, by 
triclosan. 
Minimal K+ loss is induced from E. coli and S. aureus upon incubation with triclosan 
concentrations up to 10xMIC. 
The inability of E. coli and S. aureus to withstand incubation with the supra-
inhibitory triclosan concentration was evident from flow cytometry data. 
Development of tolerance by E. coli and S. aureus to the inhibitory triclosan 
concentration by 72 hours was elucidated by flow cytometry. 
Examination of bacterial morphology via SEM revealed inhibition of normal bacterial 
septation and the formation of cellular aggregates in all test species. 
b) Colistin 
Concentration dependent retardation in onset of bacterial growth, without reduction 
in final bacterial density of all test species by colistin. 
Incubation with colistin resulted in the induction of significant K+ loss from S. 
aureus and E. coli but not P. aeruginosa.  
P. aeruginosa and S. aureus but not E. coli developed resistance to the inhibitory 
colistin concentration over the experimental period. 
The stress of incubation with colistin resulted in the production of small colony 
variants by P. aeruginosa.  
SEM examination of bacterial morphology revealed colistin incubation produced the 
formation of spherical aggregates; membrane blebbing and inhibition of normal 
bacterial septation in all test bacteria. 
c) NP101 and NP108 
An all or nothing effect on bacterial growth of E. coli, S. aureus and P. aeruginosa 
by NP101 and NP108. 
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Suppression of second-phase logarithmic growth in S. aureus by both NP101 and 
NP108. 
Incubation with NP108 resulted in significant K+ loss in all test bacteria. 
Examination of outer morphology of E. coli, S. aureus and P. aeruginosa after 
incubation with NP101 and NP108 produced bacterial size and shape alterations; 
induced extrusion of intracellular material; caused blebbing of membranes; 
inhibited bacterial septation and interrupted replication through binary fission.  
Formulation of lyophilised wafers containing either NP101 or NP108 was 
undertaken, tested for in vitro topical antibacterial efficacy and found to possess 
antibacterial activity against all test species. 
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